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Abstract
Natural Killer (NK) cells are cytotoxic lymphocytes important in immune responses to cancer 
and mulƟ ple pathogens because of their ability to kill pathogen infected and tumour cells, and to 
regulate the funcƟ on of other immune cells by the secreƟ on of soluble factors. It has been described 
that chronic acƟ vaƟ on of NK cells can induce a hyporesponsive state. This situaƟ on has been described 
as one evasion strategy used by tumours or viruses to escape immune system surveillance.
The molecular basis of the mechanisms that allows the generaƟ on and maintenance of this 
hyporesponsive state on NK cells are unknown, and the main objecƟ ve of this thesis was to establish 
and in vitro system to induce hyporesponsiveness on healthy human NK cells to study the molecular 
basis of NK cell hyporesponsiveness. 
IL-2 acƟ vated human NK cells treated with ionomycin lose their ability to degranulate when 
cocultured with diﬀ erent target cells, and to secrete IFN-γ even aŌ er IL-12 and IL-18 sƟ mulaƟ on. 
However, they are able to degranulate when sƟ mulated through CD16. Cytotoxic and secretory 
funcƟ ons were restored by IL-2 sƟ mulaƟ on. The expression of acƟ vaƟ ng and inhibitory receptors was 
normal in ionomycin treated NK cells, however, we observed lower expression of the αL, αM and β2 
integrins. Study of diﬀ erent NK killing steps demonstrated that ionomycin treated NK cells are less 
able to form conjugates with target cells. Transcriptomic analysis of acƟ vated NK cells treated with 
ionomycin revealed diﬀ erenƟ al expression of mulƟ ple genes; however this transcripƟ onal signature 
was diﬀ erent to those previously defi ned for other hyporesponsive lymphocytes. Treatment of freshly 
isolated NK cells from healthy donors with ionomycin induces a hyporesponsive state similar to that 
observed aŌ er the treatment of acƟ vated NK cells. However, these cells did not recover their ability to 
degranulate and produce IFN-γ enƟ rely in the presence of IL-2, and are unable to exert degranulaƟ on 
as eﬃ  ciently as control cells when sƟ mulated through CD16.
Ionomycin treatment has shown to be an useful tool to understand the NK cell unresponsiveness 
induced aŌ er chronic acƟ vaton. NK cells. The molecular basis of the lack of response has not been 
fully elucidated. However the integraƟ on of the data described in this thesis provides a conceptual 
framework that will be useful to understand NK cell biology and NK cell hyporesponsiveness.
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Resumen
Las  células “Natural Killer” (NK), son linfocitos citotóxicos capaces de inducir la lisis de células 
tumorales o infectadas por diferentes patógenos. También pueden regular la función de otras células 
inmunes mediante la secreción de disƟ ntos factores solubles. Sin embargo, una acƟ vación crónica 
de las células NK, puede dar lugar a un descenso de su capacidad efectora. Este fenómeno ha sido 
descrito como una posible estrategia usada por tumores o diferentes virus para escapar de la vigilancia 
mediada por el sistema inmune.
Actualmente se desconocen las bases moleculares de esta pérdida de acƟ vidad mantenida en las 
células NK, así, el objeƟ vo principal de este trabajo fue establecer un sistema experimental para poder 
inducir y estudiar en células NK humanas de donantes sanos las bases moleculares de esta pérdida de 
función.
El tratamiento de las células NK humanas acƟ vadas con IL-2 con ionomicina provoca una pérdida de 
su capacidad de ejecutar un ataque citotóxico frente a diferentes células diana, y la de secretar de IFN-γ 
incluso tras su esƟ mulación con las citoquinas IL-12 e IL-18. Sin embargo, si conservan capacidad de 
degranular cuando fueron esƟ muladas a través del receptor CD16. Las funciones citotóxica y secretora 
pudieron ser recuperadas en estas células culƟ vándolas en presencia de IL-2. Esta pérdida de función 
no fue debida a cambios en la expresión de receptores acƟ vadores o inhibidores, sin embargo, sí que 
se observó menor expresión de las integrinas αL, αM y β2. El estudio detallado de los disƟ ntos pasos 
del ataque citotóxico, mostró que las células NK desensibilizadas, eran incapaces de formar conjugados 
con células diana con la misma efi ciencia que las células control. Análisis de la expresión génica de 
las células NK tratadas con ionomicina, permiƟ ó idenƟ fi car diferencias en la expresión de múlƟ ples 
genes, siendo este perfi l génico disƟ nto a los descritos en otras células inmunes que han perdido su 
funcionalidad. El tratamiento de células NK recién purifi cadas de donantes sanos con ionomicina, les 
induce un estado de pérdida de respuesta similar al observado en células acƟ vadas. No obstante, estas 
células no recuperan totalmente su capacidad de degranular y de secretar IFN-γ en presencia de IL-
2; ni son capaces de responder a la esƟ mulación por CD16 de manera tan efi ciente como las células 
recién aisladas control.
El análisis de las células NK tratadas con ionomicina, muestra que esta estrategia puede ser un 
método efi caz para el estudio de la pérdida de función descrita en las células NK tras su esƟ mulación 
crónica. Aunque más experimentos serán necesarios para lograr entender completamente este estado, 
los datos descritos en esta tesis pueden ayudar a comprender mejor la biología de las células NK y su 
pérdida de función.
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Abbreviations
7-AAD 7-aminoacƟ nomycin d
ADCC Antobody dependant cell cytotoxicity
AICD AcƟ vaƟ on induced cell death
AINR AcƟ vaƟ on induced non responsiveness
ANOVA Analysis of variance 
APCs AnƟ gen presenƟ ng cells
APC Allophycocyanin
BCR B cell receptor
CD  Cluster of diferenƟ aƟ on
cDNA Complementary DNA
CFSE Carboxyfl uorescein succinimidyl ester
CMAC 7-amino-4-chloromethylcoumarin
cSMAC Central supramolecular acƟ vaƟ on cluster
Ct  Cycle threshold
CTLA4 Cytotoxic T-lymphocyte anƟ gen 4
DMEM Dulbecco modifi ed eagle medium
DMSO Dimethyl sulfoxide
dNK Decidual NK cells
DR4 Death receptor 4
DTT Dithiothreitol
e.g. Exempli graƟ a – For example
E:T  Eﬀ ector :  target
EGTA Ethylene glycol tetra-aceƟ c acid
ERM Ezrin/radixin/moesin 
EtOH Ethanol
FACS Fluorescent-acƟ vated cell sorter
F-acƟ n Filamentous acƟ n 
Fas-L Fas-ligand
FBS Fetal bovine serum
Fc  AnƟ body crystallizable region
FcγR  Fcγ receptor
FDR False discovery rate
Fig. Figure
FITC Fluorescein isothiocyanate
fNK Freshly isolated NK cells
GAM Goat anƟ  mouse
GAR Goat anƟ  rabbit
GM-CSF Granulocyte macrophage colony sƟ mulaƟ ng factor
HBSS Hank's balanced salt soluƟ on
HCST HematopoieƟ c stem cell transplantaƟ on
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
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Abbreviations
HIV Human immunodefi ciency virus
HLA Human leukocyte anƟ ge
HPCs HematopoieƟ c progentor cells
HRP Horseradish peroxidase 
HS  Human serum
ICAM Intercellular adhesion molecule
IDO Indoleamine-pyrrole 2,3-dioxygenase
IFN Interferon
IL  Interleukin
IL-12R Interleukin 12 receptor
IL-18R Interleukin 18 receptor
IL-18RAP Interleukin 18 receptor adaptor molecule
IP3  Inositol 1,4,5-trisphosphate
ITAM Immunoreceptor tyrosine-based acƟ vaƟ on moƟ f
ITIM Immunoreceptor tyrosine-based inhibiƟ on moƟ f
KIR Killer-cell immunoglobulin-like receptor
Lamp1 Lysosomal-associated membrane protein 1
LFA-1 Lymphocyte funcƟ on-associated anƟ gen 1
mAbs Monoclonal anƟ body
MAPK Mitogen-acƟ vated protein kinase
MCMV Mouse cytomegalovirus
MDSCs Myeloid-derived suppressor cells
MFI Mean fl uorescence intensity
MHC Mayor histocompaƟ bility complex
MIF Macrophage migraƟ on inhibitory factor
min Minutes
MOPC Mouse igg1 kappa isotype anƟ body
mRNA Messenger RNA
MTOC Microtubule organizing center
n.s. Non signifi caƟ ve
NCAM Neural cell adhesion molecule
NCR Natural cytotoxicity receptor
NFAT Nuclear factor of acƟ vated T-cells
NK  Natural Killer cell
NKT Natural Killer T cell
p  P-value 
PAMP Pathogen associated molecular paƩ ern
PBMC Peripheral blood mononuclear cells
PBS Phosphate buﬀ ered saline
PCR Polymerase chain reacƟ on
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Abbreviations
PD-1 Programmed death 1
PE  Phycoerythrin
PFA Para-formaldehyde
PGE2 Prostaglandin E2
PI  Propidium iodide
PKC Protein kinase C
PMA Phorbol ester 12, 13-dibutyrate 
pSMAC Peripheral supramolecular acƟ vaƟ on cluster
PVDF Polyvinylidene fl uoride
qPCR QuanƟ taƟ ve PCR
RasGRP RAS guanyl nucleoƟ de-releasing protein
rhIL Recombinant human interleukin
RNA Ribonucleic acid
RPMI Roswell Park Memorial InsƟ tute medium 
RQ  RelaƟ ve quanƟ ty
RT  Room temperature
RT-PCR Real Ɵ me-PCR
SD S tandard deviaƟ on
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SOCs Store-operated Ca2+ channels 
TBS Tris buﬀ er soluƟ on
TCR T cell receptor
TGF-β Transforming growth factor β
TILN Tumour infl iltraƟ ng lymph nodes
TLRs Toll like receptors
TNF-a Tumour necrosis factor α
TRAIL TNF-related apoptosis-inducing ligand
U  Units
vs.  versus
WT Wild type
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Introduction
1. Natural Killer cells
Organisms have evolved a powerful collecƟ on of defense mechanisms collecƟ vely known as the 
immune system to protect themselves against harmful environmental agents foreign to their body. 
The immune system must be competent to specifi cally recognize pathogens and provide eﬀ ecƟ ve 
protecƟ on, and at the same Ɵ me, it must have the ability to self-regulate to minimize autoimmunity, 
and further to generate an immunological memory. First the innate immune response and later the 
adapƟ ve response will ensure the eradicaƟ on of infected or transformed cells, and the establishment 
of memory.
Natural killer cells (NK) are part of the immune system which were described for the fi rst Ɵ me in 
1975 (Herberman et al. 1975; Kiessling et al. 1975) as large granular lymphocytes able to spontaneously kill certain 
target cells in vitro without any prior sensiƟ zaƟ on. They have been classifi ed as part of the innate 
immune system due to their ability to mediate a rapid response on exposure to an infecƟ ous organism 
in the absence of prior anƟ genic sƟ mulaƟ on, and for not being a response mediated by anƟ gen-specifi c 
receptors. However, nowadays, it is also known that they share properƟ es with adapƟ ve responses such 
as clonal expansion, the generaƟ on of long-lasƟ ng immunologic memory, the need to be “educated” 
or “licensed”, the requirement of priming for fully responsiveness, or their ability to shape adapƟ ve 
responses (Sun et al. 2009; Vivier et al. 2011).
1.1 Origin and education of human NK cells
Natural killer cells are the third largest lymphoid cell populaƟ on and represent between 10 and 15% 
of the lymphocytes in peripheral blood (Cooper et al. 2001). They share a CD34+ hematopoieƟ c progenitor 
with T and B lymphocytes (Miller et al. 1994; Galy et al. 1995) however; some studies report that NK cells can also 
be generated from myeloid progenitors (Grzywacz et al. 2010). NK cell development starts in the fetal liver, 
but aŌ er birth it occurs mainly in the bone marrow (Haller et al. 1977), although lymph nodes, the thymus, 
the gut and the liver are also sites of NK cell development (Freud et al. 2005; Di Santo and Vosshenrich 2006; Chinen et 
al. 2007; Wu et al. 2012). NK cell maturaƟ on requires extrinsic regulaƟ on by other immune cells as dendriƟ c 
cells, monocytes and neutrophils, which provide maturaƟ on and survival signals that sustain their 
diﬀ erenƟ aƟ on towards a mature NK cell (Soderquest et al. 2011; Ganal et al. 2012; Jaeger et al. 2012). 
The diﬀ erent stages of NK cell lineage commitment, maturaƟ on and funcƟ on are regulated by 
many transcripƟ on factors including E4BP4, ID2, BLIMP1, Eomes, ETS-1, HELIOS, KLF4, T-bet, or TOX 
(Ramirez and Kee 2010; Hesslein and Lanier 2011; Luevano et al. 2012; Cichocki et al. 2013; HunƟ ngton et al. 2013), and progress of the 
maturing NK cell through the diﬀ erent developmental stages has been correlated with the sequenƟ al 
acquisiƟ on of diﬀ erent cell surface receptor proteins such as c-kit (CD117), CD56, CD16, CD11b, CD25, 
CD57, CD94 or CD62-L (HunƟ ngton et al. 2007).
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NK cells display a heterogeneous array of cell surface receptors, and signals from these receptors 
allow them to maintain self-tolerance and diﬀ erenƟ ate between normal cells and stressed/transformed 
or infected cells. NK cells determine if a cell should be considered a target or not, depending on the 
balance of signals originated from the many diﬀ erent acƟ vaƟ ng and inhibitory receptors expressed 
by these cells (Vivier et al. 2004). For example if a putaƟ ve target cell expresses low levels of self-major 
histocompaƟ bility complex (MHC) class I molecules, then there will be a dominance of acƟ vaƟ ng signals 
over inhibiƟ on; similarly, if there is an increased expression of acƟ vaƟ ng ligands, but not inhibitory 
ligands, then the acƟ vaƟ on threshold will also be exceeded leading to acƟ vaƟ on (Raulet and Vance 2006) 
(Scheme 1). Given that some of the ligands of acƟ vaƟ ng receptors are self–molecules which normally 
are expressed at low levels (Long and Rajagopalan 2002), this fi ne tuning implies that NK cells have to undergo 
an educaƟ on process that selects for those cells able to disƟ nguish between healthy and stressed cells, 
allowing them to adapt their eﬀ ector capacity to their host (Shafi  et al. 2011). During this educaƟ on process 
NK cells acquire receptor expression, the self-tolerance property, but also their eﬀ ector funcƟ on license. 
To date, there is sƟ ll no consensus about how NK cells acquire their educaƟ on, and diﬀ erent theories 
are sƟ ll being discussed (Raulet and Vance 2006). However, all models proposed for NK cell licensing agree on 
an important role for the interacƟ on between MHC class I molecules and the inhibitory receptors on 
NK cells during this process (Hoglund and Brodin 2010).
Most human NK cell clones express at least one inhibitory receptor which is acquired stochasƟ cally, 
and which recognizes self-MHC class I proteins (Valiante et al. 1997), but around 13% +/- 6% of circulaƟ ng 
NK cells in an MHC suﬃ  cient host don’t express any inhibitory receptor able to interact with self MHC 
class I (Anfossi et al. 2006). These cells, instead of being eliminated like thymocytes that cannot engage their 
TCRs with self-MHC class I molecules, are maintained, but they exhibit weaker cytolyƟ c and cytokine 
producƟ on abiliƟ es aŌ er in vitro sƟ mulaƟ on through several acƟ vaƟ ng receptors (Fernandez et al. 2005; Kim 
et al. 2005; Anfossi et al. 2006; Yu et al. 2007). However, these hyporesponsive NK cells are able to respond robustly 
in case of viral (Tay et al. 1995; Polic et al. 1996; Sun and Lanier 2008; Orr et al. 2010), bacterial (Fernandez et al. 2005), protozoal 
infecƟ on (Denkers et al. 1993), PMA-Ionomycin sƟ mulaƟ on (Fernandez et al. 2005), IL-2 culture (Johansson et al. 1997), IL-12 
plus IL-18 sƟ mulaƟ on (Yokoyama and Kim 2006), or transplantaƟ on (Yu et al. 2009).
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CirculaƟ ng hyporesponsive NK cells are also found in MHC defi cient human paƟ ents, although the 
recovery of their funcƟ onality aŌ er sƟ mulaƟ on with cytokines is controversial (Zimmer et al. 1998; Furukawa et 
al. 1999; Vitale et al. 2002). InteresƟ ngly, both educated and hyporesponsive NK cells in mice express a mature 
phenotype in the periphery (Fernandez et al. 2005), indicaƟ ng that their educaƟ on most likely occurs aŌ er the 
achievement of a mature stage. In humans the hyporesponsive cells are also similar to normal NK cells 
in cell-surface phenotype, perforin and granzyme content, and ability to respond to PMA-Ionomycin, 
however lower levels of inhibitory receptors, DNAM1 and a reduced size of the CD56bright subset has 
been reported (Vitale et al. 2002; Anfossi et al. 2006). NK cells that develop in an MHC class I defi cient host do not 
exhibit autoreacƟ vity (Zimmer et al. 1998; Furukawa et al. 1999; Vitale et al. 2002), although recurrent bacterial infecƟ ons 
and chronic infl ammaƟ on have been described in TAP2 (AnƟ gen pepƟ de transporter 2) defi cient 
paƟ ents (Vitale et al. 2002). Thus, MHC class I expression in the environment regulates NK cell funcƟ on and 
those cells that don’t fulfi ll the requirement for expression of an inhibitory receptor for self MHC class 
I are allowed to seed the periphery, but calibrated to be not funcƟ onally competent (unlicensed), 
Scheme 1: NK cell acƟ vaƟ on. NK cells express diﬀ erent acƟ vaƟ ng and inhibitory receptors, which allow them to 
disƟ nguish between healthy cells, which express inhibitory ligands; and transformed cells, which show an altered 
expression of acƟ vaƟ ng or inhibitory ligands. The balance between the signals coming from acƟ vaƟ ng and inhibi-
tory receptors will determine if the NK cell becomes acƟ vated or not. Diﬀ erent scenarios can acƟ vate NK cells: 
appearance of non-self acƟ vaƟ ng ligands, increased expression of self acƟ vated ligands, decreased expression of 
inhibitory ligands or opsonized target cells.
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although able to respond under certain circumstances. InfecƟ on and infl ammaƟ on have been shown 
to sƟ mulate licensed and unlicensed NK cells in a similar way, and unlicensed NK cells can respond even 
more strongly, as shown in MCMV infecƟ on (Orr et al. 2010) (although this acƟ vity is controversial (Sungur et al. 
2013)), and in ADCC. Indeed, in this context unlicensed NK cells could react beƩ er against tumour cells 
precisely because they are not inhibited by self-MHC class I, suggesƟ ng a novel therapeuƟ c approach 
for use in neuroblastoma (Tarek et al. 2012) and demonstraƟ ng the potenƟ al funcƟ onality of unlicensed NK 
cells when the restricƟ on to respond is overridden. 
NK cell responsiveness is not an on/oﬀ  situaƟ on, instead it is thought to be gradual, as NK cells 
that express more inhibitory receptors for self MHC class I, are also more responsive (Yu et al. 2007; Brodin et 
al. 2009; Joncker et al. 2009), and hosts that express diﬀ erent MHC class alleles also generate greater responses 
(Johansson et al. 2005). This implies that each NK cell is going to undergo a tuning process depending on the 
number and type of inhibitory receptors, the strength of the engagement, the sƟ mulatory receptors 
expressed, and the ligands expressed by the host, establishing a threshold or set point, and the 
signaling necessary for response is going to vary depending on the cell (Joncker et al. 2009). Importantly, 
the engagement of only one inhibitory ligand for each NK cell clone, despite the expression of mulƟ ple 
diﬀ erent inhibitory receptors, is suﬃ  cient to inhibit the NK cell response (Yu et al. 2007). 
This threshold is not fi xed during development, and mature NK cells can also ‘tune’ their capability 
to react. This was fi rst demonstrated by Johansson et al, in mice with mosaic expression of MHC class 
I (Johansson et al. 1997), and also in experiments where mature WT NK cells were transferred into mice 
consƟ tuƟ vely expressing an acƟ vaƟ ng ligand (Tripathy et al. 2008). Later this plasƟ city or recalibraƟ ng ability 
has been further demonstrated. When NK cells generated in MHC class I defi cient mice are placed in 
an MHC class I-suﬃ  cient seƫ  ng, they are able to readapt and don’t cause autoimmunity to their new 
host, and in the same manner, funcƟ onal mature NK cells lose their eﬀ ector capabiliƟ es when placed 
in an environment devoid of MHC class I molecules (EllioƩ  et al. 2010; Joncker et al. 2010).
Further support for this model of constant educaƟ on and tuning of NK cells, comes from studies 
in human leukemia where KIR mismatched hematopoieƟ c stem cell transplantaƟ on (HSCT) is used. 
Normally HSCT consist of a graŌ  depleted in T and B cells, where mature NK cells and hematopoieƟ c 
progenitors cells are transferred into the paƟ ent. During the fi rst months aŌ er transplant, the presence 
of mismatched NK cells expressing KIRs not adapted for the donor favours the eliminaƟ on of host 
leukemic cells, host APCs and exacerbated T cells that could cause graŌ  versus host disease. Indeed, not 
only licensed NK cells are alloreacƟ ve in this seƫ  ng, but non-licensed NK cells also become reacƟ vated 
(Hsu et al. 2005; Yu et al. 2009). However, this NK cell alloreacƟ vity disappears approximately 3 months aŌ er 
transplant, when the circulaƟ ng NK cell pool begins to represent mainly reconsƟ tuted cells, and the 
new NK cells, generated from the CD34+ progenitors, became tolerant, not for the HLA they express, 
but for the HLA of their new host (Ruggeri et al. 1999; Ruggeri et al. 2002; Babor et al. 2013).
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KIR/MHC class I interacƟ ons are not the only factors able to shape NK cell response. ConsƟ tuƟ ve 
expression of NKG2D ligands (Oppenheim et al. 2005; Wiemann et al. 2005) or m157 (Sun and Lanier 2008; Tripathy et al. 2008; 
Mazumdar et al. 2013), an MCMV encoded ligand for the murine Ly49H acƟ vaƟ ng receptor, renders NK cells 
from these mice hypofuncƟ onal for sƟ mulaƟ on via these, and other, receptors (Sun and Lanier 2008; Tripathy 
et al. 2008), insensiƟ ve to IL-12 plus IL-18 sƟ mulaƟ on (Tripathy et al. 2008) and reduces either the number of 
receptor posiƟ ve cells (Sun and Lanier 2008; Tripathy et al. 2008) or induces a downregulaƟ on of the receptor 
(Oppenheim et al. 2005; Wiemann et al. 2005). In the m157 model it was shown that this hyporesponsiveness was 
reversible in the WT NK cells when they were sƟ mulated with IL-2, but not in m157 expressing NK 
cells because of conƟ nuous cis interacƟ on (Tripathy et al. 2008), although both WT and m157 expressing NK 
cells were funcƟ onal when sƟ mulated with PMA/Ionomcycin (Tripathy et al. 2008). In the case of transgenic 
mice consƟ tuƟ vely expressing NKG2D ligands, the higher complexity of the system due to the possible 
role for soluble ligands, and their eﬀ ects on NK cells and CD8+ T cells expressing NKG2D, weakens the 
conclusions. However in experiments done in vitro where NK cells are cultured with targets expressing 
NKG2D ligands for three days, the interacƟ on is able to shut down NK cell responses mediated not only 
by NKG2D but also via other receptors (Coudert et al. 2005; Coudert et al. 2008). This role of acƟ vaƟ ng receptors in 
educaƟ on has also been shown in humans where NK cells expressing the acƟ vaƟ ng receptor KIR2DS1 
are ineﬃ  cient if derived from donors bearing its ligand HLA-C2 (Fauriat et al. 2010). In agreement with these 
observaƟ ons it has also been described that mice defi cient in either the acƟ vaƟ ng receptor NKp46 
(Narni-Mancinelli et al. 2012), or in NKG2D (Zafi rova et al. 2009) generate hyperacƟ vated NK cells, demonstraƟ ng that 
acƟ vaƟ ng receptors interacƟ on with their endogenous ligands, is also associated with downmodulaƟ on 
of NK cell responsiveness. Overall these data imply that acƟ vaƟ ng ligands expressed in the bone 
marrow also collaborate in NK cell educaƟ on, shaping their responsiveness to their host, and that 
these cells able to recognize the ligand, instead of being deleted, analogous to the eliminaƟ on of 
thymocytes that have high aﬃ  nity for self-pepƟ de-MHC complexes, are rather maintained, but in a 
hyporesponsive state.
This educaƟ on process confers to NK cells the properƟ es of being tolerant to self and reacƟ ve to 
non-self, but also ensures the plasƟ city of their responsiveness thanks to a dynamic evaluaƟ on of the 
environment that occurs during the enƟ re lifeƟ me of the NK cell. The mechanisms involved are not 
well understood, but educaƟ on and diﬀ erenƟ aƟ on are uncoupled processes, since uneducated NK cells 
are able to diﬀ erenƟ ate and proliferate, maintaining their cytotoxic potenƟ al under control (Bjorkstrom 
et al. 2010). These results also suggest that NK cells may end-up deregulated and in a hyporesponsive 
state aŌ er excessive exposure to their ligands, which could be overcome if the pro-infl ammatory 
environment persists. 
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1.2 Functions of NK cells
NK cell are involved in both innate and adapƟ ve immune responses. They are able to parƟ cipate 
in an early response as they can directly eliminate virally infected or transformed cells through target-
cell lysis, but they can also exert a range of other funcƟ ons including the recruitment of other innate 
immune cells such as neutrophils and macrophages, the acƟ vaƟ on or eliminaƟ on of dendriƟ c cells, 
and the priming of adapƟ ve lymphocytes (T or B cells) through the release of soluble factors. Thus 
NK cells can act to integrate innate and adapƟ ve responses that will act in concert. They also have 
important roles in pregnancy (Moﬀ eƩ  et al. 2004) immune homeostasis (Flodstrom-Tullberg et al. 2009), and can display 
long lasƟ ng memory (Vivier et al. 2008).
There is increasing evidence that this versaƟ lity is possibly due to the existence of disƟ nct NK-cell 
subsets. These may represent diﬀ erent lineages of NK cells, for example uterine NK cells represent 
a very specialized subset of NK cells which express a unique set of receptors and funcƟ ons (Moﬀ eƩ -King 
2002). Also, other populaƟ ons as liver NK cells which appeared to originate from hepaƟ c hematopoieƟ c 
progenitor cells (HPCs) but not from the bone marrow (Peng et al. 2013); and a subpopulaƟ on of IL-22 
producing NK cells dependant on the RORγT transcripƟ on factor, instead of E4BP4, and which are 
found mainly in mucosal Ɵ ssues has also been described (Cella et al. 2009). Classically NK cells have been 
divided between CD56dim - CD16bright cells, which are mainly cytotoxic cells and respond beƩ er to target-
cell expressed ligands, and CD56bright - CD16-/CD16dim cells which are potent secretory cells and respond 
more quickly to IL-12 or IL-15 triggering (Jacobs et al. 2001). A subset of CD56-CD16+ cells is also found in 
blood of healthy individuals. These CD56- cells possess lower killing and cytokine producƟ on abiliƟ es 
than CD56+ cells, and were found expanded in chronic HIV and hepaƟ Ɵ s C infecƟ on, following allogenic 
hematopoieƟ c transplantaƟ on and in cord blood (Bjorkstrom et al. 2010). The majority of NK cells in circulaƟ on 
(90%) are CD56dim cells, while in secondary lymph Ɵ ssues the NK cell populaƟ on is primarily CD56bright 
(Vosshenrich et al. 2006).
To exert their funcƟ ons, mature resƟ ng NK cells need priming from cytokines (Trinchieri 1995; Chaix et al. 
2008) or other immune cells (Ganal et al. 2012), but tumor cells (North et al. 2007) or exosomes (Reiners et al. 2013) have 
also been proposed to be able to provide these signals.
Natural killer cells carry out their funcƟ ons through two major eﬀ ector mechanisms. The fi rst 
described, and the one for which they are named, is their cytotoxic role. However, NK cells are also 
potent regulators of innate and adapƟ ve immune system responses due to their ability to secrete a 
range of diﬀ erent cytokines and chemokines.
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Among the cytokines produced by NK cells can be found pro-infl ammatory cytokines such as 
IFN-γ, TNF-α or IL-6; immunosuppressive cytokines including IL-10, IL-13 or TGF-ß,  growth factors 
such as GM-CSF, G-CSF, IL-3; and a range of diﬀ erent chemokines including XCL1, CCL1, CCL2, CCL3, 
CCL4, CCL5, CCL8, CCL17, CCL26, CXCL8, CXCL16, XCL1 or CXCL8 (Souza-Fonseca-Guimaraes et al. 2012). ResƟ ng 
NK cells contain preformed IFN-γ mRNA (De Maria et al. 2010), and are an important early source of this 
infl ammatory cytokine. IFN-γ producƟ on by NK cells is known to shape the Th1 immune response, 
acƟ vate APCs to upregulate expression of MHC class I and class II molecules, acƟ vate macrophage 
killing of intracellular pathogens, and have anƟ proliferaƟ ve eﬀ ects on viral and malignant transformed 
cells (Schroder et al. 2004; Strowig et al. 2008). Natural killer cells can also secrete other immune mediators as nitric 
oxide (NO), indoleamine 2,3-dioxygenase (IDO) or α-defensins (Souza-Fonseca-Guimaraes et al. 2012).
NK cell cytotoxicity, and the inducƟ on of target cell apoptosis, depends on two diﬀ erent pathways: 
the granule exocytosis pathway and the death receptor pathway. Experiments done at the single cell 
level have shown that most mature NK cells are unable to directly exert ‘natural’ cytotoxicity in isolaƟ on, 
highlighƟ ng their need to be primed for eﬃ  cient killing (Guldevall et al. 2010; Christakou et al. 2013). ResƟ ng NK cells 
contain preformed specialized secretory lysosomes that upon target cell recogniƟ on are polarized and 
rapidly exocytosed, so that they secrete their content into the site of contact between the NK cell and 
the target cell, the immune synapse. The components of these cytotoxic granules include the proteases 
granzymes (A, K, B, H, M), pore forming protein perforin, Fas ligand (FasL), TRAIL, granulysin, cathepsin, 
cathelicidin and defensins 1-3 (Krzewski and Coligan 2012) and cause caspase dependent and independent 
apoptosis of the target cell.
The death receptor pathway involves the secreƟ on of FasL, TNF-α or TRAIL. Similar to the granule 
exocytosis method, upon sƟ mulaƟ on and synapse formaƟ on these ligands are polarized and secreted 
resulƟ ng in a caspase-dependent apoptosis of the target cell (Vujanovic et al. 1996; Wallin et al. 2003; Smyth et al. 2005). 
NK cells are also able to augment the expression of death receptors on target cells through the release 
of IFN-γ (Siegmund et al. 2005). 
These apoptosis mechanisms will ensure that in the case of viral infecƟ on, the viral load will be 
destroyed together with the target cell.
1.3 NK cell receptors
T or B cells populaƟ ons express a diverse set of anƟ gen-specifi c receptors, however each clone only 
expresses a single anƟ gen receptor. Unlike T and B lymphocytes, each NK cell displays a heterogeneous 
array of acƟ vaƟ ng and inhibitory cell surface receptors, which cooperaƟ vely makes them able to 
discriminate between normal or unhealthy cells depending on the balance of signals induced by them 
(Vivier et al. 2004). Some of these receptors are expressed in a stochasƟ c paƩ ern, resulƟ ng in many subsets 
of funcƟ onally disƟ nct NK cells. 
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NK express many diﬀ erent acƟ vaƟ ng receptors that allow them to recognize target cells through 
diﬀ erent strategies. With the excepƟ on of the CD16 receptor which is able to act alone, they act as 
coacƟ vaƟ ng receptors as they need to cooperate in order to elicit a response (Augugliaro et al. 2003; Bryceson et al. 
2006). This need for synergisƟ c acƟ vaƟ on, could serve as a mechanism of control for NK cells or as a way 
to detect and react to diﬀ erent targets and elicit diﬀ erent types of responses. Many of the acƟ vaƟ ng 
NK cell receptors recognize self-anƟ gens that under normal situaƟ ons are not expressed or expressed 
at low levels, as for example the NKG2D receptor which recognize MIC and ULBP molecules which are 
encoded in human genome, and can be upregulated aŌ er viral infecƟ on, genotoxic damage or tumor 
transformaƟ on, a strategy called stress induced self recogniƟ on (Mistry and O’Callaghan 2007) (Scheme 1). Other 
NK cell receptors are also able to directly recognize non self molecules as the NKp46 receptor which 
can recognize viral haemagluƟ nin (Arnon et al. 2001; Mandelboim et al. 2001). The low-aﬃ  nity Fc receptor CD16 
(FCγRIII), allow NK cells to detect opsonized cells and mediate anƟ body dependent cell cytotoxicity 
(ADCC) (Ojo and Wigzell 1978) (Scheme. 1). Most of these acƟ vaƟ ng receptors lack intracellular signaling 
moƟ fs. Instead, they associate noncovalently via a posiƟ vely charged residue (lysine or arginine) in the 
transmembrane with homo or heterodimeric signal-transducing adaptor molecules, that contain an 
aspartate residue in the transmembrane, and either one immunoreceptor tyrosine-based acƟ vaƟ ng 
moƟ f (ITAM) in the cytosol (FcεRγI and DAP12), three ITAMs (CD3-ζ) (Wirthmueller et al. 1992),  or the Tyr-Ile-
Met-Asn moƟ f of the adaptor DAP10 (Wu et al. 1999). Other molecules such as SAP can also act as signal-
transducing adaptors for NK cell acƟ vaƟ on (Meinke and Watzl 2013). AŌ er the engagement of the receptor, 
Src family protein tyrosine kinases became acƟ vated and phosphorylate the tyrosine residues of the 
ITAMs. This phosphorylaƟ on recruits and acƟ vate Syk or ZAP70 tyrosine kinases in the case of ITAM 
adaptors, or PI3-kinase and Grb2-Vav1 in the case of DAP10 (Lanier 2008).
Most of the inhibitory receptors expressed by NK cells recognize self MHC class I molecules: 
the NKG2A/CD94 heterodimer interacts specifi cally with non classical HLA-E (Lee et al. 1998) while the 
Killer-cell immunoglobulin-like receptors (KIRs) are specifi c for classical MHC class Ia ligands HLA-A, 
B and C (Wagtmann et al. 1995). The LILR genes ILT2 and ILT4 can bind both classical and non-classical HLA 
molecules including HLA-G, and –F (Navarro et al. 1999; Lepin et al. 2000). Thus loss of MHC Class I expression 
can lead to NK cell acƟ vaƟ on via loss of inhibiƟ on by MHC class I expression: the “missing-self” 
hypothesis (Scheme. 1). In this way NK cell acƟ vaƟ on by loss of MHC Class I is a complementary way 
of acƟ vaƟ on to that used by CD8+ T cells where the TCR posiƟ vely recognizes MHC class I molecules, 
acƟ ng as a synergic strategies for target cell recogniƟ on (Karre et al. 1986). The expression of KIR and CD94 
proteins occurs in a stochasƟ c manner, and each NK cell expresses its own repertoire of receptors 
(Valiante et al. 1997; Raulet et al. 2001). Further, since mulƟ ple alleles of KIR genes are present in the populaƟ on 
and the KIR locus also varies in the number of genes present (Suto et al. 1998; Parham 2005), a variegated 
diversity of inhibitory receptor expression is generated, with disƟ nct paƩ erns of reacƟ vity for each 
host. NK cells also express non-MHC inhibitory receptors such as KLRG1, TIGIT, Siglecs, LAIR-1, or 
CEACAM1 that bind a diverse set of ligands including cadherins, sialic acid or collagen. All the inhibitory 
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receptors in humans contain intracellular immunoreceptor tyrosine-based inhibitory moƟ fs (ITIM) in 
their cytoplasmic tail. Following inhibitory receptor interacƟ on with its ligand and crosslinking, the 
phosphorylaƟ on of tyrosine residues within the ITIM elements by Src family protein tyrosine kinases 
recruited to the synapse by acƟ vaƟ ng receptors (Blery et al. 1997), lead to the recruitment of cytoplasmic 
tyrosine phosphatases ‘SH2 domain-containing protein tyrosine phosphatase’ 1, or2 (SHP-1 or SHP-
2) (Vely et al. 1997) for KIR or CD94/NKG2A receptors, or the lipid phosphatase ‘SH2 domain-containing 
inositol phosphatase’ (SHIP) which acts as a 5’inositol phosphatase, in the case of 2B4, KLRG1 or TIGIT 
(Tessmer et al. 2007; Liu et al. 2012). Several signaling molecules involved in NK cell acƟ vaƟ on can be targets for 
SHP mediated dephosphorylaƟ on including Src kinases, ITAMs, Zap70, Syk, PLCγ, Vav, LAT, PI3’kinase or 
SLP76. In parallel to this dephosphorylaƟ on, ITIM-containing receptors also mediate phosphorylaƟ on 
events as the disrupƟ on of the signaling complex c-Cbl with CRK and C3G, by phosphorylaƟ on by 
c-Abl (Peterson and Long 2008). InhibiƟ on occurs very early aŌ er NK cell-target cell contact, prevenƟ ng the 
generaƟ on and propagaƟ on of acƟ vaƟ ng signals, rather than silencing them (Abeyweera et al. 2011).
Integrins, immunoglobulin superfamily receptors, selecƟ ns, cadherins and mucins comprise the 
fi ve major groups of cell adhesion molecules. Integrins are cell-surface transmembrane glycoproteins 
that are expressed as α-ß heterodimers and mediate mulƟ ple cell-cell and cell-matrix interacƟ ons. They 
are involved in survival/apoptosis, proliferaƟ on, cell-cycle progression, cell shape, polarity, adhesion, 
migraƟ on and diﬀ erenƟ aƟ on. Integrins exist in diﬀ erent conformaƟ onal states. Newly synthesized 
integrin arrives to cell surface in a “bent” or closed conformaƟ on. Upon acƟ vaƟ on by “inside-out 
signals” they change to an open conformaƟ on and form clusters (Luo et al. 2007). Finally, upon ligand 
binding, “outside-in signals” will lead to the fi nal acƟ vated conformaƟ on. To transmit their signals, ß2 
chain integrins associate with diﬀ erent molecules aŌ er phosphorylaƟ on of the ß2 chain or its cleavage 
by Cathepsin X (Hogg et al. 2011; Jevnikar et al. 2011). The importance of the ß2 chain in NK cell maturaƟ on and 
funcƟ on, migraƟ on (Crozat et al. 2011), and lyƟ c granule polarizaƟ on has been described; being the signalling 
through LFA-1 (αMß2 integrin) suﬃ  cient to induce granule polarizaƟ on, but not degranulaƟ on (Bryceson 
et al. 2010), and sƟ mulaƟ on with a ß2 chain acƟ vaƟ ng anƟ body is enough to increase killing (Sadhu et al. 2007). 
Integrins expressed by NK cells include LFA-1, Mac-1, LFA-3, VLA-4, VLA-5. Other adhesion molecules 
expressed by NK cells are PSGL-1, CD2, DNAM1, CD96, CD44, ICAM-1, L-selecƟ n (mainly expressed by 
CD56bright) and PEN5 (mainly expressed by CD56dim) (Farag and Caligiuri 2006).
Natural killer cells express consƟ tuƟ vely interleukin receptors. The CD56bright subset express the 
high aﬃ  nity IL-2 receptor together with c-kit, which enhances IL-2 induced proliferaƟ on. The CD56dim 
NK cells, in contrast, express only the low aﬃ  nity IL-2 receptor, and are c-kit-. NK cells also express 
receptors for IL-1, IL-10, IL-12, IL-15, IL-18, and in general higher levels of these receptors are found 
expressed by the CD56bright subset. Diﬀ erent chemokine receptors are also found in NK cells and these 
again are diﬀ erenƟ ally expressed between the CD56bright and CD56dim subsets (Inngjerdingen et al. 2001).
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The diﬀ erenƟ al expression of all these receptors between CD56dim and CD56bright subpopulaƟ ons 
infl uences how they respond to diﬀ erent sƟ muli, and their homing to lymphoid Ɵ ssues and sites of 
infl ammaƟ on (Cooper et al. 2001).
The importance of the nanoscale organizaƟ on of NK cell receptors was highlighted using 
superresoluƟ on microscopy in murine (Guia et al. 2011) and human (Pageon et al. 2013) NK cells. By analyzing the 
transit Ɵ me of acƟ vaƟ ng and inhibitory surface receptors through diﬀ erent volumes of educated and 
uneducated NK cells, Guia et al. demonstrated that NK cell receptors were diﬀ erenƟ ally restricted 
in their movement at the cell surface. AcƟ vaƟ ng receptors were confi ned in nanodomain structures 
favorable for signaling, while inhibitory receptors were trapped by the acƟ n meshwork structures. 
However, when these experiments were repeated in uneducated NK cells, taken from mice defi cient in 
MHC class I, acƟ vaƟ ng and inhibitory receptors were both confi ned together by the acƟ n meshwork. 
In complementary experiments Pageon et al., studied the organizaƟ on of inhibitory receptors, and 
how acƟ vaƟ on of the NK cell through NKG2D infl uences the clustering of KIR2DL1 mediated by acƟ n 
cytoskeleton. These arƟ cles demonstrate the existence of crosstalk between acƟ vaƟ ng and inhibitory 
receptors on their membrane localizaƟ on and suggest a mechanism for signal integraƟ on and control 
of NK cell acƟ vaƟ on.
1.4 The NK cell killing process
The killing of target cells by NK cells is a rapid, mulƟ -step process that occurs in sequenƟ al stages 
beginning with iniƟ al adhesion and conƟ nuing all the way to the directed release, or not, of cytolyƟ c 
granules (Orange et al. 2003). Normally, NK cell acƟ vaƟ on in vivo depends on the coordinated acƟ on of 
various receptors with acƟ vaƟ ng potenƟ al (Bryceson et al. 2006; Kim et al. 2010), although signalling through CD16 
alone can result in granule release if suﬃ  cient sƟ mulaƟ on is given, while sƟ mulaƟ on of LFA-1 by itself 
can induce polarizaƟ on (Bryceson et al. 2005). ResƟ ng NK cells contain preformed lyƟ c granules, so the enƟ re 
cytolyƟ c process must be very Ɵ ghtly regulated at the diﬀ erent check points during the killing steps. 
In vitro experiments have shown that NK cells can form an eﬀ ecƟ ve cytolyƟ c synapse against one 
target cell, while simultaneously receiving inhibitory sƟ mulaƟ on from other sites (Eriksson et al. 1999) so 
signals from inhibitory and acƟ vaƟ ng synapses are spaƟ ally restricted to one area.
Following the fi rst contact that is mainly stabilized by the interacƟ on of L-selecƟ ns, integrins and 
CD2 with the suscepƟ ble target cell, when the integraƟ on of signals from acƟ vaƟ ng and inhibitory 
receptors results posiƟ ve, diﬀ erent molecular reorganizaƟ on steps take place, which will allow the 
formaƟ on of an immune synapse. The NK cell stops and spreads, and LFA-1 and Mac-1 segregate 
forming a peripheral supramolecular acƟ vaƟ on cluster (pSMAC) creaƟ ng a fi rm conjugate between 
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both cells, and generaƟ ng iniƟ al acƟ vaƟ on signals. Subsequently other molecules such as talin, ezrin-
radixin-moesin, and Wasp polarize to the pSMAC. All these signals induce acƟ n polymerizaƟ on and 
the accumulaƟ on of fi lamentous acƟ n at the pSMAC. At the same Ɵ me, acƟ vaƟ ng receptors in lipid 
raŌ s plaƞ orms cluster and accumulate in the central supramolecular acƟ vaƟ on cluster (cSMAC) where 
their synergisƟ c interacƟ ons potenƟ ate signaling leading to the recruitment of signal transducƟ on 
molecules. These signals from the pSMAC and the cSMAC synergize to contribute to polarizaƟ on of 
the MTOC and lyƟ c granules. The cSMAC also plays roles in receptor synergy, receptor degradaƟ on and 
signal terminaƟ on (Cemerski et al. 2008).
LyƟ c granules move along microtubules towards the MTOC thanks to dynein-dynacƟ n motors, 
and then translocate with the MTOC toward the immunological synapse. Once the MTOC polarizes to 
the site of contact it get anchored at the plasma membrane, and lyƟ c granules have to travel through 
hypodense regions of the corƟ cal acƟ n network helped by the myosin IIA motor protein and kinesin, 
and the acƟ on of diﬀ erent docking and priming proteins. Finally lyƟ c granules fuse with the plasma 
membrane of the immune synapse in a process mediated by proteins of the SNARE family. The fusion 
with the membrane will create a pore allowing the secreƟ on of the granule content. ParƟ al fusion 
has also been described causing minimal secreƟ on. Not all of the lyƟ c granules are secreted at once, 
allowing NK cells to carry out serial target cell killing, and this might be due to the lower penetrability 
of the corƟ cal acƟ n area that limits the number of granules that can be exocytosed (Rak et al. 2011). AŌ er 
the killing of the target cell, the NK cell detaches and the immunological synapse is disassembled. 
If the balance of signals is negaƟ ve, spreading and stop signals will not be generated, KIR receptors 
will cluster to the cSMAC, while adhesion molecules polarize to the pSMAC. With Ɵ me inhibitory 
receptors disperse in the immunological synapse, while adhesion molecules polarize to the center. 
Finally both cells detach and the inhibitory immune synapse becomes disrganised. FormaƟ on of 
the inhibitory synapse is not associated with the accumulaƟ on of fi lamentous acƟ n and lipid raŌ  
polarizaƟ on.
Although these general characterisƟ cs are now well established (Krzewski and Strominger 2008; Orange 2008; 
Krzewski and Coligan 2012; Vanherberghen et al. 2013), many quesƟ ons sƟ ll remain unanswered about the details of the 
NK cell killing process, and for example, analyses at the single cell level showed a very high variability 
between diﬀ erent NK cells from the same donor (Vanherberghen et al. 2013).
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2. Immune evasion strategies
The fact that immunocompetent individuals may develop cancer, or suﬀ er infecƟ ons, implies that 
the immune system does not always succeed in its mission, and while organisms evolve beƩ er defense 
strategies, pathogens and tumors are also able to generate new escape manieuvers in response to 
the selecƟ ve pressure imposed by the immune system. Indeed, this escape from immunosurveillance 
has been proposed as another hallmark, or biological capability, acquired during the development 
of tumors (Hanahan and Weinberg 2011). Evasion mechanisms are very diverse, varying from passive to highly 
aggressive strategies and include dormancy, the use of immune-privileged regions, secreƟ on of 
molecules to alter immune responses or alteraƟ on of anƟ gen display. This anƟ -immune response can 
also aﬀ ect directly the immune system causing immunosuppression and allowing the appearance of 
opportunisƟ c diseases.
2.1 NK cell evasion
NK cell evasion mechanisms generated by virus and tumor cells can be divided in two groups: Those 
able to mask transformed or infected cells, and those that aﬀ ect directly the NK cell and modulate its 
response. This diverse panel of mechanisms highlights the importance of NK cell funcƟ on in driving 
protecƟ on against tumors and pathogens.
In the group of strategies that involve making the altered cells “invisible”, changing their phenotype 
to avoid NK cell recogniƟ on, are found changes in the repertoire of ligands exposed by cell; the 
upregulaƟ on of classical MHC class I molecules or homologues (Beck and Barrell 1988; Classen et al. 2003; Balsamo et 
al. 2012) or the decrease of acƟ vaƟ ng receptor ligands by shedding (Raﬀ aghello et al. 2004; Kaiser et al. 2007; Ashiru et 
al. 2010; Reiners et al. 2013), sequestering them inside the cell (Dunn et al. 2003; Fuertes et al. 2008), targeƟ ng them for 
degradaƟ on (Nejentsev et al. 2008), by expressing diﬀ erent microRNAs (KrmpoƟ c et al. 2002; Stern-Ginossar et al. 2008) or by 
cytokines secreted by tumor-infi ltraƟ ng infl ammatory cells (Mishra et al. 2013). 
Those mechanisms that directly aﬀ ect NK cell funcƟ on include the secreƟ on of acƟ vaƟ ng receptor 
antagonists that will cause the loss of expression of the acƟ vaƟ ng receptor (Groh et al. 2002), the blocking of 
Ca2+ channels that will block the acƟ vaƟ on signal (Zocchi et al. 1998), the secreƟ on of chemokine or cytokine 
inhibitors (Inngjerdingen et al. 2001), the acƟ vaƟ on of T regulatory cells that will control NK cell proliferaƟ on 
and cytotoxicity (Ghiringhelli et al. 2005), tumor microenvironment hypoxia (Sarkar et al. 2013), or the secreƟ on of 
soluble factors as IL-10 (D’Andrea et al. 1993), TGF-ß (Lee et al. 2004; Wilson et al. 2011), PGE2 (Pietra et al. 2012), MIF (Krockenberger 
et al. 2008; Reiners et al. 2013), IDO (Pietra et al. 2012), viral hemaggluƟ nin (Mao et al. 2010), tumor derived mucins (Zhang et 
al. 1997; Patankar et al. 2005) or L-Kynurenine (Della Chiesa et al. 2006). It has also been proposed, that NK cells can be 
converted into immunosuppressive MDSCs by tumor-derived GM-CSF (Kang et al. 2013).
Apart from this immunoinhibitory tumor microenvironment, another evasion strategy that has 
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been proposed is the induced hyporesponsiveness of NK cells (Hoglund and Brodin 2010) or “split anergy” (JeweƩ  
and Tseng 2011). However, cells in split anergy have been described to show increased cytokine producƟ on 
(induced by CD16 and IL-2) (JeweƩ  and Tseng 2011).
The fi rst in vitro experiments of target induced NK cell hyporesponsiveness trying to understand 
the nature of unresponsive NK cells were performed by Brahmi  et al. in 1985 (Brahmi et al. 1985), where 
they showed that aŌ er interacƟ on with target cells during 4 hours, NK cells lost their lyƟ c potenƟ al 
towards the same or other target cells. Moreover, they also concluded that this NK cell inacƟ vaƟ on was 
independent of calcium, as inacƟ vaƟ on can be induced also in the presence of EGTA supplemented 
with Mg2+., although cell-cell contact and intracellular Ca2+ pools were necessary. This arƟ cle, and 
the following ones published by Z.Brahmi et al, represents the fi rst eﬀ ort to study induced NK cell 
unresponsiveness. They described that cell-cell contact was necessary for inducing hyporesponsiveness, 
and it caused also lost of the NK cell ability to mediate ADCC (Abrams and Brahmi 1988). However, the ability 
of unresponsive NK cells to form conjugates was maintained. They also showed that NK cells parƟ ally 
recovered their cytolyƟ c acƟ vity aŌ er treatmentwith IFN-ß, and completely on exposure to IL-2 (Abrams and 
Brahmi 1986). Unresponsive NK cells were not able to inhibit fresh NK cells (Xiao and Brahmi 1989). Phenotypically 
they only found an increase of CD11b expression (Abrams and Brahmi 1988) and biochemically they observed 
weak PKC translocaƟ on (Shenoy and Brahmi 1991) and no phosphaƟ dylinositol turnover (Gibboney et al. 1992) in K562 
induced unresponsive NK cells. Moreover, they also described an induced downregulaƟ on of perforin 
and granzyme mRNAs (Bajpai et al. 1991).
Since this work, many arƟ cles have described examples of NK cell hyporesponsiveness. These 
include, in vitro experiments where NK cells are incubated for prolonged Ɵ mes with target cells (JeweƩ  
and Bonavida 1995; JeweƩ  and Bonavida 1996; Coudert et al. 2005; Oppenheim et al. 2005; Wiemann et al. 2005; Roda-Navarro et al. 2006; Balsamo 
et al. 2009; Hasenkamp et al. 2010; Johann et al. 2010; Gill et al. 2012), transgenic mouse models where there is conƟ nuous 
expression of ligands for NK cell acƟ vaƟ ng receptors (Oppenheim et al. 2005; Tripathy et al. 2008; Bolanos and Tripathy 2011; 
Mazumdar et al. 2013), in NK cells isolated from paƟ ents with diﬀ erent types of cancer (Hersey et al. 1979; Neri et al. 
1981; Tursz et al. 1982; White et al. 1982; LeFever and Funahashi 1991; Espi et al. 1996; Konjevic et al. 1999; Costello et al. 2002; Doubrovina et al. 2003; 
Schleypen et al. 2006; Ciszak et al. 2007; Konjevic et al. 2007; Carrega et al. 2008; Verhoeven et al. 2008; Conry et al. 2009; Garcia-Iglesias et al. 2009; 
Szczepanski et al. 2009; Piroozmand and Hassan 2010; Al Omar et al. 2011; Mamessier et al. 2011; Platonova et al. 2011; Balsamo et al. 2012; Pietra et 
al. 2012; Fregni et al. 2013; Reiners et al. 2013) or viral infecƟ ons (Confer et al. 1990; Sirianni et al. 2002; De Maria et al. 2003; Mavilio et al. 
2003; Mao et al. 2010; Murugin et al. 2011; Yoon et al. 2011; Dupuy et al. 2012) or mouse models of cancer (Gill et al. 2012), it has 
been observed that these NK cells when tested ex vivo or in vivo, and exposed to another target cell, 
or another unrelated recogniƟ on strategy (ADCC or missing self recogniƟ on for example), are unable 
to eﬃ  ciently exert their funcƟ ons.
However, despite all these examples, very liƩ le is known about the molecular events that cause 
this loss of NK cell funcƟ on.  
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In some of these studies NK cell funcƟ on could be recovered by treatment with poly (I:C) which 
acƟ vates NK cells by engaging Toll-like receptor 3  in vivo (Oppenheim et al. 2005), but not in others (Tripathy 
et al. 2008). Similarly treatment with IL-2 was reported to be able to totally restore NK cell funcƟ on in 
some arƟ cles (Abrams and Brahmi 1986; LeFever and Funahashi 1991; Coudert et al. 2005; Konjevic et al. 2007; Tripathy et al. 2008; Reiners et al. 
2013), but not in others (JeweƩ  and Bonavida 1995; JeweƩ  and Bonavida 1996; Fregni et al. 2013). Treatment with other sƟ muli 
including IL-12 (Mazumdar et al. 2013), IL-15 (Verhoeven et al. 2008; Szczepanski et al. 2009; Balsamo et al. 2012), IFN-ß (Abrams and 
Brahmi 1986; Mazumdar et al. 2013), IFN-α (Konjevic et al. 2007), and TNF-α have also been reported to a produce parƟ al 
restoraƟ on of NK funcƟ on (Mazumdar et al. 2013). Intriguingly, the funcƟ on of these hyporesponsive NK cells 
was also recovered aŌ er viral infecƟ ons (Mazumdar et al. 2013).
In some experiments the hyporesponsive NK cells could degranulate when exposed to P815 cells 
loaded with CD16 anƟ body (De Maria et al. 2003; Mavilio et al. 2003; Fauriat et al. 2007), and sƟ mulaƟ ng the acƟ vity of 
CD16 has been demonstrated both in vitro and in vivo to be a promising strategy able to overcome 
NK cell inhibiƟ on and increase tumor cell killing by using bispecifi c anƟ bodies which targets CD30 on 
tumor cells and CD16 on NK cells (Reiners et al. 2013). However, in other studies, ADCC acƟ vity was also lost 
(Brahmi et al. 1985). 
Some arƟ cles also reported an altered phenotype of hyporesponsive cells; 
CD16dimCD2dimCD56dimCD69brightCD11bbright (JeweƩ  and Bonavida 1995; JeweƩ  and Bonavida 1996), NCRdull (Sivori et al. 1999; Costello 
et al. 2002; De Maria et al. 2003; Mavilio et al. 2003; Fauriat et al. 2007; Garcia-Iglesias et al. 2009; Szczepanski et al. 2009; Johann et al. 2010; Mamessier 
et al. 2011; Platonova et al. 2011; Sanchez-Correa et al. 2011; Dupuy et al. 2012; Pietra et al. 2012). Lower levels of DNAM1 (Mamessier et al. 
2011; Mamessier et al. 2011; Sanchez-Correa et al. 2011), 2B4 (Fauriat et al. 2006; Mamessier et al. 2011), NKG2D (Konjevic et al. 2007; Garcia-Iglesias 
et al. 2009; Szczepanski et al. 2009; Mamessier et al. 2011; Mamessier et al. 2011; Sanchez-Correa et al. 2011; Gill et al. 2012; Pietra et al. 2012; Reiners 
et al. 2013), CD94/NKG2C (Sanchez-Correa et al. 2011), CD16 (LeFever and Funahashi 1991; Lai et al. 1996; Patankar et al. 2005; Fauriat et al. 
2006; Schleypen et al. 2006; Mamessier et al. 2011; Platonova et al. 2011), NKp80 (Mamessier et al. 2011; Platonova et al. 2011), NKp46 (Al Omar 
et al. 2011; Gill et al. 2012), NKp30 (Mamessier et al. 2011), NKp46 (Fregni et al. 2013), ILT2 (Platonova et al. 2011), CD6 (Sanchez-Correa et 
al. 2011), CD161 (Konjevic et al. 2007; Dupuy et al. 2012), CD56 (CD56dim/-) (Mavilio et al. 2003; Schleypen et al. 2006; Sconocchia et al. 2009; 
Johann et al. 2010), CD57 (Bruno et al. 2013), CD49b (Gill et al. 2012), CD57, KIR and TRAIL (Mamessier et al. 2011), granzyme 
A (Schleypen et al. 2006; Pietra et al. 2012), perforin (Carrega et al. 2008; Al Omar et al. 2011), perforin and granzyme B (Schleypen 
et al. 2006; Mamessier et al. 2011) have also been reported to be characterisƟ cs of hyporesponsive NK cells. 
UpregulaƟ on of NKG2A, CD85j, CD27 or CD94 (Mamessier et al. 2011), the CD56bright CD16- populaƟ on (Carrega et al. 
2008), or the appearance of PD1 (Benson et al. 2010), CD27 and CD70 (Titanji et al. 2008), KIRs (Mavilio et al. 2003; Al Omar et al. 
2011), LIR1 (Mavilio et al. 2003), NKp44 (Fregni et al. 2013),or increment of the CD16- populaƟ on (Holtan et al. 2011; Bruno et al. 
2013), have also been described as features associated with hyporesponsiveness. The downregulaƟ on of 
some of these receptors could be explained by conƟ nuous engagement and consequent internalizaƟ on 
(Oppenheim et al. 2005; Sanchez-Correa et al. 2011), but modifi caƟ on of the mRNA levels of some of these receptors 
has also been described (Mamessier et al. 2011; Gillard-Bocquet et al. 2013) including decreased levels of mRNA for 
granzyme A and B (Al Omar et al. 2011) and perforin (Bajpai et al. 1991). Decreased levels of Eomes and T-bet 
transcripƟ on factors have been described for hyporesponsive NK cells, indeed forced overexpression 
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of Eomes was reported as inducing recovery of some NK cell funcƟ onality (Gill et al. 2012). However, other 
arƟ cles didn’t fi nd any diﬀ erence in NK cell receptor expression (Verhoeven et al. 2008).
Other publicaƟ ons have described that sustained receptor engagement alters the formaƟ on of 
complexes between NK cell receptors and adaptor proteins, due to reducƟ ons in the expression of 
adaptor proteins such as CD3-ζ (Patankar et al. 2005; Ciszak et al. 2007), FcεRI-γ (Lai et al. 1996) or Lck (Lai et al. 1996). This 
phenomenon could be reversed aŌ er IL-2 treatment (Coudert et al. 2005). 
Finally, NK cells isolated from tumour microenvironments have been proposed to secrete 
proangiogenic factors as VEGF, PIGF or IL-8 (Bruno et al. 2013), and the NK cell populaƟ ons undergoing 
inacƟ vaƟ on, have been reported to correspond to those cells able to form conjugates with target cells 
(JeweƩ  and Bonavida 1995).
On the other hand, mulƟ ple arƟ cles studying NK cells from cancer paƟ ents have not observed 
any loss of NK cell funcƟ on (Tursz et al. 1982; Caldera et al. 1992; Portner et al. 2012), or only lower cytotoxicity, but 
normal IFN-γ and TNF-α secreƟ on (Carrega et al. 2008), despite in some cases the conƟ nuous expression of 
NK ligands (Buddingh et al. 2011). Indeed while in some cases the expression of, for example, NKG2D ligands, 
has been related with a poor prognosis in cancer (Li et al. 2009; McGilvray et al. 2010), in others expression of 
these molecules is associated with good prognosis (McGilvray et al. 2009; de Kruijf et al. 2012). The complexity 
associated with the diversity of individuals studied, and their tumours, the eﬀ ects of heterogeneity in 
tumour microenvironments as well as the variety of ligands and NK cell receptors, generaƟ ng diﬀ erent 
outcomes of NK cell mediated tumour immunosurveillance, cancer immunoediƟ ng and evasion, could 
explain why in some cases the outcome of immunosurevillance is tumour or virus eliminaƟ on, while 
in others evasion or even immunosuppression takes place. This same range of factors may also explain 
the wide diversity of characterisƟ cs described as associated with NK cell unresponsiveness. 
The thin line between self and non-self, the conƟ nuous tuning of fully pre-armed NK cells and 
the variegated phenotypes and characterisƟ cs described for hyporesponsive NK cells are probably 
all responsible for the fact that the quesƟ on of which are the changes in the NK cell originated by 
target cells sƟ mulaƟ on that modulates reacƟ vity versus inacƟ vity, sƟ ll remains to be answered. A full 
understanding of the processes that contribute to the inability of NK cells to detect targets and cause 
this potenƟ ally dangerous “tolerizaƟ on” is necessary in order to be able to prevent this phenomenon.
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2.2 Unresponsive lymphocytes and calcium
Clemens von Pirquet in 1908 observed a transient loss of hypersensivity reacƟ on to the tuberculin 
skin test associated with acute measles infecƟ on, and was the fi rst to use the word anergy, to describe 
this situaƟ on where, in contrast to allergy, viruses induce a suppression of immunity (von Pirquet 1908). 
This word was used later by Nossal & Pike to name the funcƟ onal inacƟ vaƟ on of B cells triggered aŌ er 
the administraƟ on of high doses of anƟ gen (Nossal and Pike 1980). Later the term was also used to describe 
a T cell hyporesponsive state aŌ er defecƟ ve co-sƟ mulaƟ on (Chai and Lechler 1997), and its usage has been 
extended to describe a variety of diﬀ erent phenomena of immune cell suppression aﬀ ecƟ ng diﬀ erent 
types of cells including CD4+ and CD8+ T cells, B cells or NKT cells (Schwartz 2003; Sullivan and Kronenberg 2005). With 
Ɵ me, study of a range of diﬀ erent models of unresponsive states of lymphocytes has shown that many 
of them represent diﬀ erent biological situaƟ ons of hyporesponsiveness with diﬀ erent characterisƟ cs 
(Schwartz 2003; Choi and Schwartz 2007). Some characterisƟ cs of these models are outlined below.
Anergy or Clonal anergy has been mainly studied for CD4+ T cells and B cells. For T cells anergy has 
been described as a state induced in T cells following anƟ gen encounter which renders the lymphocyte 
hyporesponsive, with no ability to produce IL-2 and other cytokines, and in growth arrest (Jenkins et al. 1990). 
In CD4+ T cells it has been mainly studied aŌ er TCR strong sƟ mulaƟ on in the absence of cosƟ mulaƟ on 
or aŌ er weak TCR sƟ mulaƟ on, and can be reverted with IL-2 sƟ mulaƟ on (Beverly et al. 1992). A predominant 
acƟ vaƟ on of the calcium/NFAT pathway and a blocking of the Ras-MAP kinase (Li et al. 1996) pathway 
have been idenƟ fi ed as criƟ cal steps in anergy generaƟ on. In vitro, inducƟ on of anergy by calcium 
ionophores or mTOR inhibitors (Powell and Delgoﬀ e 2010), and its blocking by cyclosporine A (Schwartz 2003), has 
been used to study the biochemical events related to this state. 
AdapƟ ve tolerance or in vivo anergy describes a process in which the T cell becomes desensiƟ zed 
when anƟ gen sƟ mulaƟ on persists (in contrast to clonal anergy where unresponsiveness is maintained 
even in the absence of anƟ gen presentaƟ on). It is also characterized by a block in producƟ on of IL-2 and 
other cytokines by T cells accompanied by a block in proliferaƟ on. Moreover, it cannot be reversed with 
IL-2 sƟ mulaƟ on (Rocha et al. 1993). These cells show a decreased ability to induce the Calcium-Calcineurin-
NFAT pathway, but normal acƟ vaƟ on of Ras/MAPK signaling (Chiodeƫ   et al. 2006) (which represents the 
opposite paƩ ern to that described for anergic cells). 
AcƟ vaƟ on-induced nonresponsiveness (AINR) or exhausƟ on is characterized by an inability to 
produce IL-2, but these cells can sƟ ll be rescued by IL-2, and have been demonstrated to be able to 
survive in the absence of conƟ nuous anƟ gen sƟ mulaƟ on maintaining a stable phenotype (Wherry 2011). 
This process has mainly been studied in CD8+T cells during chronic infecƟ ons (Moskophidis et al. 1993) as well 
as in human cancer, although it has been described also in CD4+T cells (Han et al. 2010).  It appears at the 
peak of the CD8+ T cell response aŌ er long exposure to anƟ gen and has been suggested to act to 
control proliferaƟ on. These cells are described to have Ras/MAPK signaling defects (Tham and Mescher 2001; 
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Mescher et al. 2007). It is characterized by a progressive loss of eﬀ ector funcƟ ons, and of the proliferaƟ on 
of memory T cells, together with the upregulaƟ on of receptors such as PD-1, CTLA-4, Tim-3 or LAG-
3, related to inhibitory pathways (Wherry 2011). These exhausted cells, could also exert cytotoxicity and 
proliferate in response to acute infecƟ ons, and PD-1 blockade can rescue them (Utzschneider et al. 2013). 
AcƟ vaƟ on-induced cell death (AICD) can be induced aŌ er repeated TCR sƟ mulaƟ on, and it has 
been argued that this process acts to ensure tolerance and eliminate autoreacƟ ve T cells, or as a 
feedback mechanism to guarantee the terminaƟ on of an ongoing immune response eliminaƟ ng 
chronically acƟ vated T cells. It is mediated mainly by death receptors, and IL-2, IL-4 or IFN-γ play an 
important roles in AICD inducƟ on (Brenner et al. 2008). This process has also been described for NK cells, and 
CD16 mediated acƟ vaƟ on or IL-2 sƟ mulaƟ on (Ortaldo et al. 1995) or even co-culture with target cells (Hasenkamp 
et al. 2010) can cause AICD on NK cells.
Suppression of immune cells can be also be mediated by regulatory T cells, the producƟ on of 
regulatory cytokines such as IL-10, IL-4 or TGF-ß, or nutrient and energy deprivaƟ on.
AlteraƟ ons in calcium levels has been related to T cell anergy since 1987 (Jenkins et al. 1987), In those 
studies, Jenkins et al. demonstrated that increases of intracellular calcium levels triggered, in a dose 
dependent manner, by ionophores like ionomycin could establish an unresponsive state similar to 
anergy. From that moment ionomycin has been used as an anergy-inducing agent in CD4+ T cells by 
several groups (Macian et al. 2002). Ionomycin is a calcium ionophore which causes an infl ux of external 
calcium and the leak of intracellular Ca2+ stores, which will acƟ vate the Calcium-Calcineurin-NFAT 
cellular pathway. However, ionomycin generated anergic CD4+ T cells gradually regain (aŌ er 4 days) 
their proliferaƟ ve and IL-2 producƟ on abiliƟ es, and the ionomycin treated cells not only lose their ability 
to produce IL-2, but also other cytokines, so the characterisƟ cs of this phenomenon are somewhat 
diﬀ erent from other models of anergy (Schwartz 2003). Ionomycin has been used to study anergy in other 
cell types such as NKT cells (Kojo et al. 2009). Increased intracellular calcium basal levels (Cooke et al. 1994) and 
deregulated use of NFAT transcripƟ on factors is also observed in tolerant B cells generated by chronic 
self-anƟ gen sƟ mulaƟ on (Healy et al. 1997). 
As discussed previously, Natural killer cell acƟ vaƟ on is regulated by a balance of signals from 
diﬀ erent acƟ vaƟ ng and inhibitory receptors. The acƟ vaƟ ng NK receptors, with the excepƟ on of CD16, 
act as co-receptors so that NK cells require the cooperaƟ on of diﬀ erent signals to iniƟ ate an eﬀ ector 
response and a potent Ca2+ fl ux. Diﬀ erent signaling pathways have been described to be preferenƟ ally 
acƟ vated via diﬀ erent families of receptors due to the use of diﬀ erent adaptor molecules. For 
example, NCRs which signal through ZAP-70 and Syk, trigger LAT phosphorylaƟ on, acƟ vaƟ ng MAPK, 
JNK and Calcium-NFAT signals, while the 2B4 receptor also acƟ vates LAT via SAP and Fyn signaling. In 
contrast, the NKG2D receptor via DAP10 directly acƟ vates PI3K-JNK and MAPK pathways (Lanier 2008). 
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The necessity for synergy between diﬀ erent families of receptors could indicate that receptors need 
to cooperate to achieve a suﬃ  cient quanƟ ty of posiƟ ve signals, or that they cooperate to have access 
to the acƟ vaƟ on of diﬀ erent signaling pathways engaged by each receptor. It is important to note that 
diﬀ erent combinaƟ ons of receptors will cause synergisƟ c acƟ vaƟ ons, but not all of them: two NCRs 
would not synergize, implying that they are able to achieve some level of acƟ vaƟ on but never as much 
as the synergy between NCR or 2B4 with NKG2D receptor. In any case, contrary to what happens in 
T cells where free Ca2+ concentraƟ ons increase in response to TCR engagement, single sƟ mulaƟ on 
through NK cell receptors, except CD16, induce no or weak intracellular Ca2+ mobilizaƟ on, whereas 
those combinaƟ ons able to synergize induce a strong enhancement in free Ca2+ inside the cell, that 
correlates with cytotoxicity and cytokine secreƟ on (Bryceson et al. 2006). Thus calcium only sƟ mulaƟ on of 
NK cells mediated by ionomycin could then mimic a chronic sƟ mulaƟ on mediated by combinaƟ ons of 
diﬀ erent acƟ vaƟ ng receptors or imbalanced sƟ mulaƟ on.
The characterisƟ cs of hyporesponsive NK cells are very diverse as described in the previous secƟ on, 
sharing some of their properƟ es with other unresponsive lymphocytes. 
NK cell 
poresponsiveness Clonal  anergy
AdapƟ ve anergy. 
Tolerance AINR. ExhausƟ on AICD
Caused by subopƟ -
mal acƟ vaƟ on
?
SubopƟ mal inhibi-
Ɵ on? (licensing)
Yes No No No
Caused by chronic 
opƟ mal acƟ vaƟ on Yes No Yes Yes Yes
ConƟ nous sƟ mula-
Ɵ on required No
No           
(Quill and Schwartz 1987)
Yes            
(Rocha et al. 1993)
No  
 (Tham and Mescher 2001)
-
IL-2 driven recovery Yes/No
Yes
(Beverly et al. 1992)
No        
 (Rocha et al. 1993)
Yes          
(Tham and Mescher 2001)
-
In order to gain insight into the phenomenon of hyporesponsiveness in NK cells, we wanted to 
establish a simple, reproducible model which could help us to understand beƩ er the processes that 
lead to induced NK cell hyporesponsiveness. We decided to use overnight sƟ mulaƟ on with the calcium 
ionophore ionomycin to simulate a conƟ nuous NK cell sƟ mulaƟ on, as this strategy has previously been 
producƟ vely used to study CD4+ T cell anergy (Macian et al. 2002). 
Objectives
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Diﬀ erent characterisƟ cs have been described for unresponsive NK cells. However, there 
is no hint about the mechanisms that allows the generaƟ on and maintenance of this state. 
The inducƟ on of a calcium fl ux and its maintenance is one of the fi rst steps during NK cell 
acƟ vaƟ on. We propose the use of a sustained calcium fl ux as a hyporesponsiveness inducing 
method for NK cells, as an approach to mimic chronic acƟ vaƟ on by sƟ muli.
To study the infl uence of maintained calcium acƟ vaƟ on on NK cells we proposed the 
following objecƟ ves:
1. Study the impact of ionomycin treatment on acƟ vated and freshly isolated NK cells.
 
2. Examine at mRNA levels, the consequences of ionomycin treatment on NK cells, 
and compare these diﬀ erences with unresponsive NK cells or other unresponsive 
lymphocytes.
1.1  Analyze if ionomycin treatment is able to induce an unresponsive state on NK 
cells at cytotoxic and cytokine producƟ on levels.  
1.2  OpƟ mize ionomycin treatment protocol for NK cell unresponsiveness 
inducƟ on.
1.3  Evaluate the reversion of the hyporesponsive state by cytokine sƟ mulaƟ on.
1.4  Characterize diﬀ erenƟ al receptor expression on unresponsive NK cells.  

Materials 
and methods
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1. NK cell isolation
NK cells were isolated from buﬀ y coats, donated by healthy volunteers, obtained from the “Centro 
de Transfusiones de la Comunidad de Madrid”. Peripheral blood mononuclear cells (PBMC) were 
isolated using Ficoll-Paque (GE Healthcare) gradient centrifugaƟ on. Briefl y, buﬀ y coats were diluted 
with PBS 1:3, layered on top of Ficoll in a 2:1 proporƟ on and centrifuged for 30min at 400 g. PBMCs, 
found at the interface between the plasma and the Ficoll, were harvested and washed. NK cells were 
further isolated and purifi ed from PBMCs using a magneƟ c bead isolaƟ on kit by negaƟ ve selecƟ on 
(Human NK isolaƟ on kit, Miltenyi Biotec) according to the manufacturer instrucƟ ons. 
AŌ er isolaƟ on, NK cells were cultured in the presence of irradiated (40 Gray) Daudi and RPMI-
8866 as feeder cells, and irradiated autologous PBMCs in Roswell Park Memorial InsƟ tute medium 
(RPMI 1640, Lonza) supplemented with 10% FBS, 10% Human Serum (Sigma Aldrich), 50 U/mL rhIL-2 
(Peprotech) the fi rst week and later with 5% FBS, 5% Human Serum, 50 U/mL rhIL-2. This media was 
supplemented with 4mM L-glutamine, 0.1mM non essenƟ al amino-acids, 10mM HEPES, 1mM sodium 
pyruvate, 100 U/mL penicillin, 100 U/mL streptomycin and 50μM ß-mercaptoethanol. The NK cells 
were resƟ mulated and diluted weekly during one month, and only if the culture was >85% pure NK 
cells.
ResƟ ng NK cells (rNK) were isolated by negaƟ ve selecƟ on from leukapheresis from healthy 
donors provided by the NIH department of transfusion medicine. 
 
2. Cell lines
All cell lines were maintained at 37°C and 5% CO2 in a humidifi ed incubator and split as necessary.
The cell lines RMPI 8866, Daudi, K562, 721.221, P815 and Jurkat were maintained in RPMI medium 
and the 293T cells were culƟ vated in Dulbecco’s Modifi ed Eagle medium (DMEM). All media were 
supplemented with 10% heat-inacƟ vated FBS, 2mM L-Glutamine, 0.1mM non essenƟ al amino-
acids, 10mM HEPES, 1mM sodium pyruvate, 100 U/mL penicillin, 100 U/mL streptomycin and 50μM 
ß-mercaptoethanol.
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3. Ionomycin treatment of NK cells
NK cells were washed and resuspended at 1x106 cells/mL in RPMI 10% FBS (without human serum 
or IL-2). Cells were then treated with either Ionomycin 1 μM (Sigma) or DMSO (Sigma), as vehicle 
control, and cultured for 16 hours. Control and ionomycin-treated cells were then washed and allowed 
to rest for 24 hours at 2x106 cells/mL in RPMI 10% FBS. Where indicated, during this rest day, cell 
cultures were supplemented with 50U/ml IL-2 (Peprotech), IL-12 10ng/mL (Peprotech), IL-18 10ng/ml 
(MBL) or 100/1000 U/mL IFN-α (Peprotech).
4.  Flow cytometry analysis
Live NK cells were stained with fl uorescently labeled or unlabelled anƟ bodies followed by PE or 
FITC fl uorophor labeled F(ab’)2 fragments of goat anƟ -mouse immunoglobulin (Dako). For staining, cells 
were washed and incubated in a PBS / 0.5% (w/v) Bovine serum albumin / 1% (v/v) Fetal bovine serum 
/ 0.1% Sodium azide buﬀ er (PBA buﬀ er) with the anƟ bodies specifi ed in each parƟ cular experiment 
using the amounts recommended by the manufacturer. When the staining was fi nished, cells were 
washed twice with PBA buﬀ er. All the staining was performed on ice, and the labelled cells were 
maintained on ice unƟ l analysis.
For intracellular staining, cells were fi rst stained with anƟ bodies on ice, washed with PBA and 
then fi xed using 2% para-formaldehyde (PFA) fi xaƟ on buﬀ er for 10 minutes at room temperature in 
the dark. AŌ er fi xaƟ on, cells were washed twice with PBA, and resuspended in PBA containing 0.5% 
Saponin (permeabilizaƟ on buﬀ er) and incubated with the desired anƟ bodies at room temperature and 
in the dark. When the staining was fi nished, cells were washed twice with permeabilizaƟ on buﬀ er and 
once with PBA. 
For staining cytotoxic granules, the cells were washed twice with PBS and fi xed with 70% EtOH, 
adding the EtOH dropwise while vortexing. Samples were kept overnight at -20°C. For staining, cells 
were washed twice in abundant PBS at 1,700 rpm. Cells were then stained as before with primary and 
secondary anƟ bodies in PBA buﬀ er.
Cells were analyzed using a FACScalibur Becton Dickinson cytometer (BD Biosciences), Cytomics 
FC500 (Beckman Coulter) or Gallios (Beckman Coulter) depending on the experiment. Data were 
analyzed with either Kaluza Flow Cytometry Analysis v1.2, Summit V4.3.02 or FlowJo V9.6.2 soŌ ware.
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The anƟ bodies used are detailed below:
Molecule Clone Supplier
CD2-APC LT2 Immunotools
CD9 MEM-192 V. Horejsi (InsƟ tute Molecular GeneƟ cs AS AR)
CD11a HI111 BioLegend
CD11a open NK1-L16 C.G.Figdor (Nijmegen Centre for Molecular Life Sciences)
CD11-CD18 Ab24 Abcam
CD11b ICRF44 BioLegend
CD11b acƟ vated CBRM1/5 Biolegend
CD11c-APC BU15 Immunotools
CD16 B73.1 J.L. Strominger (Harvard University)
CD18 ascites LIA3/2 F.Sánchez-Madrid (H. La Princesa)
CD25-FITC HI25a Immunotools
CD27-PE LT27 Immunotools
CD28 CD28.2 BD Pharmingen
CD29-FITC MEM-101A Immunotools
CD44-APC MEM-85 Immunotools
CD45-FITC MEM-28 Immunotools
CD49d-FITC BU49 Immunotools
CD53-FITC HI29 Immunotools
CD54(ICAM1)-FITC 1H4 Immunotools
CD56 unlab/-PE MEM-188 BioLegend
CD58-PE MEM-63 Immunotools
CD59-APC MEM-43 Immunotools
CD61-FITC C17 Immunotools
CD62L-APC LT-TD180 Immunotools
CD69 FN50 BD Pharmingen
CD85j (LILRB1) GHI/75 BD Pharmingen
CD94-PE HP-3D9 BD Pharminegn
CD95 IM2446 Immunotech
CD107a-APC H4A3 BioLegend
CD152-PE (CTLA4) BN13 Immunotech
CD158a (KIR2DL1) EB6 Immunotech
CD158b (KIR2DL2/DL3) GL183 Serotec
CD158e1 (KIR3DL1)-PE DX9 B&D Pharmingen
CD161 (KLRB1) HP-3G10 M. López-Botet (Universidad Pompeu Fabra)
CD244 (2B4) 2-69 B&D Pharmingen
DNAM1 MAB666 R&D
HLA-ABC-PE W6/32 Immunotools
HLA-DR-PE LT-DR Immunotools
IFN-γ - PE 4S.B3 Biolegend
Mouse IgG1 MOPC-21 Sigma
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5. Degranulation assay
NK cell degranulaƟ on was analyzed following the 2 hour protocol described in (Bryceson et al. 2010). This 
assay quanƟ fi es secretory lysosome release by measuring changes in the cell surface expression of the 
transmembrane protein Lamp1 (CD107a) which resides in secretory lysosomes, but upon acƟ vaƟ on 
becomes incorporated into the NK cell surface as lyƟ c granules fuse with the NK cell membrane. NK 
cells were coincubated with K562 target cells (or other target cell lines when indicated) for 2 hours 
in round boƩ om 96 well plates, in an eﬀ ector to target cell (E:T) raƟ o of 1:2. (generally 100,000 NK 
cells and 200,000 targets were used). The co-culture was harvested and stained with anƟ -Lamp1*APC 
and anƟ -CD56*PE anƟ bodies for 30 minutes and the percentage of CD56 posiƟ ve - Lamp1 posiƟ ve 
cells quanƟ fi ed by fl ow cytometry. Where indicated the cells were sƟ mulated with PMA 100ng/ml 
(Calbiochem) / Ionomycin 0.5 μM (Sigma) as a posiƟ ve control.
6. Cytotoxicity assay
Cytotoxicity was assessed by the analysis of Propidium Iodide (PI) (Beckman) posiƟ ve K562 or Jurkat 
cells, aŌ er coculture with NK cells for diﬀ erent Ɵ me points, following the protocol described in (Slezak and 
Horan 1989) and based on the observaƟ on that only dead cells stain with PI as this compound is membrane 
impermeant. Briefl y, target K562 or Jurkat cells were stained with CFSE (Invitrogen) membrane dye 
following the recommendaƟ ons of the manufacturer. Target cells were then cocultured with NK cells 
at a 3:1 E:T raƟ o for 1h, 3h or 5 hours in 96 well round boƩ om plates (generally 250,000 NK : 75,000 
Targets were used). Target cells and eﬀ ector cells cultured alone were used to measure spontaneous 
cell death. The cocultures were collected and stained with 100μg/mL PI during 10 minutes. Samples 
were analyzed by fl ow cytometry. CFSE only posiƟ ve cells represent live target cells, while CFSE & PI 
double posiƟ ve cells were scored as dead target cells.
NKG2D MAB139 R&D
NKp30 210845 R&D
NKp46 195314 R&D
Perforin dG9 Biolegend
PD1 EH12.2H7 BioLegend
ß-acƟ n AC-15 Sigma
Annexin-V-FITC 731725 Beckman
7-AAD
Propidium iodide 660755 Beckman
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For quanƟ fying target cell death the following formula was used:
    
% target cell death: 
7. Redirected antibody dependent cytotoxicity
FcγR-posiƟ ve P815 cells are not normally suscepƟ ble to NK cell lysis, but when incubated with 
anƟ bodies specifi c for NK cell acƟ vaƟ ng receptors, these anƟ bodies bind to the P815 cells via Fc/FcR 
interacƟ ons and to the NK cell via the anƟ body variable regions to act as a bridge that triggers NK 
cell cytotoxicity via specifi c receptors. They were cocultured with NK cells in the presence of diﬀ erent 
combinaƟ ons of anƟ bodies at 5μg/mL for 2 hours, following the same “DegranulaƟ on assay” described 
previously, or 1, 3 and 5 hours, following the “Cytotoxicity assay” described earlier. As controls, P815 
cells loaded with MOPC-21 (Mouse IgG1 monoclonal isotype control anƟ body) and P815 cells that had 
not been incubated with anƟ body were used. Before staining with anƟ -CD56*PE and anƟ -Lamp1*APC 
anƟ bodies, unoccupied P815 Fc-receptors were blocked with 10% mouse serum. Samples were 
analyzed by fl ow cytometry.
8. Measurement of the IFN-γ production 
IFN-γ producƟ on was analyzed by fl ow cytometry following the 6 hour protocol described in (Bryceson 
et al. 2010). NK cells were coincubated with target cells for 6 hours in a 96 well round boƩ om plate, in a E:T 
raƟ o of 1:2 (generally 150,000 NK : 300,000 Targets were used), in the presence of 2,5 μM Monensin 
(Sigma) which blocks exocytosis and so leads to the intracellular retenƟ on and accumulaƟ on of IFN-γ 
for subsequent detecƟ on of producer cells by intracellular fl ow cytometry. Briefl y, the cells were 
fi xed with ice cold 2% para-formaldehyde (PFA) fi xaƟ on buﬀ er for 10 minutes and aŌ er washing, cells 
were permeabilized with 0.5% Saponin (permeabilizaƟ on buﬀ er) and and stained with anƟ -IFNγ*PE 
anƟ bodies for 30 minutes and quanƟ fi ed by fl ow cytometry the percentage of IFN-γ posiƟ ve cells. 
9. Conjugate formation assay
The formaƟ on of stable conjugates between K562 target cells and NK cells was analyzed using 
the two color fl ow cytometry method described in (Burshtyn and Davidson 2009). Briefl y K562 target cells were 
stained with the green fl uorescent dye PKH2 (Sigma) while NK cells were labeled with the red dye 
PKH26 (Sigma), following the recommendaƟ ons of the manufacturer. NK cells were dispensed in 
diﬀ erent FACs tubes depending on the number of Ɵ me-points to analyze, and target cells were added 
% CFSE posiƟ ve & PI posiƟ ve
CFSE posiƟ ve cells
x 100
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in an E:T raƟ o of 1:2 (generally 100,000 NK : 200,000 Targets were used). Cells were centrifuged at 4°C 
and 100g for 1 minute to iniƟ ate the cell:cell interacƟ ons and the tubes were incubated for the desired 
Ɵ me points at 37°C to allow the formaƟ on of conjugates, tubes were then vortexed for 3 seconds to 
separate weakly aƩ ached cells and immediately fi xed with 4% ice cold PFA (fi nal concentraƟ on 1%). 
Control samples containing NK and target cells alone were also fi xed. One NK-Target cell coculture 
control tube was kept at 4°C during the length of the experiment and fi xed when the experiment was 
fi nished. Finally, the PKH26 and PKH2 double posiƟ ve events were quanƟ fi ed as conjugates, and the 
percentage of NK cells forming conjugates calculated as follows:
10. Analysis of cell viability
NK cells were stained with CD56*PE and Lamp1*APC anƟ bodies. AŌ er staining, cells were washed 
fi rst with PBA and then with cold PBS, before being stained with Annexin-V FITC (Beckman) and 
7-AAD (7-AminoacƟ nomycin D) in Annexin Binding buﬀ er (Invitrogen) following the manufacturer 
instrucƟ ons. Cells were incubated 15 minutes on ice and analyzed by fl ow cytometry. Annexin-V 
stains phosphaƟ dylserine (PS), which appears on the cell surface in non-permeabilized cells in early 
apoptoƟ c states when cells have lost their PS asymmetric distribuƟ on. 7-AAD has high aﬃ  nity for 
DNA and intercalates with it, and as it is membrane impermeable, only stains cells with disrupted 
membranes, such as cells from late apoptoƟ c states.
11. Calcium flux measurement
NK cells were stained with 4μg/mL Fluo-4 AM (Life technologies F-14201) and 10 μg/mL FuraRed 
AM (Life Technologies F-3021) dyes in HBSS with calcium and magnesium, supplemented with 1% FBS 
and 4mM Probenecid during 30 minutes at 37°C. Cells were washed and kept on ice unƟ l experiment. 
For anƟ body sƟ mulaƟ on, aŌ er dye loading, NK cells were stained with primary anƟ bodies on ice during 
30 minutes. Excess anƟ body was washed away and cells were resuspended in HBSS with calcium and 
magnesium plus 1% FBS. Cells were incubated at 37°C during 5 minutes prior to acquisiƟ on of the data 
in the fl ow cytometer. For sƟ mulaƟ on, aŌ er 30 seconds of acquisiƟ on to establish a baseline, either 
ionomycin, to a fi nal concentraƟ on of 0.5 μM or Goat anƟ -mouse F(ab’)2 (added to a fi nal concentraƟ on 
of 10 μg/mL to cross-link the primary mAb) were added.  Events were acquired, using a FACScalibur 
Becton Dickinson cytometer, for 5 minutes, and then analyzed with FlowJo soŌ ware (Treestar, Ashland, 
% conjugates: 
% PKH2-PKH26 double posiƟ ve events
   % PKH26 posiƟ ve cells
X 100
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OR, USA. Version 9.6.2). Monoclonal anƟ bodies used to sƟ mulate the diﬀ erent NK cell receptors, 
either individually or in combinaƟ on, were NKG2D (clone 149810 R&D), NKp46 (clone BD 9E2), 2B4 
(clone C1.7) or CD56 (clone BD B159) as a negaƟ ve control. Where indicated 1mM EGTA was added 5 
minutes 37°C prior to data acquisiƟ on to chelate calcium from the media and so be able to follow the 
release of Ca2+ from intracellular stores only. To study the infl uence of the acƟ n cytoskeleton on NK cell 
responsiveness to receptor crosslinking by mAbs, Latrunculin was added, to a fi nal concentraƟ on of 
1μM, during the 5 minutes at 37°C prior to data adquisiƟ on.
12. Gene expression analysis by microarray
Gene expression experiments were done in collaboraƟ on with the Genomics Unit of the CNB. AŌ er 
the ionomycin treatment protocol, total RNA was isolated by TRIZOL reagent (Invitrogen) according to 
the manufacturer’s instrucƟ ons, and subsequent purifi caƟ on by RNA column cleanup (Qiagen RNeasy). 
A minimum of 4μg of RNA was used for the gene expression analysis by microarrays. The following 
steps were performed by the CNB-Genomic Unit. Once RNA quality was confi rmed by Bioanalyzer2100, 
cDNA was synthesized and labeled with Cy3 or with Hyper5 Mono NHS ester (DMSO treated cells vs 
Ionomycin treated cells). The whole genome transcripƟ onal profi le was determined by hybridizaƟ on 
with the two color AGILENT human gene expression 4x44K v2 microarray kit (Agilent G4845A) which 
analyzes the expression of 27,958 genes. Data were collected, and preprocessed for further analysis. 
Finally data were visualized using the FIESTAviewer v.1.0 soŌ ware (hƩ p://bioinfogp.cnb.csic.es/
tools/FIESTA/index.php). Diﬀ erenƟ ally expressed genes were selected from the FIESTAviewer when 
they show a False Discovery Rate (FDR) < 0.05 by Rank Products analysis, and a Fold Change <= -1.6 
(repressed genes) or >= +1.6 (induced genes). 
Diﬀ erenƟ ally expressed genes were subjected to deeper analysis using diﬀ erent online tools (e.g. 
Babelomics-Genecodis, Panther, g:Profi ler), and compared with published data sets of diﬀ erenƟ ally 
expressed genes under diﬀ erent treatments by Venn diagrams, as indicated. QuantaƟ ve RT-PCR was 
used to confi rm the diﬀ erenƟ al expression of genes of interest idenƟ fi ed in the cDNA microarray 
experiments.
13. Quantitative RT-PCR
Total RNA was extracted with the TRIZOL reagent (Invitrogen). cDNA was prepared using 1μg of 
this RNA by retrotranscripƟ on with Random Hexamers (Roche) and SuperScript II Reverse Transcriptase 
(Invitrogen) in the presence of RNAse inhibitors (Promega), in a fi nal volume of 20 μL, according to the 
manufacturer’s instrucƟ ons.
qPCR reacƟ ons were carried using Fast Plus EvaGreen® qPCR Master Mix (BioƟ um) in a fi nal volume 
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of 8 μL. 18S levels were used as controls. 
The primers used are detailed below:
GENE           Forward primer           Reverse primer
dap10 5’- GCACTTCAGGCTCTTGTTC 5’- GCCTGGCATGTTGATGTAGA
itgb2 5’- CAAGCTGGCTGAAAACAACA 5’- ATTGCTGCAGAAGGAGTCGT
itgam 5’- GCCGGTGAAATATGCTGTCT 5’- GCGGTCCCATATGACAGTCT
myom2 5’- GAACCCCACAATTCCTCTGA 5’- TCGATCCATCACCATCTCAA
gzmh 5’- CAGAAGGACTGCCAGTGTGA 5’- ACTCCTGGAGGTGTCCCTTT
cd300a 5’- GTCCTGCAAACCTCAGCTTC 5’- CCCACTGCAAACAGGGTAGT
il18r1 5’- TAGTGCCTGGAGGAGCTGTT 5’- ATTGGGGCAAGAATGTGAAG
egr1 5’- TGACCGCAGAGTCTTTTCCT 5’- TGGGTTGGTCATGCTCACTA
ncr3 5’- CCTGAGATTCGTACCCTGGA 5’- GAAACGGGAAGAAGCAAGTG
ctsw 5’- CCACCCCAAGAAGTACCAGA 5’- GTGGCCTTGATCACACCTTT
sell 5’- AAACCCATGAACTGGCAAAG 5’- CGCAGTCCTCCTTGTTCTTC
matk 5’- TACCGCGTCAAGCACCACACCAG 5’- CACTCTCCACTCTCTCGGTCCTCTG
cd56 5’- TATTTGCCTATCCCAGTGCC 5’- CATACTTCTTCACCAACTGCTC
gnly 5’- TCTCTCGTCTGAGCCC 5’- GCAGCATTGGAAACACT
id2 5’- CGGATATCAGCATCCTGTCC 5’- TCATGAACACCGCTTATTCAG
18s 5’- GGGACTTAATCAACGCAAGC 5’- GCAATTCCCCATGAACG
ß-acƟ n 5’- CCCAGCACAATGAAGATCAA 5’- CGATCCACACGGAGTACTTG
PCR condiƟ ons were as follows: 50°C for 10’, 95°C for 2’, 40 cycles at 95°C 15’’ and 60°C 1’. DissociaƟ on 
analysis was performed at the end to confi rm the specifi city of the reacƟ on This program consisted 
of 15’’ at 95°C, 15’’ at 60°C and a gradual increase to 90°C for 20’, during which Ɵ me fl uorescence was 
measured. ReacƟ ons were run with the Applied Biosystems 7900HT system.
Samples for each experimental condiƟ on were analysed in triplicates. Purifi ed water was included 
as a non-template control. The relaƟ ve expression of each gene was calculated from the fl uorescence 
increase data vs. cycle number, from which the Ct value is obtained; aŌ er correcƟ on for 18S control 
amplifi caƟ on, the ΔCt is obtained. Finally, the sample is compared with a reference sample, and the 
relaƟ ve expression of the gene is calculated by applying the equaƟ on 2−(ΔΔCt ) to obtain the relaƟ ve 
quanƟ fi caƟ on as relaƟ ve quanƟ ty (RQ).
14. Western blotting
Cells were lysed in ice-cold lysis buﬀ er (1% Igepal CA-630, 50mM Tris pH 7.5, 150mM NaCl, 5mM 
EDTA) with protease inhibitors (1μM PepstaƟ n A, 1μM LeupepƟ n and 0.5mM Iodoacetamide) for 
30min on ice. Lysates were then centrifuged (13,000 rpm for 5min) to pellet nuclei and the protein 
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concentraƟ on of the supernatant quanƟ fi ed using the Coomassie protein assay reagent (Thermo 
ScienƟ fi c) before analysis by SDS-PAGE and Western Blot. 2xloading buﬀ er (125mM Tris pH6.8, 4% SDS, 
20% glycerol and bromophenol blue) with or without 100mM DTT (reducing / non reducing condiƟ ons) 
was added to lysates.
Proteins were separated in acrylamide gels (Electrophoresis running buﬀ er: 195mM Glycine, 
24.8mM Tris base, 0.1% SDS) and then transferred onto acƟ vated polyvinylidene fl uoride (PVDF) transfer 
membranes (Immobilon-P. Millipore) using a semi-dry electrobloƫ  ng system (BioRad) in transfer 
buﬀ er (25mM Tris base, 192mM Glycine, 20% methanol), and blocked with a soluƟ on containing TBS 
(100mM NaCl, 10mM Tris Base) and 0,05% Tween20 (TBS-T) with 5% non-fat milk for 45 minutes. AŌ er 
washing, the membrane was incubated with appropriate primary anƟ body diluted in TBS-T overnight 
at 4oC. The following day, membranes were washed and incubated with secondary anƟ bodies labelled 
with Horseradish Peroxidase (HRP) for 60 min. The membranes were then washed and bound anƟ body 
visualized by reacƟ on with Amersham ECL western bloƫ  ng detecƟ on reagents (GE Healthcare) and 
X-ray fi lms (Konica Minolta).
The primary anƟ bodies used are detailed below:
Molecule Clone Supplier DiluƟ on
CD3 ζ 488 Dr. Balbino Alarcón 
(Risueno et al. 2008)
1:5,000
ß-acƟ n AC-15 Sigma 1:15,000
15. Confocal microscopy
Borosilicate microscopy cover glasses were coated with 25μg/mL Poly-L-lysine (Sigma) for 30 
minutes at room temperature (RT). AŌ er washing with PBS, NK cells alone or NK cell/K562 cocultures 
(1:1 raƟ o) were applied. When K562 were used, they were stained previously with CMAC (Molecular 
Probes) to disƟ nguish between NK cells and K562. AŌ er 1 hour to allow cell aƩ achment to the Poly-
L-Lysine coated slides, each coverslip was washed and fi xed with 4% PFA during 15 minutes. For 
intracellular staining cells were permeabilized with PBS containing 0.3% Triton X-100. Samples were 
blocked with 10% Human Serum (HS). AnƟ bodies were diluted in 1% HS-PBS for extracellular staining or 
1%HS-PBS-0.3%Triton if intracellular staining was necessary. Cells were stained with primary anƟ body 
for 45 minutes at RT, washed and stained with secondary anƟ body for another 45 minutes at RT. For 
F-acƟ n staining, Phalloidin-Alexa 488 was used and incubated together with the secondary anƟ bodies. 
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The secondary anƟ bodies used were GAM-Alexa 568, GAM-Alexa 488, GAM-Alexa 648, GAR-Alexa 546 
all from (Invitrogen). Coverslips were carefully mounted using 15μL Prolong-Gold AnƟ fade Reagent 
(Invitrogen) and the sample was allowed to cure in the dark at room temperature for 24 hours. Finally, 
each coverslip was sealed at the corners with nail polish to prevent the coverslip from moving. Before 
inspecƟ on, the samples were stored in dark at 4°C. Coverslips were visualized using the Olympus 
Fluoview 1000 or the Leica TCS SP5 confocal microscope. Images were analyzed using ImageJ soŌ ware 
and its Fiji image processing package (Schindelin et al. 2012).
Reagents used are detailed below:
Primary anƟ bodies CD11a (mouse) HI111 Biolegend
Perforin (mouse) dG9 Biolegend
Pericentrin (rabbit) 4488 Abcam
Secondary anƟ bodies Goat anƟ  mouse Alexa Fluor 568 Invitrogen
Goat anƟ  mouse Alexa Fluor 648 Invitrogen
Goat anƟ  rabbit Alexa Fluor 546 Invitrogen
Phalloidin-Alexa Fluor 488                 Invitrogen
16. Statistical analysis
Data are represented as the mean values, and error bars show Standard deviaƟ ons. StaƟ sƟ cal 
analysis was done with the GraphPad soŌ ware (Prism). Student’s t-test or Mann-Whitney test was 
performed to compare pairs of data. MulƟ ple data were compared with one-way analysis of variance 
(ANOVA) and Tukey-Karmer post-test.  When two variables were analyzed, two-way ANOVA and 
Bonferroni post-test were used. When the p-value < 0.05, diﬀ erences were considered staƟ sƟ cally 
signifi cant. p-values are indicated by asterisks as follows:* p<0.05; ** p<0.01; *** p<0.001. 
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List of reagents
ReacƟ ve Supplier Reference
30% Acrylamide/Bis soluƟ on Biorad 161-0156
Amersham ECL GE Healthcare RPN1231
BX795 Invivo Gen tlrl-bx7
CFSE Invitrogen C34554
CMAC Molecular probes C2110
Coomasie protein assay reagent Thermo ScienƟ fi c 23200
DMSO Sigma D2650
DNPs Roche 11969064001
Ficoll-Paque GE Healthcare 17-1440-02
Human NK cell isolaƟ on kit Miltenyi Biotech 130-092-657
Human serum Sigma H4522
IFN-α Peprotech 300-02A
Igepal-CA630 Sigma I7771
Iodoactamide Sigma I612
Ionomycin Sigma I9657
LeupepƟ n Calbiochem 108975
Monensin Sigma M5273
Paraformaldehyde Sigma 158127
PepstaƟ n A Calbiochem 516481
PKH2 Sigma PKH2GL
PKH26 Sigma PKH26-GL
PMA Calbiochem 524400
Poly-L-Lysine Sigma P4832
Fast Plus EvaGreen® qPCR Master Mix BioƟ um 31020
Prolong Gold Invitrogen P36930
Propidium iodide Beckman 660755
Protamine sulfate Sigma P4020
Puromycin Calbiochem 540411
PVDF transfer membranes Millipore IPVH00010
Random Hexamers Roche 58002113-01
rh IL-12 p70 Peprotech 200-12
rh IL-18 MBL B001-5
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rh IL-2 Peprotech 200-02
RNAse inhibitors Promega N251A
Saponin Sigma S7900
SuperScript II RT Invitrogen 18064-022
T4 DNA ligase New England Biolabs M0202S
Triton X-100 Sigma T9284
Trizol Reagent Invitrogen 15596-026
Tween-20 Sigma P5927
X-ray fi lms Konica Minolta
Results
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1. Establishment of an in vitro system to study NK 
cell hyporesponsiveness
As described in the introducƟ on, previous studies analyzing NK cell induced hyporesponsiveness 
have been performed using transgenic mice, NK cells isolated from paƟ ents with diﬀ erent types of 
cancer or suﬀ ering virus infecƟ ons, or cocultures of NK cells with target cells during prolonged Ɵ mes. 
The main problem of these approaches is the use of a non-human mammal system in the case of 
transgenic mice, or the low numbers of available cells when working with paƟ ent-derived samples. 
The coculture strategy allows the generaƟ on of large numbers of induced-hyporesponsive NK cells but 
diﬀ erent receptor-ligand interacƟ ons between NK cells and diﬀ erent target cells may induce diﬀ erent 
eﬀ ects. 
In view of the extensive heterogeneity in receptor-ligand interacƟ ons as well as the variability 
between donors, and with the hypothesis that diﬀ erent strategies used by target cells to induce 
NK hyporesponsiveness, will probably at the end aﬀ ect the same processes or produce similar 
changes in NK cells, we decided to establish a model based on pharmacological inducƟ on of NK cell 
hyporesponsiveness.
Diﬀ erent chemicals have previously shown to aﬀ ect NK cell funcƟ ons e.g. histone deacetylase 
inhibitors (Ogbomo et al. 2007), demethylaƟ ng agents (Gao et al. 2009), glucocorƟ coids (Krukowski et al. 2011), staƟ ns (Raemer 
et al. 2009) or haemagluƟ nin (Mao et al. 2010). We decided to study the impact of ionomycin on NK cells as a 
way to mimic chronic exposure to sƟ muli, as it has been extensively used for study of CD4+ T cell anergy 
(Macian et al. 2002), with the aim to characterize some of the processes underlying hyporesponsiveness in 
NK cells.
1.1 Optimization of the Ionomycin treatment protocol 
Ionomycin has been used as an anergy inducing agent in CD4+ T cells from 1987 (Jenkins et al. 1987) as it 
sƟ mulates the Ca2+-Calcineurin-NFAT pathway mimicking the T-cell receptor signaling (Signal 1) in the 
absence of cosƟ mulaƟ on (Signal 2) (Laﬀ erty and Cunningham 1975), a combinaƟ on which results in the inducƟ on 
of hyporesponsiveness (Schwartz 2003). Using this in vitro model Anjana Rao’s lab and others described 
the geneƟ c program, and biochemical changes that lead to CD4+ T cell anergy (Macian et al. 2002; Heissmeyer 
et al. 2004). In those experiments CD4+ T cells were resuspended at 1million cells/mL and treated with 
0.5 or 1μM ionomycin, in an overnight culture (16 hours). To study the eﬀ ect of ionomycin on NK cell 
funcƟ on, NK cells maintained in vitro with feeder cells and IL-2, were washed and resuspended at a 
concentraƟ on of 1 million cells/ml in RPMI 10% FBS in the absence of IL-2, and treated with ionomycin 
1μM (or DMSO, vehicle control) for 16 hours as previously used with CD4+ T cells. AŌ er this treatment, 
cells were washed and rested for 24 hours at 2 million cells/mL in RPMI 10% FBS before coculture 
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with K562 target cells for 2 hours at an Eﬀ ector:Target (E:T) raƟ o of 1:2. K562 is a classical NK cell 
target cell line that does not express MHC class I molecules, but does express acƟ vaƟ ng ligands such 
as ULBP1 and ULBP2 (Fernandez-Messina et al. 2011). Immune recogniƟ on by NK cells was analyzed by assessing 
the ability of these cells to degranulate on contact with the K562 target cells by quanƟ fying secretory 
lysosome release by the increased cell surface expression of the transmembrane protein Lamp1 
(CD107a) which, as lyƟ c granules are released, becomes incorporated into the NK cell surface (Fig. 
1-A). An approximately 40% (-39.85 +/- 13.93) decrease in the degranulaƟ on of the NK cells treated 
with ionomycin was observed, confi rming that ionomycin treatment had a negaƟ ve eﬀ ect on NK cell 
funcƟ on.
AŌ er establishing that exposure to ionomycin had a negaƟ ve impact on NK cell degranulaƟ on 
ability, the concentraƟ ons needed and the kineƟ cs of this eﬀ ect were defi ned to opƟ mize the ionomycin 
induced NK cell loss of funcƟ on protocol. To assess the minimum amount needed, ionomycin was 
Ɵ trated over a range of concentraƟ ons from 0.25μM to 2μM. The maximum eﬀ ect was achieved aŌ er 
2μM treatment but this was accompanied by a decrease in NK cell viability. Thus, furhter experiments 
were carried out using a concentraƟ on of 1μM. The necessity for an overnight culture (16 hours), 
was also studied by comparing the eﬀ ects of 2, 4, 8, 16 hours of 1μM ionomycin treatment on NK cell 
funcƟ on. The highest reducƟ on in the NK cell degranulaƟ on capacity was observed aŌ er 16 hours 
of treatment (Fig. 1-B). The diﬀ erence in response between 8h (-19.48% +/- 11.48 lower response 
Fig. 1: Ionomycin treatment protocol opƟ mizaƟ on. (A) Example and scheme of the fl ow cytometry analysis of 
Lamp1 expression on NK cells aŌ er coculture with K562. (B) NK cells were treated with increasing amounts 
of ionomycin (from 0.25μM to 2μM). Treatment of NK cells with 1μM ionomycin was also Ɵ trated along Ɵ me 
(from 2 hours to 16 hours). Cells were washed and rested for 24 hours. To evaluate the infl uence of ionomycin 
treatment, cells were cocultured with K562 target cells during 2hours, and the percentage of Lamp1+ NK cells 
analyzed by fl ow cytometry.(n=5). The data show mean +/- SD. One way ANOVA and Bonferroni post-test analysis 
was used to calculate staƟ sƟ cal signifi cance using the logarithms of crude data. *p<0.05, **p<0.01, ***p<0.001.
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compared with control) and 16 hours (-42.95% +/- 14.09%) of ionomycin treatment was surprising. This 
necessity for a prolonged treatment suggests that novel protein synthesis processes are involved in the 
ionomycin induced NK cells loss of response. In summary, the inducƟ on of NK cell hyporesponsiveness 
aŌ er ionomycin treatment was dose and Ɵ me-dependent.
The fi nal protocol used for studying the eﬀ ect of ionomycin on NK cells was as follows:
During the course of the experiments outlined in this thesis, this degranulaƟ on experiment was 
performed prior to further experiments, to confi rm that the ionomycin treated cells to be used were in a 
hyporesponsive state. A few cell lines almost disappeared by cell death aŌ er treatment with ionomycin 
1μM, whereas the responsiveness of a few other cell lines was not aﬀ ected by ionomycin 1μM, and 
higher amounts of the calcium ionophore had to be used for them to become hyporesponsive. All 
data shown were obtained using NK cells treated with ionomycin 1μM, and using only those cells that 
showed a reduced degranulaƟ on response aŌ er this treatment. 
1.2 The cytotoxic function of Ionomycin treated NK cells 
To cause apoptosis on target cells, NK cells secrete preformed cytotoxic granules which contain 
pore forming proteins and several proteases. NK cells can also release members of the TNF-α family 
including Fas-Ligand, TNF-α or TRAIL which acƟ vate the death receptor pathway by binding to the 
target cell. To study the ability of NK cells to kill target cells by these mechanisms, cytotoxic granule 
release was analyzed by assessing the inducƟ on of surface Lamp1 on NK cells, while the inducƟ on of 
target cell death (caused by both mechanisms) was followed by fl ow cytometry (propidium iodide 
staining).
Scheme 2: Diagram of the protocol used ito study the ionomycin induced NK cell loss of funcƟ on
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1.2.1 The effect of ionomycin treatment on NK cell degranulation
NK cell lyƟ c granules, upon target cell recogniƟ on, are polarized and secreted to the immune 
synapse formed between the NK cell and the target cell. To study cytotoxic granule release ionomycin 
treated NK cells and control NK cells were cocultured with K562 target cells in a E:T raƟ o of 1:2 during 
2 hours and then, the presence of Lamp1 on the NK cell surface was studied (Fig. 2-A). To control for 
the variability between donors, the percentage of Lamp1+ cells in the control condiƟ on was considered 
as the potenƟ al maximum number of degranulaƟ ng NK cells for each donor, and the percentage of 
ionomycin-treated degranulaƟ ng NK cells, compared to the control condiƟ on, was calculated (Fig. 2-B). 
AŌ er ionomycin treatment, only around 40% (39.72 +/- 18.85) of the potenƟ al degranulaƟ ng NK cells 
were sƟ ll able to secrete lyƟ c granules when exposed to target cells, confi rming the previous results. 
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Fig. 2: Ionomycin treated NK cells 
showed lower ability to degranulate 
in response to K562, but responded 
eﬃ  ciently to PMA /Ionomycin 
sƟ mulaƟ on. (A) Flow cytometry 
analysis of the percentage of NK cells 
presenƟ ng Lamp1 on surface aŌ er 
coculture with K562 or aŌ er PMA/
Ionomcin (P/I) sƟ mulaƟ on during 2 
hours. (B and C) RelaƟ ve numbers 
of NK cells able to degranulate, 
compared to control cells, aŌ er 
coculture with K562. (A and B) 
Mean data and standard deviaƟ on 
are represented. Two tailed paired 
Student’s t test analysis. *p<0.05, 
***p<0.001. (C) Each line corresponds 
to one experiment. (n=10).
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To verify that ionomycin treated cells were sƟ ll able to secrete their lyƟ c granules, we sƟ mulated 
ionomycin treated cells with 100ng/mL PMA and 0.5μM ionomycin during 2 hours, in the absence 
of target cells, and stained for Lamp1 on the NK cell surface. SƟ mulaƟ on by the phorbol ester 
12,13-dibutyrate (PMA) and ionomycin sƟ mulates the RasGRP/PKC cascade and induces calcium 
mobilizaƟ on, bypassing proximal receptor signaling and driving NK cell acƟ vaƟ on. Ionomycin treated 
NK cells were able to respond to these sƟ muli (82.72% +/- 14.56%). These data indicate that ionomycin 
treated NK cells contained preformed lyƟ c granules, and that the degranulaƟ on machinery downstream 
PKC and IP3 was able to signal eﬃ  ciently and sƟ mulate the degranulaƟ on machinery, poinƟ ng to defects 
in either, or both, target cell recogniƟ on and in proximal receptor signaling. However the possibility of 
some defect downstream of PKC and IP3 could not be discarded from these data since, although the 
diﬀ erence between control and ionomycin treated NK cells was low (Fig. 2-B), ionomycin treated cells 
normally didn’t reach the level of degranulaƟ on of control cells also sƟ mulated with PMA/Ionomycin 
(Fig. 2-C). 
This experiment was repeated using a panel of diﬀ erent cell lines as targets (Jurkat, Molt4 and 
721.221) and similar levels of dysfuncƟ on were observed in each case, demonstraƟ ng that ionomycin 
treated NK cells were unable to degranulate eﬃ  ciently aŌ er sƟ mulaƟ on with target cells, independently 
of the target cells used (Fig. 3).
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Fig. 3: Ionomycin treated NK cells showed lower ability to degranulate in response to diﬀ erent target cells. (A) 
Flow cytometry analysis of the percentage of NK cells presenƟ ng Lamp1 on surface aŌ er coculture with K562, Jurkat, 
Molt-4 or 721.221 target cells during 2 hours. (B) RelaƟ ve quanƟ Ɵ es of NK cells able to degranulate compared to 
control cells.  (A and B) Mean data and standard deviaƟ on are represented (n=6). Two tailed paired Student’s t test 
analysis was used. *p<0.05, **p<0.01, ***p<0.001.
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1.2.2 The effect of ionomycin treatment on NK cell killing
While degranulaƟ on is a reasonable measure of NK cell acƟ vaƟ on it doesn’t necessarily correlate 
with target cell lysis, as killing also depends on mulƟ ple other factors such as the adhesion between 
target and eﬀ ector cell, the polarized secreƟ on of lyƟ c granules, proper lyƟ c granules content, and 
the eﬀ ect of apoptosis-inducing molecules which bind to death receptors on target cells (Fas-Ligand, 
TNF-α or TRAIL). 
To directly analyze target cell lysis, two diﬀ erent target cell lines: K562 and Jurkat cells were used. 
Both cell lines are sensiƟ ve to the eﬀ ect of lyƟ c granules, but Jurkat cells express Fas and DR4, and 
so are also sensiƟ ve to Fas-Ligand and TRAIL induced death, whereas K562 doesn’t express these 
molecules and so cell death depends exclusively on cytotoxic granule release by NK cells (Zamai et al. 1998). 
Target cells were labeled in green with a membrane dye (CFSE or PKH-2), mixed with the NK 
cells at an E:T raƟ o of 3:1 and incubated for 1, 3 or 5 hours. As a control for spontaneous cell death, 
target cells were also incubated alone. At the end of the coculture, cells were stained with Propidium 
iodide (PI), and analyzed by fl ow cytometry. The percentage of dead target cells was quanƟ fi ed as the 
percentage of green cells (CFSE or PKH-2 labeled) that acquired PI. PI is excluded from viable cells as it 
is membrane impermeable, labeling DNA and RNA of the dead cell populaƟ on only. 
Ionomycin treatment triggered a marked reducƟ on in NK cell killing of both types of target cells 
(Fig. 4). Although ionomycin treatment markedly reduced NK cytotoxicity against both targets, some 
diﬀ erences could be observed between K562 and Jurkat cells. In parƟ cular, the relaƟ ve killing of Jurkat 
cells by ionomycin treated cells was higher than that observed for K562 targets (30.4% +/- 12% of 
relaƟ ve to control target cell death aŌ er 5 hours of coculture for Jurkat cell as targets, compared to 
17.15% +/- 6.107% aŌ er 5 hours for K562). This higher relaƟ ve killing of Jurkat cells compared to K562 
by ionomycin treated cells could be due to some level of apoptosis inducƟ on by death receptors which 
could imply that the release of Fas-Ligand or TRAIL is somewhat resistant to ionomycin treatment, but 
it could also be due to the diﬀ erent sensiƟ viƟ es to NK cell killing of these diﬀ erent target cell lines by 
the expression of diﬀ erent ligands.
One surprising result from this experiment was the low level of target cell killing by the ionomycin 
treated NK cells with both target cell lines, even though almost 40% of these NK cells sƟ ll degranulate 
aŌ er coculture with these target cells (Fig. 3).  This result could be explained by defi ciencies in the 
content of the cytotoxic granules, in polarized secreƟ on of granules or defects in the adhesion between 
NK and target cells. These features were analyzed later and are described in secƟ on 2.
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1.2.3 Effect of IL-2 on the degranulation ability of ionomycin treated NK cells 
The previous data suggested that NK cells were becoming hyporesponsive aŌ er treatment with 
1μM ionomycin, as occurs with CD4+ T cells. IL-2 treatment of ionomycin induced anergic CD4+ T cells, 
rescues the funcƟ onality of these cells (Beverly et al. 1992; Macian et al. 2002). In some prior studies hyporesponsive 
(not ionomycin-induced) NK cells could be rescued by IL-2 sƟ mulaƟ on (Abrams and Brahmi 1986; LeFever and 
Funahashi 1991; Coudert et al. 2005; Tripathy et al. 2008; Sarkar et al. 2013), but not in others (JeweƩ  and Bonavida 1995; JeweƩ  and Bonavida 
1996). Thus it was of interest to study the eﬀ ect of IL-2 on ionomycin treated NK cells. 
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Fig. 4: Ionomycin treated NK cells were unable to kill eﬃ  ciently K562 or Jurkat target cells. (A) Flow cytometry 
analysis of the percentage of PI posiƟ ve K562 or Jurkat cells aŌ er coculture with DMSO or 1μM ionomycin treated 
NK cells during 1h, 3h or 5 hours. (B) Percentage of PI posiƟ ve K562 or Jurkat target cells relaƟ ve to the percentage 
of PI posiƟ ve target cells aŌ er 5 hours of coculture with DMSO treated NK cells. (A and B) Mean data and standard 
deviaƟ on, are represented. (n=4). Two way paired ANOVA analysis and Bonferroni posƩ est. *p<0.05, **p<0.01, 
***p<0.001.
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As shown in fi gures 5 A and B, when ionomycin treated NK cells were sƟ mulated with 50U/mL 
of IL-2 during the rest day (aŌ er washing to remove the ionomycin) normal degranulaƟ on was re-
established implying that the ionomycin imposed defect was reversible. 
1.2.4 Effect of IL-12 / IL-18 and IFN type 1 on degranulation by ionomycin treated NK cells
Infl ammatory cytokines have been proposed to be the third signal needed for T cell acƟ vaƟ on 
(aŌ er TCR and cosƟ mulatory signals), and for example IL-12 is known to rescue exhausted CD8+ T cells 
(Schurich et al. 2013). IL-12, IL-18 and type 1 interferons have also been used to recover hypofuncƟ onal NK 
cells (Abrams and Brahmi 1986; Yokoyama and Kim 2006; Tripathy et al. 2008; Mazumdar et al. 2013). Type 1 interferons and IL-12/
IL-18 are cytokines secreted by diﬀ erent cell types including acƟ vated macrophages, dendriƟ c cells or 
neutrophils, and are known to directly sƟ mulate NK cell acƟ vity (Trinchieri 1995; Swann et al. 2007; Chaix et al. 2008; 
MarƟ nez et al. 2008). In the context of infl ammaƟ on these cytokines will be secreted and can act as potent 
acƟ vators of NK cells funcƟ on.
To study the infl uence of these cytokines on ionomycin treated NK cells, we sƟ mulated them 
during the resƟ ng day with a combinaƟ on of 10ng/mL IL-12 plus 10ng/mL IL-18, or with 100 and 
1000U/mL of IFN-α in combinaƟ on or not with 10ng/mL IL-18.
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Fig.5:  Ionomycin treated NK cells recovered their degranulaƟ on ability aŌ er being cultured in the presence of 
IL-2. (A) NK cells were washed and sƟ mulated with 50 U/mL IL-2 during one day, aŌ er washing from the ionomycin 
/ DMSO treatment. Cells were cocultured with K562 during 2 hours and stained for Lamp1 expression. (B) RelaƟ ve 
quanƟ ty of NK cells able to degranulate aŌ er ionomycin treatment, and IL-2 sƟ mulaƟ on, compared to control cells. 
(n=12). (A and B) Mean data and standard deviaƟ on are represented. Two tailed paired Student’s t test analysis. 
***p<0.001.
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Although both sƟ muli, IL-12 + IL-18 and IFN-α were able to increase the number of NK cells 
degranulaƟ ng, the diﬀ erence between control and ionomycin treated cells was maintained (Fig.6). 
Therefore, sƟ mulaƟ on with these cytokines does not restore the funcƟ onality of ionomycin-treated 
NK cells.
1.3 Cytokine production by ionomycin treated NK cells
Another important role of NK cells is the producƟ on of cytokines and chemokines that can regulate 
the funcƟ on of other immune cells. One of the main cytokines secreted by NK cells is IFN-γ (Fauriat et al. 
2010). It has been reported that freshly isolated CD56dim NK cells contain preformed IFN-γ mRNA and 
so are able to produce and secrete IFN-γ very quickly (De Maria et al. 2010). However, when NK cells were 
cocultured with K562 target cells during 6 hours in the presence of monensin, which impairs protein 
traﬃ  cking and leads to the accumulaƟ on of IFN-γ in the Golgi apparatus, IFN-γ producƟ on by NK cells 
Fig. 6: Ionomycin treated NK cells did 
not recover their funcƟ onality aŌ er 
exposure to IL-12 / IL-18 or to IFN-α. 
NK cells were sƟ mulated with (A and 
B) IL-12 / IL-18 (C) or IFN-α +/- IL-18, 
during the freshly isolated day, and 
stained with Lamp1 anƟ bodies aŌ er 
2 hours coculture with K562. (B and 
C) RelaƟ ve quanƟ ty of NK cells able 
to degranulate compared to control 
condiƟ on (DMSO). (A and B n=14; 
C n= 3) (A, B and C) Mean data and 
standard deviaƟ on are represented. 
(A) Two tailed paired Student’s t 
test analysis was used. ***p<0.001. 
(C) Paired two way ANOVA analysis 
and Bonferroni post-test. *p<0.05, 
**p<0.01.
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was not detected by intracellular fl ow cytometry, perhaps due to the lower sensiƟ vity of the fl ow 
cytometry technique.
Therefore to increase the producƟ on of IFN-γ, control and ionomycin treated NK cells were 
sƟ mulated with IL-12 and IL-18 (10ng/mL of each) during the resƟ ng day. This is a sƟ mulus that NK 
cells can receive from macrophages and dendriƟ c cells and enhances IFN-γ producƟ on by NK cells (Chaix 
et al. 2008). When sƟ mulated with IL-12/IL-18, hyporesponsive NK cells produced much less IFN-γ than 
untreated NK cells and while the producƟ on of IFN-γ  by control NK cells was further increased on 
exposure to target cells, this was not observed for ionomycin treated NK cells. When sƟ mulated with 
IL-2 both control and ionomycin treated cells were able to produce similar amounts of IFN-γ  when 
exposed to target cells (Fig. 7), implying that the changes suﬀ ered by ionomycin-treated NK cells were 
reversible. We also sƟ mulated control and ionomycin treated cells with 100ng/mL PMA and 0.5μM 
ionomycin during 6 hours, in the absence of target cells, and observed no diﬀ erence between the 
percentage of IFN-γ posiƟ ve control and ionomycin treated cells, however, the median fl uorescence 
of the ionomycin treated IFN-γ posiƟ ve cells was lower (62.41 % +/- 31.55 of the median fl uorescence 
intensity seen for the control cells treated with PMA/Ionomycin) (data not shown), suggesƟ ng that 
each cell made less of this cytokine.
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Fig. 7: Ionomycin treated NK cells 
were unable to secrete IFN-γ as 
eﬃ  ciently as control cells aŌ er 
IL-12 / IL-18 sƟ mulaƟ on, but they 
were eﬀ ecƟ ve producers when 
sƟ mulated with PMA/Ionomycin 
or aŌ er overnight sƟ mulaƟ on with 
IL-2. IFN-γ producƟ on by NK cells 
was analyzed by fl ow cytometry. For 
all sƟ mulaƟ on condiƟ ons control 
(white bars), ionomycin treated 
(grey), control cocultured with K562 
for 6h (lined white) or ionomycin 
treated cocultured with K562 for 6 
hours (lined grey) where analyzed. 
Cells were unsƟ mulated, sƟ mulated 
with IL-2 overnight, sƟ mulated 
with IL-12/IL-18 overnight or with 
PMA/Ionomycin during 6 hours. 
Mean data and standard deviaƟ ons 
are represented (n=6). Two tailed 
paired Student’s t test analysis. 
*p<0.05, **p<0.01, ***p<0.001.
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The low levels of IFN-γ induced by target cells on ionomycin treated NK cells might be explained 
by failures of target cell recogniƟ on, adhesion or sƟ mulaƟ on, which are upstream of PKC and IP3 
sƟ mulaƟ on. However, the lower levels of IFN-γ producƟ on observed when the cells were sƟ mulated 
with IL-12 and IL-18 in the absence of target cells implied signaling defects or lack of proper cytokine 
recogniƟ on. A lower stability of IFN-γ mRNA, or epigeneƟ c changes around to the IFN-γ gene may also 
explain these defects. Some of these possibiliƟ es were analyzed in secƟ on 3.
1.3.1 Autoregulation
NK cells are known to be able to secrete a range of immunoregulatory cytokines including IL-10, 
IL-13 or TGF-ß. Thus a possible explanaƟ on for the defects observed in ionomycin treated cells, was 
that they were secreƟ ng molecules which acted to inhibit their capacity to mediate cytotoxicity or 
secrete pro-infl ammatory cytokines. 
To test this hypothesis, PKH-2 stained NK cells maintained with IL-2 were cocultured with either 
vehicle control or ionomycin (1μM) treated NK cells, for 24 hours in the absence of IL-2. AŌ er the 
coculture, the degranulaƟ on ability of acƟ vated NK cells (PKH-2 stained) as well as the control and 
ionomycin treated NK cells (PKH-2 negaƟ ve) was analyzed.
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Fig. 8: Ionomycin treated NK cells were not secreƟ ng 
any immunosuppresive factor. NK cells were treated 
with 1μM ionomycin (light grey) or DMSO (white) 
during 16 hours. AŌ er washing, PKH-2 stained NK cells 
from the IL-2 cultures were added and cocultured with 
DMSO or ionomycin treated NK cells for 24 hours (dark 
grey). The percentage of NK cells presenƟ ng Lamp1 
on surface aŌ er coculture with K562 was evaluated by 
fl ow cytometry. Data represent the relaƟ ve percentage 
of Lamp1+ cells, related to the DMSO alone condiƟ on. 
Mean data and standard deviaƟ ons are represented 
(n=4). Paired one way Anova analysis and Tukey´s 
mulƟ ple comparison test.
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No diﬀ erences in the ability of the PKH-2 labeled NK cells to degranulate on exposure to target 
cells was observed aŌ er coculture with either DMSO or ionomycin treated NK cells (Fig. 8). These 
observaƟ ons strongly suggest that ionomycin treated NK cells do not release any immunosuppressive 
factors into the culture media and suggest that the defect is intrinsinc to the hyporesponsive NK cell.
1.4 Effect of ionomycin treatment on NK cell viability
Although ionomycin treated NK cells were funcƟ onal as they responded to PMA/Ionomycin 
sƟ mulaƟ on as eﬃ  ciently as control cells and culture in IL-2 rescued the hyporesponsive phenotype, 
it was important to analyze the viability of these cells to discard the possibility that the Lamp1+ 
populaƟ on observed in ionomycin treated cells (Fig.1-A) was due to cells which enter into apoptosis 
aŌ er the ionomycin treatment.
To analyze NK cell viability we cocultured NK cells with K562 for 2 hours, and stained them with 
CD56 (to disƟ nguish between NK cells and target cells), Lamp1 (to defi ne degranulaƟ ng and non-
degranulaƟ ng NK cells) and Annexin-V /7-AAD (7-AminoacƟ nomycin D) to analyze the viability of 
degranulaƟ ng and non-degranulaƟ ng NK cells in the control and ionomycin treated NK cells. Annexin-V 
stains phosphaƟ dylserine which appears on the surface of non-permeabilised cells in early apoptosis 
states due to the loss of the normal asymmetric distribuƟ on of phosphaƟ dylserine. 7-AAD, similar to 
propidium iodide, has high aﬃ  nity for DNA and intercalates with it, but since it is cell impermeant, 
7-AAD only stains cells with disrupted membranes, such as cells in late apoptosis states, or necroƟ c 
cells. 
These experiments demonstrated that the ionomycin treated NK cells were as viable as control 
cells, although the few ionomycin treated Lamp1+ NK cells stained slightly more Annexin V posiƟ ve 
than control cells (Fig.9). It was surprising to fi nd this high level of phosphaƟ dylserine posiƟ ve cells 
in the Lamp1+ populaƟ on in both control and ionomycin treated cells. However, this staining was 
probably not due to NK cell apoptosis, but rather to the process of degranulaƟ on, as this extracellular 
Annexin-V staining has also been described in mast cell degranulaƟ on processes (Demo et al. 1999), and 
diﬀ erent members of the Annexin family have been described to have a role in membrane fusion 
processes, including degranulaƟ on (Gerke et al. 2005). Thus phosphaƟ dylserine expression at the cell surface 
would be a consequence of the degranulaƟ on process similar to the increased exposure of Lamp1 at 
the cell surface. 
These data confi rmed the viability of the ionomycin treated cells; and the observed co-staining 
of Lamp1 and Annexin-V strongly suggests that ionomycin treated cells were able to exert real 
degranulaƟ on processes.
75
Results
An
ne
xi
n
V+
An
ne
xi
n
V+
 &
 7
AA
D+
An
ne
xi
n
V+
An
ne
xi
n
V+
 &
 7
AA
D+
An
ne
xi
n
V+
An
ne
xi
n
V+
 &
 7
AA
D+
Total Lamp1- Lamp1+
%
 N
K 
ce
lls
0
20
40
60
+ DMSO              
+ 1μM ionomycin
Fig. 9: Ionomycin treated NK cells were as viable as control cells. The Lamp1+ populaƟ on was more Annexin-V 
posiƟ ve than the Lamp 1– in control and treated cells. Control and ionomycin treated NK cells were stained with 
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2. Cytotoxic recognition by ionomycin treated     
 NK cells
The previous work characterizing the responsiveness of ionomycin treated NK cells, had shown that 
they were ineﬀ ecƟ ve killers (Fig. 3 and 4), and unable to produce IFN-γ aŌ er IL-12 / IL-18 sƟ mulaƟ on 
and coculture with target cells (Fig. 7). These data established the existence of defects on target cell 
recogniƟ on, but leŌ  open the stage(s) of the killing process in which ionomycin treated NK cells were 
defecƟ ve.
2.1 Conjugate formation
AŌ er the very iniƟ al stages of NK cell/target cell contact and recogniƟ on, the interacƟ on between 
cells has to be stabilized. This process requires the specifi c interacƟ on of adhesion molecules such as 
integrins that collaborate in iniƟ al cell to cell contacts, and later when the cell is selected as target, 
produce strong binding following acƟ vaƟ on of these integrins by inside-out signaling. 
The ability of NK cells to form Ɵ ghtly bound conjugates with target cells was studied using a fl ow 
cytometry based protocol where NK cells and target cells were labeled with diﬀ erent fl uorescent dyes 
(PKH-2 - green, and PKH-26 - red were used) and co-incubated at 37oC. Samples were collected aŌ er 
2, 5, 10, 20, 30, 45, and 60 minutes and vortexed to disrupt loosely associated cells and fi xed. AŌ er 
collecƟ ng all the Ɵ me points, the double posiƟ ve events which represent NK cells fi rmly adhered to 
target cells (Fig. 10-A) were quanƟ fi ed by fl ow cytometry.
Ionomycin treated NK cells were less able to form conjugates, with the maximum diﬀ erences 
observed between 20 and 45 minutes (Fig. 10-B). Due to high variaƟ on between NK cells from diﬀ erent 
donors, the data are presented as the percentage of ionomycin treated NK cells forming conjugates 
with K562 relaƟ ve to the percentage of DMSO treated NK cells (control cells) forming conjugates with 
K562 at the same Ɵ me points (Fig. 10-C). In this analysis all the Ɵ me points except the 60 minutes 
point were <1 (control cells level), and represent between a 44% (at 2 minutes) and a 26% (45 minutes) 
reducƟ on in the percentage of ionomycin treated cells that form conjugates compared to the formaƟ on 
of conjugates by control NK cells. 
This diﬀ erence in the percentage of cells forming conjugates could be due to the existence of a 
lower percentage of NK cells able to form stable conjugates with targets, or to the formaƟ on of less 
stable conjugates. Less stable conjugates could be explained by defects in target cell recogniƟ on, by 
diﬀ erenƟ al expression of NK cell acƟ vaƟ ng or inhibitory receptors; or to an inability to form stable 
interacƟ ons with target cells, by for example lower levels of adhesion molecules.
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However, ionomycin treated NK cells were sƟ ll able to form a signifi cant amount of conjugates 
with target cells, and the diﬀ erence between ionomycin treated and control cells was just 15% aŌ er 
60 minutes of coculture with K562 (ionomycin treated cells forming conjugates referred to the cells 
able to form conjugates in the control condiƟ on Fig.10-C). This small diﬀ erence didn’t correlate with 
the much lower levels of target cell killing observed (17.154% +/- 6.107% aŌ er 5 hours Fig. 4). For this 
reason, although a lower eﬃ  ciency of conjugate formaƟ on could be part of the explanaƟ on of the 
defi cient target cell killing, more steps of the NK cell killing process were analyzed.
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Fig. 10: Ionomycin treated NK cells formed conjugates less eﬃ  ciently. Conjugate formaƟ on was analyzed by fl ow 
cytometry. (A) NK cells and target cells were stained with diﬀ erent dyes. Conjugates appear as double posiƟ ve 
events. (B) The percentage of NK cells forming conjugates varies over Ɵ me.  Mean data are represented. (C) The 
number of ionomycin treated NK cells forming conjugates is expressed relaƟ ve to the percentage of NK cells forming 
conjugates in the control condiƟ on. Mean data and standard deviaƟ ons are represented. (n=15). Paired two way 
ANOVA analysis and Bonferroni posƩ est.*p<0.05, ***p<0.001.
78
Results
2.2 LFA-1 and actin polarization 
One of the fi rst steps that take place aŌ er NK recogniƟ on of a target cell is the polarizaƟ on of 
adhesion molecules as LFA-1 and Mac-1 into the pSMAC where they contribute to the formaƟ on 
of conjugates between the NK and the target cell. Integrins are then further acƟ vated by inside-
out signals provided by the acƟ vaƟ ng sƟ mulus. In contrast to TCR dependent LFA-1 acƟ vaƟ on in T 
cells, in NK cells, LFA-1 is suﬃ  cient to start its own inside-out signals (Barber and Long 2003). This acƟ vated 
LFA-1 will also start signaling cascades, and contribute to granule polarizaƟ on and acƟ n polymerizaƟ on 
(Barber et al. 2004). Rearrangements of the acƟ n cytoskeleton lead to the accumulaƟ on of fi lamentous acƟ n 
(F-acƟ n) and the formaƟ on of a talin/acƟ n/LFA-1 pSMAC collar which stabilizes the union between 
eﬀ ector and target cells, generates the plaƞ orm for a localized delivery of cytotoxic granules, aids the 
establishment of new signaling complexes and facilitates the accumulaƟ on of lipid raŌ s to the synapse 
(Vyas et al. 2002). AcƟ n polymerizaƟ on also favours integrin polarizaƟ on towards the pSMAC (Orange et al. 2003), 
and disrupƟ on of acƟ n polymerizaƟ on processes results in severe impairment of NK cell acƟ vity (Orange 
et al. 2002).
To assess if ionomycin treated cells were able to eﬃ  ciently polarize molecules towards the immune 
synapse the behaviour of LFA-1 and F-acƟ n was studied due to the important roles of these molecules 
both in the formaƟ on of stable synapses and in the further transmission of signals.
Immune synapse formaƟ on was analyzed by confocal microscopy. K562 target cells were stained 
with CMAC dye to disƟ nguish them from eﬀ ector cells. Then NK cells and CMAC labeled K562 cells 
were cocultured over poly-L-lysine coated coverslips for one hour, before the samples were fi xed 
and stained with LFA-1-specifi c monoclonal anƟ body and Phalloidin, a fungal toxin which specifi cally 
binds F-acƟ n. Samples were visualized by confocal microscopy and conjugates were selected for image 
collecƟ on. Later the raƟ o of LFA-1 and Phalloidin fl uorescence between the synapse, and non synapse 
membrane zones of control and ionomycin treated NK cells was quanƟ fi ed using ImageJ-FIJI (Schindelin 
et al. 2012). Briefl y, the signals in the LFA-1 channel of the background, membrane in the synapse-zone, 
and non synapse-zone, were measured by drawing areas with the FluorescenceRaƟ o plugin for ImageJ 
(created by C.O.Sánchez-Sorzano) which calculated the fl uorescence raƟ o from the intensity of the 
signals in the synapse vs. non synapse membrane regions. For quanƟ fying F-acƟ n polarizaƟ on, the 
Synapse measures plugin (Calabia-Linares et al. 2011) (which also measures the target cell F-acƟ n contribuƟ on 
to the immune synapse) (Fig. 11-A) was used.
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Fig. 11: Ionomycin treated NK cells were able to polarize LFA-1 and accumulate F-acƟ n in the immune synapse 
with target cells as eﬃ  ciently as control cells. NK cells were allowed to interact with CMAC labeled K562 cells 
(light blue) and to aƩ ach to poly-L-lysine coated coverslips during 1hour. Cells were fi xed and stained with primary 
and secondary anƟ bodies: anƟ -LFA-1 anƟ body (H1III clone) & GAM-Alexa 648 (dark blue), anƟ -pericentrin anƟ body 
(Ab4488) & GAM-Alexa 546 (Red); and with Phalloidin– Alexa 488 (green). (A) LFA-1 and F-acƟ n polarizaƟ on to 
the NK immune synapse was quanƟ fi ed using ImageJ plugins Fluorescence raƟ o (LFA-1) and Synapse measures 
(F-acƟ n). RepresentaƟ ve example of F-acƟ n polarizaƟ on quanƟ fi caƟ on. (B) RepresentaƟ ve examples of control 
(top) and ionomycin treated (lower) cells staining of single Alexa 648 (LFA-1) and Alexa 488 (F-acƟ n) channel colors, 
and their merge. (C) QuanƟ fi caƟ on of LFA-1 and F-acƟ n fl uorescence raƟ os. Each line corresponds to one cell 
analyzed. (D) Mean fl uorescence intensity of LFA-1 – Alexa 648 staining in control and ionomycin treated cells was 
measured by ImageJ. Mean data and standard deviaƟ ons are represented. Each symbol corresponds to one cell 
analyzed. (n=22 DMSO, n=29 Ionomycin) Mann Whitney Test. **p<0.05.
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In general, ionomycin treated NK cells expressed lower amounts of LFA-1 compared to control 
cells. To quanƟ fy LFA-1 staining the mean fl uorescence of each cell was measured using ImageJ and 
these data confi rmed our observaƟ on (Fig. 11-D), however some ionomycin treated NK cells that 
expressed high amounts of LFA-1 were also detected (Fig. 11-A2). InteresƟ ngly, despite the lower 
levels of LFA-1 expression found in ionomycin treated NK cells, those NK cells that formed conjugates 
with K562 target cells were able to polarize LFA-1 with the same eﬃ  ciency, and accumulate F-acƟ n 
in the immune synapse zone (Fig. 11-B, C). Further analyses of the decreased LFA-1 expression are 
described in secƟ on 3.
2.3 Cytotoxic granule polarization
AŌ er the formaƟ on of stable conjugates between the NK and the target cell, receptors and 
adhesion molecules polarize to the cytotoxic immune synapse accompanied by the creaƟ on of an 
F-acƟ n ring. The newly acƟ ve signaling cascades will lead to cytotoxic granule polarizaƟ on, driven by 
the MTOC (microtubule organizing centre), to the immune synapse (Orange 2008). 
The polarizaƟ on of cytotoxic granules was analyzed by confocal microscopy. As before, K562 target 
cells were stained with CMAC and cocultured with control and ionomycin treated NK cells on poly-L-
lysine coated coverslips for one hour. The samples were then fi xed and stained with a perforin-specifi c 
anƟ body to label cytotoxic granules. Finally, the number of NK cells forming conjugates with their 
cytotoxic granules polarized towards the site of contact between the NK cell and the target cell was 
quanƟ fi ed. In these experiments three diﬀ erent types of conjugates were counted depending if the 
lyƟ c granules were non polarized, fully-polarized and parƟ al polarized (when most of the granules are 
polarized but there are granules also in other zones of the cell) (Fig. 12-A).
As expected from the previous fl ow cytometry analysis (Fig.10) in these experiments the 
ionomycin treated NK cells formed lower numbers of conjugates with the target cells. A small tendency 
for ionomycin treated NK cells to have less conjugates with their granules polarized was observed, 
however, many of those ionomycin treated NK cells which formed conjugates, were able to polarize 
their granules eﬃ  ciently (Fig.12-B).
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Fig. 12: Ionomycin treated NK cells forming 
conjugates with target cells, polarized lyƟ c 
granules as eﬃ  ciently as control cells. (A) Three 
diﬀ erent granule polarizaƟ on situaƟ ons were 
defi ned: non polarized, parƟ ally polarized and 
polarized. F-acƟ n (Phalloidin-Alexa 488) appears 
in green, granules in red (Perforin anƟ body + 
GAM-Alexa 568) and target cells in blue (CMAC 
dye. (B) The state of lyƟ c granules polarizaƟ on 
was quanƟ fi ed among the conjugates formed 
between NK cells and K562 cells by confocal 
microscopy. Mean data and standard deviaƟ ons 
are represented. Paried two way ANOVA analysis 
and Bonferroni posƩ est. *p<0.05
82
Results
3. Characterization of receptors expressed by 
ionomycin treated NK cells
The data outlined in chapters 1 and 2 indicated that ionomycin treated NK cells were unable 
to kill target cells or respond to treatment with the cytokines IL-12 and IL-18 eﬃ  ciently. Analysis of 
specifi c steps of the killing process showed defects in conjugate formaƟ on with target cells, and lower 
levels of LFA-1 expression. However many of those ionomycin treated NK cells that were able to form 
conjugates, were competent to polarize LFA-1 and their lyƟ c granules towards the cytotoxic immune 
synapse.
The NK cell populaƟ on of an individual consists of cells expressing diﬀ erent inhibitory receptors 
in a stochasƟ c manner. NK cells responsiveness is thought to be established during their development 
and is infl uenced by the repertoire of receptors they express and the levels of expression of these 
molecules. According to this model (the rheostat model) the NK subset of each individual is composed 
of a heterogeneous populaƟ on of NK cells expressing variable repertoires of acƟ vaƟ ng and inhibitory 
receptors, covering a spectrum of responsiveness and adapted to the individual (Brodin et al. 2009; Shafi  et al. 
2011). This variaƟ on in the threshold required to trigger a response between circulaƟ ng NK cell clones 
of a given individual could be another explanaƟ on of why around 40% of the potenƟ al degranulaƟ ng 
NK cells were sƟ ll able to secrete lyƟ c granules aŌ er treatment with ionomycin (Fig. 2). If ionomycin 
treatment acts by “tuning” the NK cell acƟ vaƟ on threshold, then although aŌ er treatment many cells 
would be unable to reach their acƟ vaƟ on fronƟ er (rendered unresponsive), it would not be surprising 
if there also existed some cells sƟ ll able to respond to target cell sƟ mulaƟ on, form stable conjugates, 
and able to polarize LFA-1, F-acƟ n and lyƟ c granules (Fig. 11 and 12). This hypothesis would also explain 
why ionomycin-exposed NK cells sƟ ll responded to treatment with a very powerful sƟ mulus such as 
the combinaƟ on of PMA and ionomycin. Given that it is a balance of signals coming from acƟ vaƟ ng 
and inhibitory receptors that determines whether NK cells reach the threshold signalling required 
for acƟ vaƟ on, NK cells were stained for diﬀ erent acƟ vaƟ ng and inhibitory receptors. Lower levels of 
acƟ vaƟ ng receptors or adhesion molecules, and/or higher levels of inhibitory receptors could explain 
the absence of target cell recogniƟ on and less stable conjugate formaƟ on. To complement these data, 
experiments of redirected-anƟ body dependent cell cytotoxicity and analysis of calcium fl ux were 
performed to study the funcƟ onality of individual receptors or combinaƟ ons of diﬀ erent molecules. 
Finally, the expression of molecules that are diﬀ erenƟ ally expressed between diﬀ erent populaƟ ons of 
NK cells was also examined to test whether ionomycin treatment preferenƟ ally aﬀ ected, or spared, the 
funcƟ on of parƟ cular NK cell subpopulaƟ ons.
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3.1 Activating and inhibitory receptors
NK cells express a large variety of diﬀ erent acƟ vaƟ ng receptors. As described in the introducƟ on, 
various arƟ cles have described diﬀ erent changes in the phenotype of hyporesponsive NK cells. However, 
to date, no clear relaƟ onship has been established between these changes and the hyporesponsive 
state.
Flow cytometry was used to analyze the expression of diﬀ erent NK acƟ vaƟ ng and inhibitory 
receptors by DMSO and 1μM ionomycin treated cells but no consistent diﬀ erence was observed 
between these populaƟ ons. The acƟ vaƟ ng receptors analyzed were: NKG2D, NKp46, NKp30, CD16, 
CD94, 2B4 and CD28. The diﬀ erent inhibitory receptors studied were: KIR2DL1 (CD158a), KIR2DL2/DL3 
(CD158b), KIR3DL1 (CD158e1); CD94, LILRB1 (ILT2, CD85j) and CD161 (KLRB1). 
The induced expression of molecules as PD-1 and CTLA-4 has been related to T cell anergy and 
exhausƟ on (Greenwald et al. 2001; Crawford and Wherry 2007) and so the eﬀ ect of ionomcyin treatment on NK cell 
expression of these molecules was also studied. In a few donors a small PD1 posiƟ ve populaƟ on could 
be detected aŌ er ionomycin treatment, or a slight movement of the whole the cell populaƟ on was 
noted, but this was not consistent between diﬀ erent donors (Fig. 13-A). No inducƟ on of CTLA-4 was 
observed.
Fig. 13: Ionomycin treated NK cells expressed the same level of acƟ vaƟ ng and inhibitory receptors. In 
some cells lines small increases in PD1 expression could be observed but this was not consistent between 
diﬀ erent cell lines. CD3-ζ chain expression is decreased in ionomycin treated cells. (A) RepresentaƟ ve 
histogram of fl ow cytometry analysis of DMSO and ionomycin treated cells stained with isotype control and 
PD1-specifi c anƟ bodies. Numbers represent the percentage of posiƟ ve cells (percentage of cells under the 
bar), and the whole populaƟ on MFI. (B) RepresentaƟ ve western blot analysis of 50μg of total cell lysates 
using NP40 lysis buﬀ er. NK cells from two diﬀ erent donors, treated and untreated with ionomycin are shown. 
Membranes were exposed to CD3-ζ and ß-acƟ n anƟ bodies.
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The CD3-ζ chain is an adaptor molecule used by various NK cell acƟ vaƟ ng receptors (CD16, NKp46 
and NKp30) for signal transmission. DownregulaƟ on of this molecule has been reported in tumor 
associated NK cells (Lai et al. 1996; Patankar et al. 2005), and in mouse NK cells chronically exposed to NKG2D 
ligand expressing target cells (Coudert et al. 2005; Coudert et al. 2008; Hanaoka et al. 2010), further loss of CD3-ζ has 
also been related with CD4+ T cell anergy (Heissmeyer et al. 2004). Western blot analysis showed decreased 
expression of this molecule in ionomycin treated NK cells (Fig. 13-B) poinƟ ng to defects in acƟ vaƟ ng 
receptor signal transmission.
3.2 Adhesion molecules
In pevious experiments of confocal microscopy lower levels of expression of LFA-1 (αLß2 integrin, 
CD11a:CD18) in the 1μM ionomycin treated cells were noted (Fig. 11-D). Integrins are known to switch 
from a compact or closed conformaƟ on to an open acƟ ve conformaƟ on (Luo et al. 2007) changing their avidity 
(regulated by receptor clustering), and aﬃ  nity for their ligand (changes in integrin conformaƟ on, with 
three steps: closed, intermediate and open or high aﬃ  nity). Thus, to confi rm the previous observaƟ on 
by confocal microscopy of the lower expression of the αL subunit, it was analyzed by fl ow cytometry. 
Other integrin molecules as the αM subunit (CD11b) and the ß2 subunit (CD18) were also analyzed 
since both αL and αM associate with ß2 to arrive to the cell surface. A range of mAbs were used to 
study αL subunit expression. The HI111 anƟ body, which binds the I-domain of the αL chain and binds 
all forms of LFA-1 although it preferenƟ ally recognizes LFA-1 in its closed conformaƟ on, since it binds 
with lower aﬃ  nity to LFA-1 locked in the open conformaƟ on or acƟ vated by divalent caƟ ons (Ma et 
al. 2002). To study open states of LFA-1 the expression of αL was analyzed with an anƟ body (NKI-L16) 
specifi c for the acƟ ve conformaƟ on of integrins (Keizer et al. 1988). This mAb recognizes an epitope exposed 
only in αL integrins in a Ca2+-bound, extended conformaƟ on (van Kooyk et al. 1991), and reacƟ vity with this 
mAb has been related to clustering-dependent increases in the avidity of αL integrins for their ligands. 
ReacƟ vity with the ab24 anƟ body which recognizes an epitope of the β2 chain I-like domain which 
is accessible to the anƟ body only in the Mg2+-dependent extended or high aﬃ  nity conformaƟ on of 
LFA-1 (Stewart et al. 1996), and one anƟ body specifi c for the acƟ ve conformaƟ on of αM (cbrm1/5) (Diamond and 
Springer 1993) was also examined, but no cell staining was observed with these mAbs (Fig. 14-A).
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The decrease in the expression of LFA-1 observed by fl ow cytometry agreed with the previous 
observaƟ ons made in experiments of confocal microscopy (Fig.11-D). In the majority of the experiments 
performed, ionomycin treatment of NK cell lines was associated with a decrease in their expression 
of integrins. In some experiments (2/14 donors analyzed when stained for αL, 4/13 for αM, and 4/11 
for ß2) integrin expression was not aﬀ ected, indicaƟ ng that although integrin decreased expression 
may have an important role in NK cell hyporesponsiveness, ionomycin treated cells must have another 
defect which impairs their funcƟ onality. However for all the donors stained with the NKI-L16 anƟ body 
(n=10), a decrease in the reacƟ vity of this anƟ body with ionomycin treated cells was observed. When 
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Fig. 14: Ionomycin treated NK expressed lower levels of molecules of the integrin family. (A)RepresentaƟ ve 
histograms of closed αL, acƟ ve αL, αM and ß2 expression by fl ow cytometry. Isotype control: grey fi lled. 
Control cells: grey line. Ionomycin treated cells: black line. (B) RelaƟ ve decrease of the MFI expression of the 
diﬀ erent integrin molecules relaƟ ve to the expression of control cells (DMSO) (n=14 αL, n=10 αL NKL-L16, 
n=13 αM, n=12 ß2). (C) RelaƟ ve decrease of the MFI expression of the diﬀ erent integrin molecules relaƟ ve 
to the expression of control cells (DMSO), only considering those that suﬀ ered a decrease in expression. Gray 
bars: cells without IL-2 sƟ mulaƟ on (n=12 αL, n=10 αL NKL-L16, n=9 αM, n=8 ß2). White bars: IL-2 was added 
during the 24h freshly isolated day (n=7 αL, n=3 αL NKL-L16, n=5 αM, n=4 ß2). (B and C) Mean data and 
standard deviaƟ ons are represented. Two tailed paired Student’s t test analysis of the logarithm of raw data 
was used.*p<0.05, **p<0.01, ***p<0.001.
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all the experiments are considered (including those cases without integrin decreased expression, a 
signifi cant decrease of αL expression (both open conformaƟ on and total) is observed aŌ er exposure 
to ionomycin (Fig. 14-B). For analysis of these data, the mean fl uorescence intensity (MFI) of each 
molecule was quanƟ fi ed and related to the MFI of its isotype control. The fi nal graphs show the MFI 
of the ionomycin treated NK cells relaƟ ve to the DMSO staining (DMSO staining considered as a 100% 
for each molecule). If only those cases where we observed a decrease in the integrin expression are 
considered, the diﬀ erences were signifi cant also for αM and ß2, the reducƟ on of αM, αL and ß2 subunits 
being very similar, between 41.06% and a 51.1% (Fig. 14-C grey bars). Although αM expression was 
decreased in ionomycin treated cells, its expression was very low, and the variability between diﬀ erent 
samples was higher. 
Culture of the ionomycin treated cells in IL-2 led to a staƟ sƟ cally signifi cant recovery in the 
expression levels of the αM and αL molecules in those cells which had suﬀ ered a decrease in integrin 
expression (Fig. 14-C white bars), although in general they didn’t quite reach the same levels of 
expression as control cells treated with IL-2 (considered as 100% for each molecule). The increase in 
integrin expression driven by IL-2 is higher for ionomycin-treated cells, a mean increase of 27.34% in 
control cells, but a 140.26 % in ionomycin treated cells (data not shown). The expression of ß2 integrins 
and the NKL-L16 epitope were increased aŌ er IL-2 sƟ mulaƟ on, but remained signifi cantly lower than 
control cells.
The expression of other adhesion molecules, such as CD11c (integrin subunit αX, which also 
associates with the ß2 chain), CD29 (integrin subunit ß1), CD61 (integrin subunit ß3), CD44 glycoprotein, 
ICAM-1 glycoprotein (CD54, whose receptor are LFA-1 and Mac-1), CD44 glycoprotein and CD58 (LFA-
3, a ligand for CD2), did not diﬀ er signifi cantly between control and ionomycin treated NK cells.
These defects in integrin expression and acƟ vaƟ on could imply defects in NK cell migraƟ on and 
arrival to the site of infl ammaƟ on, but also defects in recogniƟ on and adhesion to target cells and so 
NK cell acƟ vaƟ on, which could explain the lower levels of conjugates and cytotoxicity observed. The 
reduced integrin expression could also explain why the degranulaƟ on machinery was acƟ vated when 
sƟ mulated directly by PMA/Ionomycin, but not by exposure to target cells. However, although the 
levels of αM, αL and ß2 integrin subunits were signifi cantly decreased in the majority of ionomycin 
treated NK cells analyzed (Fig.14-C), the levels of expression, especially those of the αL subunit, were 
sƟ ll considerable (Fig.14-A), making it diﬃ  cult to imagine that this reduced expression of integrins was 
the sole basis of the observed defects in NK cell recogniƟ on.
87
Results
3.3 Cytokine receptors
One possible explanaƟ on for previous data that ionomycin treated NK cells responded poorly to 
IL-12 and IL-18 sƟ mulaƟ on (Fig.6 and Fig.7) could be that ionomycin treated NK cells were not sensing 
IL-12 and IL-18 properly, due to defi cient expression of the IL-12 or IL-18 receptors. The IL-18 receptor 
is a heterodimeric receptor composed of an alpha (IL18R1) and a beta (IL18RAP) chain and funcƟ ons 
to enhance NK cell IFN-γ producƟ on (Chaix et al. 2008) and cytotoxicity by both lyƟ c granule release (Hyodo 
et al. 1999) and Fas-L upregulaƟ on (Tsutsui et al. 1996). LigaƟ on of the IL-12 receptor also promotes IFN-γ 
producƟ on (Sareneva et al. 2000; Ferlazzo et al. 2004) and NK cell killing (DeBlaker-Hohe et al. 1995). Moreover, IL-12 signaling 
can also induce the expression of IL-18R subunits (Sareneva et al. 2000) demonstraƟ ng crosstalk between 
these cytokines. Splenocytes from mice defi cient in IL-18R subunits are unable to produce IFN-γ in 
response to IL-12 sƟ mulaƟ on and their NK cells are ineﬃ  cient killers (Hoshino et al. 1999; Cheung et al. 2005), 
similarly NK cells from IL-12Rß1 defi cient paƟ ents are also reported to be ineﬀ ecƟ ve killers (Anfossi et al. 
2006). In the context of NK cell responsiveness, defi ciencies in degranulaƟ on and IFN-γ producƟ on in 
response to IL-12 and IL-18 priming have been described in hyporesponsive human KIR-NKG2A- NK 
cells (Anfossi et al. 2006), and in murine NK cells chronically sƟ mulated through the acƟ vaƟ ng receptor Ly49H 
(Bolanos and Tripathy 2011). These observaƟ ons indicate that a defecƟ ve response to these cytokines, which 
have important roles in NK cell funcƟ on, may be a common feature of hyporesponsive NK cells.
The expression of the IL-18Rα subunit was studied by fl ow cytometry. In normal NK cells, the 
expression of IL18-Rα was very low, therefore as the diﬀ erences in degranulaƟ on and IFN-γ producƟ on 
described previously were measured aŌ er IL-12 + IL-18 sƟ mulaƟ on during the resƟ ng day (Fig.6 and 
Fig.7), and sƟ mulaƟ on with these cytokines is able to increase the expression of IL-18Rα (Sareneva et al. 
2000), the expression of IL-18Rα aŌ er treatment with IL-12 + IL-18 was also studied. When NK cells were 
sƟ mulated with IL-2 or IL-12 the levels of expression of IL-18Rα increased slightly in both control and 
ionomycin-treated cells (Fig.15-A). Treatment with IL-18 alone did not increase IL-18Rα expression, 
but when cells were sƟ mulated with the combinaƟ on of IL-12 + IL-18, IL-18Rα expression was again 
increased. Indeed this increase was higher than that produced by treatment with IL-12 alone, as 
expected from the literature (Sareneva et al. 2000). These data indicate that both cytokines were being 
sensed properly and were able to synergize. SƟ mulaƟ on with IL-2 plus IL-12 caused the maximum 
increase in IL-18Rα expression (Fig.15-A), however no signifi cant diﬀ erences were noted between 
control and ionomycin treated cells under any of the condiƟ ons tested. in parallel the expression levels 
of the IL-18RAP subunit in these experiments were also analyzed by qRT-PCR, and again no signifi cant 
diﬀ erences were noted between control and ionomycin treated cells (Fig.15-B).
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These data suggest that the signaling pathways acƟ vated by IL-12 and IL-18 were working eﬃ  ciently 
in ionomycin treated NK cells, and although only the expression of the IL-18R subunits were measured 
in these experiments, the levels of expression of IL-12R subunits must be normal too, as sƟ mulaƟ ons 
with IL-12 alone or in combinaƟ on with IL-18, were able to increase the expression levels of IL-18Rα 
and IL-18RAP to the same levels as those observed in control cells.
The signaling pathways iniƟ ated by IL-12 sƟ mulaƟ on end in STAT4 acƟ vaƟ on and increased 
transcripƟ on of a range of genes involved in cytokine recogniƟ on including IFN-γ and TNF-α, or EGR2 as 
well as the IL-12 and IL-18 receptor subunits (Good et al. 2009). IL-18 promotes AP-1 and NF-κB translocaƟ on 
to the nucleus synergizing with the IL-12 acƟ vaƟ ng pathway (Nakahira et al. 2002). Other factors such as IκBζ 
also have roles associated with IFN-γ transcripƟ on (Kannan et al. 2011). Since IL-12 and IL-18 sƟ mulaƟ on 
induces IL-18R subunit expression, the defect in IFN-γ producƟ on aŌ er sƟ mulaƟ on with these cytokines 
is unlikely to be due to some defi ciency in signaling from these receptors, but more probably refl ects 
defects in transcripƟ on, translaƟ on or instability of the IFN-γ mRNA or protein.
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Fig. 15: Ionomycin treated NK  cells 
expressed normal levels of IL18Rα, 
and IL-18 and IL-12 were able to signal 
eﬃ  ciently. (A) Mean fl uorescence 
intensity data from fl ow cytometry 
analysis of control and ionomycin 
treated NK cells aŌ er treatment with 
diﬀ erent cytokines during the rest 
day. (n=4) (B) RelaƟ ve quanƟ Ɵ es or 
fold change of the IL-18RAP subunit as 
measured by quanƟ taƟ ve PCR.  Data 
were corrected with the 18S mRNA 
expression of each sample, and related 
to the IL-18RAP expression in control 
cells without cytokine sƟ mulaƟ on using 
the ΔΔCt method.(n=2).  (A and B) 
Mean data and standard deviaƟ ons are 
represented. Paired two way ANOVA 
analysis and Bonferroni posƩ est. 
*p<0.05
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When the expression of IFN-γ mRNA was analyzed, a high degree of variability between diﬀ erent 
experiments was found (Fig.16-A and B). When the ΔΔCt values were calculated normalizing the data 
by the amount of IFN-γ mRNA at basal condiƟ ons in control or in ionomycin treated cells respecƟ vely, 
it appeared that all cytokines were able to induce Ifng gene transcripƟ on with similar eﬃ  ciencies in 
both control and ionomycin treated cells, and although with 2 of the 4 cell lines analyzed, ionomycin 
treated cells responded less eﬃ  ciently than control cells, in other cases it was the contrary (2/4), as 
IFN-γ mRNA was induced similarly in both cases  (Fig.16-A). If the data were normalized relaƟ ve to 
the amount of IFN-γ mRNA in control cells without any cytokine sƟ mulaƟ on, more variability between 
samples was observed, however in this analysis most of the ionomycin treated NK cells appeared to 
produce much lower amounts of IFN-γ mRNA than controls, although in some cases the total levels 
of IFN-γ mRNA detected were comparable (Fig.16-B). Thus the conclusion from these analyses is that 
ionomycin treated NK cells were able to induce transcripƟ on of the Ifng gene eﬃ  ciently, although in 
some cases this inducƟ on was not enough to arrive to the same fi nal levels of mRNA found in control 
cells.
The expression of the IL-2Rα chain (CD25) was also analyzed, but no diﬀ erences were noted in the 
expression of this molecule between control and ionomycin treated NK cells.
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Fig. 16: Ionomycin treated NK induced IFN-γ mRNA as eﬃ  ciently as control cells. (A) RelaƟ ve quanƟ Ɵ es or fold change 
in Ifng gene mRNA measured by quanƟ taƟ ve PCR.  Data were normalized with the 18S mRNA expression of each sample, 
and related to Ifng gene mRNA expression on cells (DMSO or ionomycin treated) without any cytokine sƟ mulaƟ on using the 
ΔΔCt method. (B) RelaƟ ve quanƟ Ɵ es or fold change in Ifng gene mRNA measured by quanƟ taƟ ve PCR.  Data were corrected 
with the 18S mRNA expression of each sample, and related to the Ifng gene mRNA expression of control cells at the basal 
condiƟ on using the ΔΔCt method, and expressed as the relaƟ ve amount in control vs. ionomycin treated cells (control =1 
for each point). (n=4) (A and B) Each symbol corresponds to one of the diﬀ erent cell lines analyzed. (n=4). Two way Anova 
analysis and Bonferroni posƩ est. No signifi cant diﬀ erences were found.
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3.4 Other molecules
A range of other receptors which have diﬀ erent roles in NK cell biology were analyzed, but no 
diﬀ erences in expression between control cells and ionomycin treated NK cells were noted for CD28, 
CD45, CD53, CD59, CD40, CD69, CD86, HLA-DR, HLA-ABC and Fas Receptor CD95.
However, one consistent result observed in all the experiments performed was the downregulaƟ on 
of the expression of the CD56 molecule (NCAM) (Fig. 17). CD56 is a glycoprotein of the Immunoglobulin 
superfamily widely used as a cell marker for NK and NKT cells in humans, although it is also expressed 
by neurons, glia and skeletal muscle cells. Although no funcƟ on of CD56 has been found for NK cells, 
in neurons it plays important roles in cell-cell adhesion by homophilic interacƟ ons in cis or in trans, 
and as a receptor of soluble factors such as GDNF (glial cell line-derived neurotrophic factor) (Paratcha et 
al. 2003), heparin sulphate or L1-CAM. Ligand binding by NCAM can lead to the transmission of signals by 
acƟ vaƟ ng Fyn and FAK kinases. Its expression is also related to tumor growth (Liu et al. 2011). CirculaƟ ng NK 
cells are classifi ed as either CD56bright or CD56dim cells; the CD56dim populaƟ on is the most abundant in 
blood and is related to a later step on NK cell diﬀ erenƟ aƟ on. CD56dim cells are also described as more 
potent eﬀ ector cells compared to CD56bright cells (MoreƩ a 2010). In the in vitro cultured NK cells maintained in 
IL-2 used in these experiments, only one populaƟ on of very bright CD56+ cells was observed, and aŌ er 
ionomycin treatment, NK cells expressed lower levels of this molecule (Fig. 17). The funcƟ on of CD56 
on NK cells has not yet been clearly defi ned, since blockade of this molecule with anƟ bodies has no 
eﬀ ect in cell killing (Lanier et al. 1991), although CD56 expression is thought to be related to NK-NK adhesion 
as transfecƟ on of Jurkat cells with this molecule causes the formaƟ on of cell-aggregates (Paratcha et al. 
2003). Enrichment of a CD56- CD16+ populaƟ on with a decrease of the 
CD56dimCD16+ populaƟ on has been described in paƟ ents suﬀ ering 
chronic HIV-1 and HCV infecƟ ons. These cells secrete lower levels 
of cytokines, and are less cytotoxic and proliferaƟ ve, and whether 
long term IL-2 restores their funcƟ onality is sƟ ll unclear (Bjorkstrom et al. 
2010), but the basis of the lower response of these cells, and whether 
the loss of CD56 expression has any role in this loss of funcƟ on, 
have not been studied yet. Since CD56/NCAM1 has signaling and 
adhesion funcƟ ons, perhaps under some circumstances of stress, 
this molecule could exert some role in NK cell acƟ vaƟ on and 
proliferaƟ on.
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Fig. 17: Ionomycin treated cells express lower levels of CD56. CD56 
mean fl uorescence intensity of control and ionomycin treated NK cells. 
Mean data and standard deviaƟ ons are represented. (n=64). Two tailed 
paired Student’s t test analysis .**p<0.001.
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3.5 Co-analysis of the expression of different receptors and NK cell degranulation ability
Treatment with ionomycin renders the majority of the NK cells in a culture unable to degranulate 
or produce cytokines in response to target cells, however a fracƟ on of the NK cell populaƟ on are 
sƟ ll able to mobilize CD107a to the cell surface aŌ er exposure to target cells. This “ionomycin-
resistant” populaƟ on could refl ect a preferenƟ al eﬀ ect of the ionomycin treatment on diﬀ erent NK 
cell subpopulaƟ ons. AlternaƟ vely, given that NK cells show a spectrum of responsiveness, ionomycin 
treatment could act to modulate the NK cell acƟ vaƟ on threshold, so that many cells would be unable 
to reach their acƟ vaƟ on threshold (rendered unresponsive), while other cells were sƟ ll able to respond 
to target cell sƟ mulaƟ on. To test whether the ionomycin treatment diﬀ erenƟ ally aﬀ ected diﬀ erent NK 
cell populaƟ ons, degranulaƟ on experiments were performed as described before, but the staining 
of another receptor in the analysis was incorporated into the experiment so that the Lamp1+ and 
Lamp1– marker populaƟ ons could be compared between control and ionomycin treated cells. For 
these experiments the molecules analyzed were CD11b, KIR2DL1 (CD158a), KIR2DL2/DL3 (CD158b), 
CD16, CD57, CD8, CD69, HLA-DR and NKG2C that are known to be expressed by only a proporƟ on of 
NK cells, or whose expression varies with acƟ vaƟ on/maturaƟ on of NK cells. 
No signifi cant diﬀ erences were noted on the distribuƟ on of these markers between degranulaƟ ng 
and not degranulaƟ ng NK cells in both control and ionomycin treated cells. Ionomycin treated NK 
cells expressed lower levels of CD11b as described before (Fig. 14), however, they sƟ ll conserved a 
homogeneous distribuƟ on of this molecule in Lamp1+ and Lamp1- NK cells (Fig. 18). Thus these data 
argue against the hypothesis that ionomycin treatment aﬀ ects diﬀ erent subpopulaƟ ons of NK cells 
diﬀ erently.
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Fig. 18: Diﬀ erent cell markers were 
homogenously distributed between 
Lamp1+ and Lamp1- NK cells. Control 
and ionomycin treated NK cells 
were cocultured for 2h with K562 
target cells. Cells were stained for 
CD56, and in the CD56+ populaƟ on 
coanalyzed for Lamp1 and diﬀ erent 
surface markers. Here is shown the 
IgG1 isotype (MOPC-21) and CD11b 
staining. 
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3.6 Redirected antibody dependent cytotoxicity
Although NK cells express a large variety of acƟ vaƟ ng receptors, only CD16 is able to acƟ vate 
cytotoxicity by freshly isolated NK cells when sƟ mulated alone, and receptors such as NKG2D, NKp46, 
DNAM-1 or 2B4 need to cooperate synergisƟ cally in order to induce an eﬀ ecƟ ve response (Bryceson et al. 
2006).
To analyze the eﬀ ect of ionomycin treatment on NK cell responsiveness in more detail, redirected 
anƟ body dependent cytotoxicity experiments using mAbs for specifi c NK acƟ vaƟ ng receptors and P815 
cells were used. P815 is a mouse lymphoblast like mastocytoma cell line, relaƟ vely resistant to NK cell 
mediated cytotoxicity, which expresses high aﬃ  nity Fc-anƟ body-region receptors. When NK cells are 
co-cultured with the FcγR+  target cell line P815 in the presence of anƟ bodies against NK cell receptors, 
anƟ bodies will aƩ ach to P815 cells through Fc receptor-anƟ body interacƟ ons, and to NK cells through 
anƟ body-anƟ gen interacƟ ons; thus the anƟ bodies act as a bridge and crosslinker to trigger NK cell 
acƟ vaƟ on via specifi c receptors. Using this approach, NK cell responses through the NKG2D, NKp30, 
NKp46, CD16 receptors and diﬀ erent combinaƟ ons of them were analyzed. Two types of readout were 
used for this assay: 1. propidium iodide staining of labeled target cells to directly study target cell 
killing and 2. fl ow cytometry to analyze the mobilizaƟ on of Lamp1 to the NK cell surface. 
As cell lines from diﬀ erent donors made diﬀ erent responses aŌ er sƟ mulaƟ on via diﬀ erent receptors, 
fi gure 19 shows the data from 3 diﬀ erent cell lines as examples of diﬀ erent cell responsiveness to 
sƟ muli. In these examples, we used diﬀ erent y axis scales to observe beƩ er the diﬀ erences between 
control and ionomycin treated cells with the same anƟ body sƟ mulaƟ on. Of the three lines represented, 
NK1 and NK2 cells were much more eﬀ ecƟ ve killers than NK3; P815 cells loaded with a CD16-specifi c 
mAb were killed eﬃ  ciently by both NK1 and NK2 cells, but lysis of these cells by NK cells from donor 
NK3 was at much lower levels. Strikingly treatment with ionomcyin, has very liƩ le eﬀ ect on CD16-
triggered of cells from the donors NK1 and NK2, whereas NK3 ionomycin treated cells did not respond 
to this sƟ mulus (Fig.19 second column). In contrast when anƟ bodies against NKG2D were used to 
trigger lysis, ionomycin treatment markedly reduced the ability of the three cell lines to kill P815 
cells as well as control cells (Fig.19 third column). NKp30 anƟ bodies were poor sƟ muli for triggering 
lysis by NK3 and NK1 cells. However untreated NK2 cells eﬃ  ciently killed P815 cells loaded with anƟ -
NKp30 anƟ bodies, but ionomycin treated NK2 NK cells were unable to lyse these target cells (Fig.19 
fourth column). When NKG2D-specifi c mAb was used in combinaƟ on with NKp30 specifi c anƟ bodies, 
cytotoxicity of P815 cells was increased in the three cell lines compared with killing elicited by NKG2D 
or NKp30 anƟ bodies alone, but killing by ionomycin treated cells was sƟ ll signifi cantly impaired (Fig.19 
fi Ō h column). In summary, for the NK3 line, that was the least cytotoxic of the three NK lines tested, 
ionomycin treatment markedly reduced responsiveness to all the anƟ body combinaƟ ons (Fig.19 third 
line). For the NK1 and NK2 lines, that were much more eﬀ ecƟ ve killer cells, ionomycin treatment 
impaired killing of P815+NKG2D and P815+NKG2D+NKp30 (Fig.19 fi rst line), and in the case of NK2, 
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also of P815+NKp30 (Fig.19 second line), but ionomycin did not signifi cantly reduce NK lysis triggered 
by potent anƟ -CD16 sƟ mulaƟ on.
The decision as to whether or not an NK cell kills a parƟ cular target cell depends on the balance of 
signals from acƟ vaƟ ng and inhibitory receptors interacƟ ng with their ligands on the target cell surface. 
When acƟ vaƟ ng signals outweigh inhibitory signals, NK cells are able to respond. However, how the 
threshold, that the signals from acƟ vaƟ ng receptors have to surpass, is established for NK cells is not 
well understood and very liƩ le is known about the molecular basis of how NK cells set this threshold 
for responsiveness. Ionomycin treatment could be aﬀ ecƟ ng NK cell responsiveness by increasing the 
level of sƟ mulaƟ on required to trigger eﬃ  cient NK lysis of target cells. Ionomycin treated cells were 
unable to kill as eﬃ  ciently as control cells when sƟ mulated through intermediate sƟ muli as NKG2D in 
the three cases. on the other hand, higher sƟ muli as when acƟ vated through CD16 (NK1 and NK2), or 
lower as NKp30 (NK1 and NK3) create no diﬀ erences between control and treated cells. However, each 
cell line has a diﬀ erent threshold and sense diﬀ erenƟ ally diﬀ erent sƟ muli.
To further test the hypothesis that ionomycin treatment is modulaƟ ng the threshold for NK cell 
responsiveness, NK cell degranulaƟ on aŌ er coculture with P815 loaded with specifi c mAbs or diﬀ erent 
combinaƟ ons of anƟ bodies was analyzed. When the NK cells were sƟ mulated with single anƟ bodies, 
Fig. 19: Ionomycin treated NK cells were able to kill target cells eﬃ  ciently when the acƟ vaƟ ng sƟ mulus was 
suﬃ  ciently strong. Three representaƟ ve examples of fl ow cytometry analysis of the percentage of Propidium iodide 
(PI) posiƟ ve P815 cells aŌ er coculture with DMSO or 1μM ionomycin treated NK cells, in combinaƟ on with diﬀ erent 
anƟ bodies, during 1h, 3h or 5 hours. The target cells were labeled with the PKH-2 dye and selected for PI analysis. 
AnƟ bodies used were MOPC-21 as control, CD16, NKG2D, NKp30 and the combinaƟ on of NKG2D+NKp30. AnƟ bodies 
were used at 5μg/mL.
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CD16 was the most potent sƟ mulator of degranulaƟ on, and ionomycin treated cells made a response 
similar to that seen for control cells (Fig.20-A & B show experiments with two diﬀ erent NK cell lines). 
In contrast, the response of ionomycin treated NK cells to sƟ mulaƟ on with NKG2D alone was much 
weaker than that of control cells. SƟ mulaƟ on with NKp46 mAb triggered degranulaƟ on by control 
NK cells comparable to that seen with NKG2D specifi c mAb, but ionomycin treated cells were again 
somewhat less able to respond, although their response to NKp46 was not as impaired as their response 
to NKG2D. This experiment was repeated using NK cells from diﬀ erent donors and although each line 
showed diﬀ erent levels of degranulaƟ on to diﬀ erent receptors, the paƩ ern of responsiveness imposed 
by ionomycin treatment was similar (Fig.20-C) especially for NKG2D and CD16 triggered responses. 
Ionomycin treatment had liƩ le eﬀ ect on the degranulaƟ on response triggered by anƟ  CD16 anƟ bodies 
while the response sƟ mulated via NKG2D was the most aﬀ ected.
In this context, it was of interest to test what eﬀ ect increasing the sƟ mulaƟ on had on the ability of 
ionomycin treated NK cells to degranulate in response to target cells. For this purpose P815 cells were 
loaded with combinaƟ ons of anƟ bodies specifi c for receptors known to synergise for NK cell acƟ vaƟ on. 
However, when NK cells were confronted with P815 cells able to sƟ mulate lysis through two diﬀ erent 
receptors known to synergize for NK cell acƟ vaƟ on (Bryceson et al. 2006), more variable results were obtained 
(Fig.20-D each symbol corresponds to a diﬀ erent NK cell line). As expected, sƟ mulaƟ on via NKG2D in 
combinaƟ on with NKp30, NKp46, CD16 or 2B4, and NKp46 in combinaƟ on with 2B4 triggered increased 
degranulaƟ on in both control and ionomycin treated cells compared to that observed aŌ er sƟ mulaƟ on 
with a single anƟ body. However, ionomycin treated cells were sƟ ll unable to respond as eﬃ  ciently as 
control cells in most of the experiments. This experiment was also repeated using mulƟ ple NK cell 
lines, and although each line showed diﬀ erent levels of degranulaƟ on to the diﬀ erent receptors, the 
overall paƩ ern of responsiveness imposed by ionomycin treatment was similar. Surprisingly, for two NK 
cell lines sƟ mulaƟ on with 2B4 in combinaƟ on with NKp46 or NKG2D was able to sƟ mulate ionomycin 
treated cells as eﬃ  ciently as control cells.
In aggregate, these experiments strongly supported the hypothesis that ionomycin treatment was 
imposing an increase in the NK cell threshold for acƟ vaƟ on so that ionomycin treated cells needed more 
potent sƟ mulaƟ on to be able to respond. Thus for strong sƟ muli like CD16 (Fig.19 & 20), ionomycin 
treated NK cells were able to degranulate as eﬃ  ciently as control cells, but when the sƟ mulaƟ on 
was weaker, as with NKG2D mAb alone, ionomycin treatment rendered NK cells unable to respond. 
Contrary to expectaƟ on, increasing sƟ mulaƟ on by triggering NK cells with anƟ bodies to synergisƟ c 
combinaƟ ons of receptors did not really overcome the eﬀ ect of ionomycin treatment, however this 
might be explained if, apart from an altered threshold for responsiveness, ionomycin treated cells also 
have problems creaƟ ng synergy between receptors due, for example, to changes in receptor mobility in 
the plasma membrane as dynamic compartmentalizaƟ on of acƟ vaƟ ng NK cell receptors in membrane 
nanodomains has been proposed to be pivotal for the control of NK cell reacƟ vity (Guia et al. 2011).
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3.7 Calcium responses
Ionomycin treated NK cells were unable to generate the same levels of degranulaƟ on when 
sƟ mulated through diﬀ erent receptors. Previously, we have shown that ionomycin treated NK cells 
responses aŌ er PMA/Ionomycin sƟ mulaƟ on were almost complete, but we wanted to confi rm that 
the calcium responses triggered aŌ er ligaƟ on of specifi c receptors were comparable to control cells 
(Fig.21) . 
Fig. 20: Ionomycin treatment changed NK responsiveness to sƟ mulaƟ on via diﬀ erent acƟ vaƟ ng receptors. NK cells either 
untreated (DMSO) or treated with 1μM of ionomycin, were cocultured with P815 in the presence of diﬀ erent anƟ bodies for 
2 hours. The Fc receptors on the P815 cells were then blocked with mouse serum and the cells were stained with labeled 
CD56-PE and Lamp1-APC anƟ bodies. AnƟ bodies used for NK cell sƟ mulaƟ on in combinaƟ on with P815 cells were used at 
5μg/mL each, and were, MOPC-21 (control), CD16, NKG2D, NKp30 and NKp46 alone or in diﬀ erent combinaƟ ons. (A and 
B) RepresentaƟ ve examples of the percentage of Lamp1+ NK cells aŌ er coculture with P815 and diﬀ erent anƟ bodies. (C 
and D) RelaƟ ve numbers of NK cells able to degranulate compared to control cells cocultured with P815 cells and diﬀ erent 
anƟ bodies. Each symbol corresponds to one of the diﬀ erent cell lines analyzed.
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Monoclonal anƟ bodies against NKG2D and NKp46, followed by anƟ  mouse IgG mediated 
crosslinking of the receptor bound mAbs, were used to sƟ mulate the NK cells. The calcium responses 
of the ionomycin treated cells were slightly lower in most of the donors, although the diﬀ erence was 
not staƟ sƟ cally signifi cant, probably due to the low calcium fl ux induced by receptor sƟ mulaƟ on even 
in control cells. As a posiƟ ve control for calcium signaling, cells were sƟ mulated with 0.5μM ionomycin, 
but surprisingly, the response generated by ionomycin treated NK cells was also lower in most of the 
donors (82.18% +/- 13.56 relaƟ ve to control cells maximum Ca2+). One possible explanaƟ on for this 
result could be that the calcium stores of the ionomycin treated cells were altered, making impossible 
the existence of a response aŌ er receptor sƟ mulaƟ on. To study this possibility, NK cells were sƟ mulated 
with 0.5 μM ionomycin in the presence of 1mM EGTA, since under these condiƟ ons only the fl ux 
of calcium coming from the intracellular stores is visible. Using this protocol an early Ca2+ fl ux was 
induced, but no diﬀ erences were observed between control and ionomycin treated cells. The Ca2+ 
fl ux occurring very early aŌ er the addiƟ on of ionomycin was similar for control and ionomycin treated 
NK cells when sƟ mulated with ionomycin, while the mayor diﬀ erence was observed at later Ɵ mes. 
Ionomycin is described to be a mobile ionophore, which triggers an infl ux of Ca2+ from the extracellular 
medium, and also allows the release of the endoplasmic reƟ culum calcium stores(Yoshida and Plant 1992). 
Ionomycin has been proposed to be able create gaps between cells (Jungmann et al. 2008), and to acƟ vate 
store-operated Ca2+ channels (SOCs) (Yoshida et al. 2010), but its mechanism is sƟ ll subject to discussion. 
The similarity between control and ionomycin treated NK cells in the fast release of intracellular Ca2+, 
suggests that the observed diﬀ erences in the cell response to ionomcyin are due to diﬀ erences in 
the entry of extracellular Ca2+ later in the response which could refl ect diﬀ erences in the membrane 
composiƟ on, or some as yet unknown mechanism by which ionomycin opens membrane channels late 
in the response
Previously, it has been described that the confi nement of acƟ vaƟ ng receptors in acƟ n meshworks 
was responsible for the lower responses generated by uneducated NK cells (Guia et al. 2011). To study 
the possibility that acƟ n meshworks were responsible for the lower calcium responses of ionomycin 
treated cells, we treated NKG2D-NKp46 stained NK cells with 1μM Latrunculin B which blocks the 
formaƟ on of F-acƟ n. Treatment of both control and ionomycin treated NK cells increased the Ca2+ fl ux 
generated, by receptor crosslinking, about three Ɵ mes compared to the response seen in the absence 
of latrunculin (3,21 +/- 1.52 Ɵ mes in control cells, 2.78 +/- 0.99 in ionomycin treated cells), but the 
diﬀ erence between control and ionomycin treated cells was sƟ ll obvious. This result implies that the 
presence of acƟ n meshworks limits the response of both control and ionomycin treated cells, but that 
other factors underly the reduced response of ionomycin treated NK cells. 
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Fig. 21: Ionomycin treated NK cells showed lower Ca2+ fl ux both in response to ionomycin, and in response to 
NKG2D-NKp46 synergic sƟ mulaƟ on. (A) RepresentaƟ ve example of the fl ow cytometry analysisis of the Calcium 
fl ux detected by the raƟ o Fluo-4/Fura Red. For studying NKG2D-NKp46 triggered response NK cells were stained with 
10μg/mL of the NKG2D (149810 clone) and NKp46 (9E2 clone) mAbs, on ice, and then bound mAb were crosslinked 
by the addiƟ on of 10μg/mL Goat anƟ -mouse F(ab’)2. Where indicated ionomcyin (fi nal concentraƟ on of 0.5μM) 
was used as a control sƟ mulus, or 1mM EGTA was used to chelate extracellular Ca2+. Black line: DMSO control cells. 
Grey line: 1μM ionomycin treated cells. (B) Overlay of the same data shown in A, Top DMSO control. Lower 1μM 
ionomycin treated cells. (C) Maximum Ca2+ levels achieved aŌ er each sƟ mulaƟ on, relaƟ ve to the maximum Ca2+ 
levels induced by ionomycin in DMSO treated cells. n=8 Ionomcyin, NKG2D-NKp46. n=7 Latrunculin NKG2D-NKp46, 
n=3 EGTA Ionomycin. Two way Anova and Bonferroni post-test analysis was used to calculate staƟ sƟ cal signifi cance. 
**p<0.01, . ***p<0.001.
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4. Ionomycin treatment of freshly isolated NK cells
In all the previous experiments, NK cells that had been cultured in IL-2 were studied as this 
protocol allowed the preparaƟ on of a large number of NK cells from the same donor for use in mulƟ ple 
experiments. However, it was of interest to confi rm that the ionomycin induced hyporesponsiveness 
was not a feature only of acƟ vated NK cells and so some of the experiments were repeated using 
freshly isolated NK cells (fNK).  
4.1 fNK cell receptor expression after ionomycin treatment
The expression of a number of diﬀ erent acƟ vaƟ ng and inhibitory receptors, and molecules of the 
integrin family was evaluated in fNK cells following ionomycin treatment. No reproducible diﬀ erence in 
the expression of inhibitory receptors was found; however a consistent decrease in the expression of 
NKG2D and CD56 was observed (Fig.22). For this reason, for further funcƟ onal experiments the MHC 
class I defi cient human 722.221 cells was used instead of K562, as K562 killing has been described 
to be dependent on NKG2D ligands (Li et al. 2008), while 722.221 killing depends more on 2B4 (Sandusky et 
al. 2006), which was not diﬀ erenƟ ally expressed between control and ionomycin treated fNK cells. The 
expression of αL and ß2 integrin chains was reduced in ionomycin treated fNK cells, however, this 
reducƟ on was much less than that observed for acƟ vated NK cells (Fig.22-A).
Fig. 22: Ionomycin treated fNK expressed lower levels of NKG2D.(A) RelaƟ ve change in expression (MFI) of 
various receptorsin ionomycin treated fNK cells relaƟ ve to their expression on control, DMSO treated fNKcells. 
(B) RepresentaƟ ve histograms of the eﬀ ect of ionomycin treatment on NKG2D expression. Isotype control: lined. 
Control cells: black line. Ionomycin treated cells: grey line.
99
Results
4.2 fNKcell function after ionomycin treatment
To characterize the eﬀ ects of ionomycin treatment on fNK cell funcƟ on, NK cell degranulaƟ on and 
IFN-γ producƟ on aŌ er diﬀ erent cytokine sƟ muli were studied as described previously, using 721.221 
as target cells (Fig. 23-A). fNK showed a reduced ability to degranulate aŌ er ionomycin treatment. 
SƟ mulaƟ on with 50U/mL of IL-2 during the resƟ ng day, increased the degranulaƟ on ability of NK cells 
from all the donors, although not always to the levels of degranulaƟ on of control cells (Fig. 23-A). This 
incomplete restoraƟ on was parƟ cularly obvious when IFN-γ producƟ on was analyzed, where none 
of the ionomycin-treated NK cells analyzed were able to produce as much IFN-γ as control cells (Fig. 
23-C). InteresƟ ngly, donors where IL-2 treatment restored the same levels of degranulaƟ on as control 
cells showed clearly that  weren´t rescued for IFN-γ producƟ on by these cells was not rescued.
Similarly to acƟ vated NK cells, fNK cells treated with ionomycin also didn’t eﬃ  ciently produce IFN-γ 
when they were sƟ mulated with IL-12 and IL-18 (10ng/mL of each) during the resƟ ng day (Fig. 23-C). 
These diﬀ erences in the recovery of their funcƟ on between acƟ vated and freshly isolated NK cells, 
could indicate either that prior acƟ vaƟ on has altered the NK cells, so that IL-2 treatment can rescue 
the ionomycin induced defect in degranulaƟ on and IFN-γ producƟ on or that fNK cells are much more 
suscepƟ ble to the eﬀ ect(s) of ionomycin. Another possibility is that IL-2 is not rescuing all the possible 
defects induced by ionomycin treatment that contribute to the hyporesponsive phenotype, but rather 
acts by bypassing some of the defecƟ ve stages in acƟ vated but is unable to do so in fNK cells.
As IL-2 sƟ mulaƟ on did not produce a complete recovery of NK cell funcƟ on, it was of interest 
to test if ADCC was funcƟ onal, or not, in fNK treated with ionomycin. Redirected anƟ body mediated 
cytotoxicity was evaluated using P815 cells and mAbs to sƟ mulate either the CD16 receptor or a 
combinaƟ on of the NKp46 and 2B4 receptors. In contrast to acƟ vated NK cells, fNK cells weren’t as able 
to degranulate aŌ er CD16 sƟ mulaƟ on as control cells, and although the percentage of degranulaƟ ng 
cells were high, they never reached the levels of degranulaƟ on observed for control cells (Fig.23-B). 
Calcium responses were also evaluated on fNK cells aŌ er crosslinking of the acƟ vaƟ ng receptors 
NKp46 and 2B4. The response to ligaƟ on of this pair of receptors was much higher than that observed 
previously with NKG2D and NKp46 on acƟ vated NK cells. The calcium response was, in all the donors 
tested, slightly lower in ionomycin treated NK cells. However it was sƟ ll a very potent response. 
Moreover, in contrast to acƟ vated NK cells, treatment with 1mM Latrunculin B induced only a very 
low increase in the response in comparison with the Ca2+ fl ux generated in the absence of latrunculin 
(1.24 +/- 0.26 Ɵ mes in  control cells, 1.46 +/- 0.36 in ionomycin treated cells). The response generated 
by 0.5 μM ionomycin was also diﬀ erent between control and ionomycin treated cells (93.11 +/- 8.45 
56 relaƟ ve to control cells maximum Ca2+), being lower in hyporesponsive ionomycin treated NK cells. 
However, study of the mobilizaƟ on of intracellular stores of calcium aŌ er sƟ mulaƟ on with 0.5 μM 
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ionomycin in the presence of 1mM EGTA, showed no diﬀ erence between both groups and these data 
are similar to those obtained on study of acƟ vated NK cells (Fig.24).
Study of the calcium responses in ionomycin-treated fNK cells aŌ er 2B4-NKp46 sƟ mulaƟ on, 
showed that although slightly lower, the calcium inducƟ on in these cells was sƟ ll very eﬃ  cient (Fig.24). 
This observaƟ on was all the more striking since ionomycin treatment produced a marked reducƟ on in 
the degranulaƟ on of NK cells with P815 cells in the presence of 2B4-NKp46 anƟ bodies (Fig.24). These 
Fig. 23: Ionomycin treated fNKcells displayed a lower ability to degranulate and produce IFN-γ in response 
to 721.221 target cells, independently of IL-2 or IL-12 + IL-18 sƟ mulaƟ on. (A) Flow cytometry analysis of the 
percentage of NK cells, untreated or sƟ mulated with 50U/mL IL-2 during the rest day, that expressed Lamp1 on 
the cell surface aŌ er coculture with K562 for 2 hours. Data from fi ve diﬀ erent experiments are represented. Two 
tailed paired Student’s t test analysis was used. **p<0.01. (B) ReducƟ on in the percentage of NK cells degranulaƟ ng 
in comparison to DMSO control cells when cocultured with 721.221 target cells, P815 with 10 μg/mL of the CD16 
anƟ body (KD1 clone) or P815 with 10 μg/mL of the 2B4 (C1.7 clone) and NKp46 (9E2 clone) anƟ bodies for 2 hours. 
(C) IFN-γ producƟ on by NK cells was analyzed by fl ow cytometry. Cells were unsƟ mulated, sƟ mulated with IL-2 
overnight or sƟ mulated with IL-12/IL-18 overnight, and then cultured for 6 hours in the presence of 2,5 μM Monensin 
with/without 721.221 target cells. Three diﬀ erent experiments are represented. 
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observaƟ ons demonstrated that although there may exist some defect at the level of signaling proximal 
to the receptor, at least the calcium response is largely intact in these cells. Again in contrast to the 
observaƟ ons made with acƟ vated NK cells, treatment with latrunculin didn’t obviously enhance the 
response generated, but this may be because the response generated by the 2B4-NKp46 crosslinking 
is already very potent, perhaps close to the maximum limit of the Ca2+ fl ux that can be generated by 
the cell.
Fig. 24: Ionomycin treated fNK cells showed lower responses generated by ionomycin, and slightly lower Ca2+ 
fl ux in response to 2B4-NKp46 sƟ mulaƟ on. (A) RepresentaƟ ve example of the fl ow cytometryanalysisis of the 
Calcium fl ux detected by the raƟ o Fluo-4/Fura Red. To study the 2B4-NKp46 triggered response NK cells were 
stained with 10μg/mL of mAbs specifi c for2B4 (C1.7 clone) and NKp46 (9E2 clone) on ice, and then crosslinked 
by the addiƟ on of 10 μg/mL Goat anƟ -mouse F(ab’)2 at 37oC. Where indicated, ionomcyin (fi nal concentraƟ on of 
0.5μM) was used as a posiƟ ve control, or 1mM EGTA was used to chelate extracellular Ca2+.  Black line: DMSO control 
cells. Grey line: 1μM ionomycin treated cells.(B) Overlay of the same data shown in A, Top DMSO control. Lower 
1μM ionomycin treated cells.(C) Maximum Ca2+ levels achieved by each sƟ mulaƟ on, relaƟ ve to the maximum Ca2+ 
levels induced by ionomycin in DMSO treated cells. n=5 Ionomcyin, 2B4-NKp46. n=4 Latrunculin 2B4-NKp46 and 
EGTA Ionomycin.  Two way Anova and Bonferroni post-test analysis was used to calculate staƟ sƟ cal signifi cance. 
*p<0.05.
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5.  Transcriptome analysis of ionomycin treated NK 
cells
The processes of anergy (Macian et al. 2002), exhausƟ on (Wherry et al. 2007) or tolerance (SchieƟ nger et al. 2012) 
in T cells are refl ected in changes in the expression profi les of mulƟ ple genes and transcriptomics 
studies have been important in providing insight into the molecular mechanisms underlying these 
diﬀ erent funcƟ onal states. As ionomycin treated NK cells exhibit defi cient funcƟ onal properƟ es, it 
seemed reasonable to hypothesize that these changes in funcƟ on were accompanied by changes in 
the paƩ ern of gene expression. Therefore cDNA microarray experiments were performed to study in 
detail the changes in gene expression associated with NK hyporesponsiveness. mRNA was isolated 
from NK cells from 4 diﬀ erent donors, which had been treated with either 1μM ionomycin or the 
vehicle control (DMSO), and analysis of gene expression in these samples was performed by microarray 
using two color Agilent human gene expression 4x44 v2 chip, which allows analysis of the expression 
of 27,958 human genes. These data were collected and preprocessed by the CNB-Genomics Unit. 
Diﬀ erenƟ ally expressed genes were visualized and selected from the FIESTA viewer according to the 
following criteria: a False Discovery Rate (FDR) < 0.05 by Rank Products analysis, and a Fold Change <= 
-1.6 (repressed genes) or >= +1.6 (induced genes). 
From this analysis 75 genes were found to have higher expression in ionomycin treated cells (in 
4/4 donors), while 72 showed lower expression compared to control NK cells.
To validate the microarray data the diﬀ erenƟ al expression of a selecƟ on of the downmodulated 
genes was analyzed by qRT-PCR (cd300a, cd56, ctsw, dap10, egr1, gnly, gzmh, il18r1, itgam, itgb2, 
matk, myom, ncr3, sell) using mRNA from control and ionomycin treated NK cells isolated from other 
6 diﬀ erent donors. (Fig. 25).
Fig. 25: Gene expression analysis by 
qPCR of 14 selected genes that appeared 
as downmodulated in the microarray 
experiment, in ionomycin treated cells 
compared with DMSO condiƟ on. (n=6). 
ΔΔCt method was used for quanƟ fi caƟ on. All 
data were corrected by 18S gene expression. 
Highlighted data represent genes that were 
discarded as appeared as the downregulated 
observaƟ on in the microarray experiment 
was not confi rmed in qPCR.
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This qPCR analysis confi rmed that most, although not all, of the genes classifi ed as downmodulated 
in the microarray analysis, were downregulated in the mRNA isolated from ionomycin-treated NK cells 
from diﬀ erent donors, so validaƟ ng the data obtained from the microarray experiments. 
As ionomycin treated NK cells recovered funcƟ onality aŌ er being resƟ mulated with IL-2 during the 
rest day, it was of interest to analyze how the expression of the genes studied in Fig. 26, was aﬀ ected 
by IL-2 treatment. For these experiments, mRNA from 4 new donors was isolated from control and 
1μM ionomycin treated NK cells, that had been sƟ mulated or not with IL-2 during the 24 hour recovery 
period. IL-2 treatment rescued expression of egr1, itgam and itgb2 genes in 4 samples (Fig. 26-A), ctsw 
in 3 donors, and ncam, dap10, gnly and ncr3 in 2 donors (not shown).
The analysis of the id2 gene, which is a transcripƟ on factor with important funcƟ ons in diﬀ erenƟ aƟ on 
and development of the NK cell lineage (Ikawa et al. 2001) was also included in our analysis since although the 
downregulaƟ on of id2 was not staƟ sƟ cally signifi cant, it was downregulated in 4/4 samples. Moreover, the 
expression of ID2 has been recently shown as being diminished in the mysm1-/- mice which showed normal NK 
cell development but altered maturaƟ on (Nandakumar et al. 2013). When id2 gene expression was analyzed in mRNA 
from the 6 new ionomycin treated samples it was downmodulated in all of them (Fig. 26-B), and its expression 
recovered aŌ er IL-2 sƟ mulaƟ on in the 4 samples analyzed (Fig. 26-C).
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Fig. 26: egr1, itgam, itgb2 and id2 genes, recovered their mRNA expression on ionomycin treated NK cells 
following IL-2 sƟ mulaƟ on. (A) mRNA from DMSO and 1μM ionomycin treated NK cells, sƟ mulated or not with IL-2 
was analyzed by qPCR for egr1, itgam,itgb2 and (C) id2 genes. (B) mRNA fold change of the id2 gene in ionomycin 
treated cells (n=6). (A, B and C) ΔΔCt method was used for quanƟ fi caƟ on taking DMSO without IL-2 sƟ mulaƟ on as 
control (1=DMSO).  All data were normalised using 18S gene expression.
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5.1 Gene classification by its cell function.
Gene Ontology analysis using the Genecodis hƩ p://genecodis.cnb.csic.es/ or g:profi ler hƩ p://biit.
cs.ut.ee/gprofi ler/ suggested that several pathways or funcƟ ons were enriched in the lists of genes 
upregulated and downregulated aŌ er ionomycin treatment. Examples of these signifi cantly enriched 
pathways are presented on table 1.
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ENRICHED PATHWAYS
defense responses (GO:0006952) gimap5, mmp25, il18r1, ncr3, nt5e, ccr3, il3ra, adrb2, snca, ccr5, 
ccr1, ncf2, rnase6, gnly, itgb2, tnf, ccl4l1, ccl4, ccl3, ccr2
infl ammatory response (GO:0006954) mmp25, ncr3, nt5e, ccr3, il3ra, adrb2, ccr5, ccr1, itgb2, tnf    
,ccl4l1, ccl4, ccl3, ccr2
regulaƟ on of immune system process 
(GO:0002682)
egr1, gimap5, ncr3, snca, tnf
innate immune response (GO:0045087) ncam1, ltb, adrb2, tnf
chemotaxis (GO:0006935) ccr2, ccl3, ccl4, ccl4l1, itgb2, itgam, ccr1, ccr5, ccr3, cmklr1
locomotory behavior (GO:0007626) cmklr1, itgam, ccr3, snca, ccr5, ccr1, itgb2, ccl4l1, ccl4, ccl3, ccr2
cellular calcium ion homeostasis 
(GO:0006874)
ccr2, ccl3, cd52, ccr1, ccr5, ccr3
cell-cell signaling (GO:0007267) pcsk5, tspan32, spry2, egr2, ltb, egr1, snca, ccr5, ccr1, itgb2, tnf, 
ccl4, ccl3
cell adhesion (GO:0007155) itga6, cd300a, sell, ncam1, itgam, ccr3, ccr1, itgb2, tnf, ccl4
integrin-mediated signaling pathway 
(GO:0007229)
ncam1, ltb, adrb2, tnf
cell acƟ vaƟ on (GO:0001775) ltb, itgam, egr1, gimap5, snca, tnf
leukocyte acƟ vaƟ on (GO:0045321) itgam, egr1, gimap5, snca
immunesystem development 
(GO:0002520)
Ɵ mp1, irf8, ltb, egr1, gimap5, tnf
regulaƟ on of cell proliferaƟ on 
(GO:0042127)
matk, ifi tm1, Ɵ mp1, ltb, adrb2, tnf
cytokine producƟ on (GO:0001816) pcsk5, ltb, gimap5, tnf
posiƟ ve regulaƟ on of signal transducƟ on 
(GO:0009967)
ncam1, ltb, adrb2, tnf
posiƟ ve regulaƟ on of programmed cell 
death (GO:0043067)
ncam1, ltb, adrb2, tnf
ENRICHED CELLULAR LOCALIZATIONS
cell surface (GO:0009986) ITGA6, ccr5, ncam1, itgam, sell, tnf, mmp25
membrane raŌ s (GO:0045121) stom, adrb2, tnf
extracellular space (GO:0005615) ltb, gnly, tnf, ccl4l1, ccl4, ccl3, ccl3l3, pcsk5
ENRICHED FUNCTIONS
cytokine acƟ vity (GO:0005125) ltb, tnf, ENST00000400702, ccl4l1, ccl4, ccl3, ccl3l3
cytokine binding (GO:0019955) il18r1, il3ra, ncam1, cxcr7, cmklr1, ccr3, ccr5, cxcr6, ccr1, ccr2
pepƟ dase acƟ vity (GO:0008233) mmp25, gzmh, ctsw, gzmk, gzma, pcsk5
cell death (GO:0008219) ltb, gzmh, gzma, itgb2, tnf
natural killer cell mediated cytotoxicity 
(hsa04650)
ncr3, hcst, itgb2, tnf
cytokine-cytokine receptor interacƟ on 
(hsa04060)
il18r1, il3ra, ltb, ccr5, cxcr6, ccr1, tnf, ccl4l1, ccl4, ccl3, ccr2, ccl3l3
leukocyte transendothelial migraƟ on 
(hsa04670)
nf2, itgam, itgb2
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ENRICHED PATHWAYS
response to organic substance 
(GO:0010033)
creb3l3, cyp1b1, lef1, ptprf, igĩ p2, gng4, dusp4, cd27, cav1, 
hspb1, hmox1
regulaƟ on of signal transducƟ on 
(GO:0009966)
lef1, ptprf, igĩ p2, p2rx5, gng4, ramp1, dusp2, cd27, cav1, hmox1
posiƟ veregulaƟ on of signal transducƟ on 
(GO:0009967)
p2rx5, cd27, cav1, hmox1
posiƟ ve regulaƟ on of programmed cell 
death (GO_0043068)
ptprf, prkce, mal, tnfrsf9, cd27, hmox1
dephosphorylaƟ on (GO:0016311) ptprf, prkce, mal, tnfrsf9, cd27, hmox1
cellular ion homeostasis (GO:0006873) pmch, p2rx5, mal, cav1
ENRICHED CELLULAR LOCALIZATIONS
insoluble fracƟ on (GO:0005626) hspb1, lmna, prkce, ptprf, ppap2a, rdh10, mal, hmox1, cyp1b1, 
cav1, pon3, cd27
extracellular space (GO:0005615) ramp1, cd109, pmch, igĩ p2, vcam1, hmox1, pon3
vesicular fracƟ on (GO:0042598) ptprf, rdh10, hmox1, cyp1b1, pon3
ENRICHED FUNCTIONS
phosphatases (GO:0016791) dusp4, ptprf, ppap2a, dusp2, pon3
oxidoreductases (GO:0016491) a_23_p431853, a_23_p317056, igĩ p2, pycr1, rdh10, moxd1, 
cyp1b1, hmox1
These analyses help to understand beƩ er the nature and the consequences of the altered paƩ ern 
of gene expression of ionomycin treated NK cells. The downregulated list of genes is enriched in genes 
related to chemotaxis, adhesion and cytotoxicity, thus it is easy to imagine that defi cient expression 
of these genes will profoundly aﬀ ect NK cell response and behavior. The upregulated list of genes 
is enriched in regulatory genes, phosphatases and oxidoreductases that could modulate signal 
transducƟ on. 
As many genes didn’t appear in this analysis, diﬀ erenƟ ally expressed genes were also classifi ed 
manually as shown in table 2 according to their known funcƟ ons in NK cells and genes related to 
acƟ n reorganizaƟ on, adhesion, calcium signaling, cell cycle, cell movement, chemokine and cytokine 
signaling, DNA-RNA synthesis, cytotoxicity, cell matrix, membrane molecules, metabolism, cell 
receptors, regulatory, secreƟ on or signaling were found. Other genes (43) had no associated funcƟ on 
yet, or cannot be included in the previous groups. Many of the genes diﬀ erenƟ ally expressed have 
no well defi ned role on NK cells, and their funcƟ on is extrapolated from other cell types, thus these 
funcƟ onal associaƟ ons are speculaƟ ve (Table 2).
Table 1: Ionomycin treatment repressed and induced diﬀ erent NK cell pathways. Gene ontology analysis of dif-
ferenƟ ally expressed genes on ionomycin treated NK cells highlighted diﬀ erent pathways, cellular localizaƟ on and 
funcƟ ons. Examples of enriched features are shown in table 1.
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Some interesƟ ng genes found in this analysis were:
 Adhesion molecules: ITGB2 (-3.20) and ITGAM (-2.84) downregulaƟ on correlates with the observed 
decreased expression observed at protein levels (Fig. 14). The expression of SELL (SelecƟ n-L) (-4.03) 
was also analyzed, but no diﬀ erence in expression was found at protein level. Diﬀ erences in mRNA 
expression of other integrins such as ITGA6, ITGB5 or VCAM1 were also noted, but were not 
analyzed further.  These changes in the repertoire of adhesion molecules expressed by ionomycin 
treated cells could aﬀ ect their ability to recognize target cells and interact with them, and also 
their migraƟ on paƩ ern. The CD56 gene (NCAM, -2.67) appeared also as downmodulated, which 
correlated with its lower expression at protein levels (Fig. 17). The expression of CD9 (5.32) was 
also analyzed by fl ow cytometry but no consistent upregulaƟ on of this molecule was observed on 
ionomycin treated cells at protein level.
 Cell cycle: The IFN induced transmembrane protein IFITM1 (-2.40) mediates inhibiƟ on of cell cycle 
and ERK signaling (Yang et al. 2007).
 Chemokine and cytokine signaling: Many chemokine receptors and ligands appeared as 
downmodulated in these data, indeed this was the category of genes most enriched in the 
downmodulated group. Of special interest was CCR5 (-2.77) since downmodulaƟ on of this molecule 
has been related to CD8+ T cell tolerance (SchieƟ nger et al. 2012), and its sequestraƟ on by regulatory T 
cells has profound eﬀ ects on anƟ gen recogniƟ on (Pace et al. 2012). A number of diﬀ erent CCR5 ligands 
including CCL3 (-3.62) and CCL4 (-3.49) were also downmodulated as was CCL5 (RANTES), another 
CCR5 ligand (-2.05), but here the FDR was 0.138. Lower expression of all these molecules may 
again imply defects in the migraƟ on paƩ ern of these cells, but also funcƟ onal defects. The IL-
18 receptor α-chain gene (IL18R1 -2.23) also appeared as downregulated but expression of this 
receptor as protein was normal in ionomycin treated NK cells (Fig. 17-A).
 DNA-RNA synthesis: The expression of a number of diﬀ erent transcripƟ on factors was altered in 
ionomycin treated cells including LEF1 (2.40), EGR1 (-4.64), EGR2 (-2.94), and this could produce 
diﬀ erences in gene expression. EGR2 has been related to CD4+ T cell anergy (Saﬀ ord et al. 2005). EGR1 
is an immediate early gene induced quickly aŌ er anƟ gen or chemokine acƟ vaƟ on of T and B 
cells (McMahon and Monroe 1996), and has been shown to limit TRAIL expression on NK cells (Fu et al. 
2003; Balzarolo et al. 2013). Another interesƟ ng gene is IRF8 (-4.29) that may be involved in the 
expression of genes related to cytotoxicity induced in response to IFNs.
 Cytotoxicity: Many genes related with NK cell cytotoxicity appeared downexpressed on ionomycin 
treated NK cells as: Granzyme K (-3.25), Granzyme A (-2.98), Granzyme H (-2.67), Granulysin 
(-2.97), Cathepsin W (-2.98), Lymphotoxin B (-2.63), TNF-α (-3.10). Changes in the expression 
of all these molecules will imply profound defects in NK cell cytotoxicity, and could explain why 
although some ionomycin treated NK cells were able to degranulate(Fig. 3), they were completely 
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unable to kill K562 cells (Fig. 4).
 Extracellular Matrix: Defi ciency of TIMP1 (-2.34), a matrix metalloproteinase inhibitor, and the 
metalloproteinase leukolysinMMP25 (-2.20), could produce changes in the set of molecules 
exposed on the NK cell surface and how they interact with the extracellular matrix to aﬀ ect 
adhesiveness, migraƟ on or ligand recogniƟ on.
 Receptors: CD300A (-4.24) and CD300C (-4.81) are the two most downregulated genes in our 
analysis. The CD300 family recognizes lipids and CD300a has been described as an inhibitory 
receptor (Lankry et al. 2013), whereas CD300c acts to acƟ vate NK cells (Borrego 2013). The Dap10 gene 
(HCST, -2.74) is an NK cell adaptor molecule important for the transmission of signals from the 
NKG2D receptor, and its defi ciency may imply a decreased ability to signal through this receptor. 
In our redirected anƟ body cytotoxicity experiments we observed that aŌ er ionomycin treatment, 
lysis triggered by sƟ mulaƟ on of the NKG2D receptor is more aﬀ ected than acƟ vaƟ on through other 
receptors such as NKp46 (Fig. 22). mRNA for the NKp30 receptor also scored as downmodulated 
(NCR3, -2.27), but no diﬀ erence was observed at protein level. CD27 (7.24) has been related to 
murine (Hayakawa and Smyth 2006) and human (Fu et al. 2011) NK cell developmental states, NK cell acƟ vaƟ on 
(Yang et al. 1996), reducƟ on of the threshold for CD8+ T cells responses (van Gisbergen et al. 2011), and 
chronic ligaƟ on of this receptor has also been linked to CD8+T cell exhausƟ on (Tesselaar et al. 2003); 
however, although in some ionomycin treated cells increased cell surface expression of CD27 
could be observed, this was not seen for all donors.
 SPRY2: Sprouty2 (-2.63 ) acts to inhibit receptor tyrosine kinase signaling proteins, decreasing PLCγ 
signals in T cells, blocking T cell receptor induced calcium release and limiƟ ng anƟ gen receptor 
mediated acƟ vaƟ on (Akbulut et al. 2010), so that defi ciency of SPRY2 may lead to an overbalance of 
this pathway. This gene has been reported to be specifi cally overexpressed in iNKT, γδT and NK 
cells (in comparison with other immune cells) which suggest it may have some special regulator 
funcƟ on for these lineages (Bezman et al. 2012). It also sequesters c-Cbl inhibiƟ ng its eﬀ ects on receptor 
downregulaƟ on (Wong et al. 2002).
 The dual specifi city phosphatases DUSP2( 2.72) and DUSP4 (2.41) are nuclear members of the 
Dusp family which dephosphorylate threonine and tyrosine residues of MAP kinases p38, ERK 
or JNK. Due to their nuclear localizaƟ on they can directly inhibit transcripƟ on factor acƟ vaƟ on. 
Dusp4 is the highest expressed member of the Dusp family expressed on NK cells (Jeﬀ rey et al. 2007).
 MAL (2.92) and CAV1 (4.06) are both membrane proteins which appear in the internal detergent-
insoluble microdomains and are involved in receptor clustering, receptor trafi cking and receptor 
acƟ vaƟ on in T cells (Millan et al. 1997; Anton et al. 2011; Tomassian et al. 2011), however they are expressed at only 
very low levels on NK cells. Overexpression of these molecules could modulate receptor clustering 
and cell acƟ vaƟ on.
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5.2 Transcription factors and microRNAs associated with differentially expressed genes
Online tools like Genecodis, can also be used to predict microRNAs which could suppress our list of 
genes. The upregulated list of genes could be target of many diﬀ erent microRNAs where hsa-miR-516a-
5p ( ramp1, cd109, uchl1, mal, vcam1, hmox1, igj, cd27, kiaa1324) and hsa-miR-766 (lrrc16b, ramp1, 
igĩ p2, b3gnt7, creb3l3, itgb5, kiaa1324) are the most signifi cantly enriched. When the downregulated 
list of genes was examined, several appeared as possible targets for hsa-miR-106b* (rgl4, apobec3h, 
c10orf128, snca, ltb, cd52, ccl3, ccl3l3),hsa-miR-516b (stom, ncr3, tspan32, ccr3, spry2, tnf, cd300a, 
irf8, egr1) and hsa-miR-936 (nt5e, ltb, gnly, gzma, styk1, ccl4l1, ccl4, egr1), but many others appeared 
as regulators of 8-7 genes. However, when these analyses were repeated using a diﬀ erent program; 
g:Profi ler, only miR-343 appeared to be signifi cantly associated with the upregulated list (reep2, hes6, 
lmna, plau, igĩ p2, hoxb6, dusp4, nbl1, ramp1) and no miRNA was associated with the downregulated 
genes. From these analyses no clear microRNA candidates appeared as mediators of the altered gene 
expression in the ionomycin treated cells
Using g:Profi ler, we could associate also transcripƟ on factors associated with our genes. For the 
upregulated list, only SP1 appeared as related with some of them (cthrc1, cd9, epas1, cav1, tnfrsf9, 
cyp1b1, reep2, p2rx5, itgb5, hes6, fabp5, fl vcr2, b3gnt7, rnf130, cbfa2t3, hspb1, mal, moxd1, rdh10, 
top1mt, dusp2, uchl1, igĩ p2, tmem117, col6a1, magef1, bmf, slc7a5, ppap2a, cercam, dusp4, nbl1, 
prkcdbp, tubb2a, prkce, lrrc28, lrrc16b, pmepa1) While SRF (egr1, matk, egr2, ccr5, plac8, nt5e) and 
c-rel (irf8, matk, ccl4, xbp1, ptgdr, gzma, egr2, cd52, ncf2, gzmh, cxcr6, ccr3, tspan32, cxcr7, slamf8, 
mmp25, ENST00000400702) appeared as candidates to be involved in regulaƟ ng expression of 
molecules in the downmodulated list. 
C-Rel is a member of the NF-κB family of transcripƟ on factors and its defi ciency has been related 
to T cell tolerance and anergy suscepƟ bility. It also appears not to be acƟ vated in immature B cells 
(Deenick et al. 2009; Liou and Smith 2010). In fact, anergy inducƟ on by ionomycin in CD4+ T cells is thought to be 
driven by NFAT dimers, formed in the absence of c-Rel and AP-1, that cause the expression of anergy 
inducing genes, and the expression of proteins which could degrade c-Rel (Macian et al. 2002). C-Rel did 
not appear to be downmodulated aŌ er ionomcyin treatment of NK cells, but other proteins could be 
targeƟ ng it aŌ er ionomycin treatment and reducing its protein levels, leading to the observed lower 
expression of genes regulated by c-Rel ((irf8, matk, ccl4, xbp1, ptgdr, gzma, egr2, cd52, ncf2, gzmh, 
cxcr6, ccr3, tspan32, cxcr7, slamf8, mmp25, ENST00000400702).
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5.3 Comparison with data from the literature
To further understand the importance of the diﬀ erenƟ ally expressed set of genes obtained in the 
ionomycin treated NK cells analysis, the gene signature obtained on these cells was compared with 
data from a range of arƟ cles where the mRNAs expressed by NK cells under diﬀ erent treatments or 
from tumor of virus infected paƟ ents had been characterized. The mRNA profi le of ionomycin treated 
NK cells was also compared with those of other hyporesponsive cells such as anergic CD4+ T cells or 
exhausted CD8+ T cells. 
However, there exist other studies where funcƟ onal NK cell changes were not accompanied by 
signifi cant changes in gene expression. For example, when the transcriptome of unlicensed NK cells 
isolated from mice defi cient in MHC-I or ß-2 microglobulin genes and so hyporesponsive were analyzed 
(Guia et al. 2011) where diﬀ erent genes appeared diﬀ erenƟ ally expressed, but the only gene in common 
between the diﬀ erent models of unlicensed NK cells was Klra6 which encodes Ly49F, an inhibitory 
receptor expressed on murine NK cells, implying that, at least in mice, there was no transcripƟ onal 
signature for this NK cell licensing model. Also NK cells isolated from the peripheral blood of human 
paƟ ents with melanoma showed no diﬀ erenƟ al gene expression compared to NK cells purifi ed from 
controls (Critchley-Thorne et al. 2007), although an important limitaƟ on to this study was that the funcƟ onal 
capability of NK cells from these paƟ ents was not characterized.
The use of online tools, such as the EMBL-EBI Expression Atlas hƩ p://www.ebi.ac.uk/gxa/, or hƩ p://
marq.cnb.csic.es/, which perform automaƟ c data mining comparing gene sets with published data didn’t 
idenƟ fy signifi cant similarity between any published signature and the lists of genes downregulated 
or upregulated in ionomycin-treated NK cells. Therefore a manual comparison of the changes in gene 
expression seen in ionomycin treated NK cells, with data from diﬀ erent papers was undertaken to fi nd 
coincidences or diﬀ erences between diﬀ erent signatures. These analyses were represented using Venn 
diagrams and are presented in Appendix 1. As genes can have diﬀ erent alternaƟ ve denominaƟ ons, to 
avoid the lost of coincident genes all list were translated to Entrez numbers. For these reason, only 69 
of the 72 upregulated genes, and 72 of the downregulated 74 genes were used as the other 5 genes 
do not have an Entrez associated number.
There exist several arƟ cles analyzing NK cell gene expression signatures. In (Dybkaer et al. 2007) the 
authors compared the gene expression of human NK cells with the molecular signature of other cell 
types. Comparison of their gene analysis with the lists of genes altered by ionomycin, revealed that 3 
ionomycin upregulated genes, appeared in their gene analysis, but, 18 of the genes which defi ne their 
NK cell signature were downmodulated. These data are consistent with a possible NK-dediﬀ erenƟ aƟ on 
process. Moreover, comparison of the ionomycin signature with those of acƟ vated CD56dimCD16+NK vs. 
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CD56dimCD16+ NK cells again idenƟ fi ed mulƟ ple genes in common with the downregulatedionomycin 
signature (Hanna et al. 2004). The lists of ionomycin regulated genes were also compared with the signature 
described for human decidual NK cells (dNK) (Koopman et al. 2003) which is a special subtype of NK cells 
important in maternal-fetal tolerance. Surprisingly several upregulated genes in dNK cells were also 
upregulated in ionomycin treated cells, and there were also some genes found in common with the 
genes which have lower expression in ionomycin treated cells.  Proteomics analysis of molecules 
enriched aŌ er sƟ mulaƟ on of NK cells with IL-2 has also been published (Ma et al. 2013), and again molecules 
were found in common only between proteins upregulated by IL-2 and downregulated in ionomycin 
treated NK cells.
The molecular signature of murine NK cells has also been analyzed recently (Bezman et al. 2012). The 
signature described in this arƟ cle is, not surprisingly, somewhat diﬀ erent from that described for 
human NK cells (Dybkaer et al. 2007), but again some genes important in this NK cell signature appeared as 
downmodulated in ionomycin treated cells, and none were found in common with those upregulated 
in the ionomycin treated cells. Moreover, in this arƟ cle, the authors also analyzed the variaƟ on in the 
genes expressed by NK cells during the course of an MCMV infecƟ on. Few genes were found in common 
between the ionomycin-treated NK cells and the murine NK cells from diﬀ erent phases of MCMV 
infecƟ on, but for those that were idenƟ fi ed, the ionomycin downmodulated signature coincided with 
genes of the early eﬀ ector response, while the upregulated corresponded with genes modulated in the 
late and memory responses. These observaƟ ons imply that the transcriptome of ionomycin treated NK 
cells may be related to the gene signature of NK cells in the later stages of a response, with perhaps a 
relaƟ ve inability to mount a new eﬀ ector response.
The gene signatures of ionomycin treated NK cells were also compared to the transcriptome 
profi les of NK cells isolated from human cancer paƟ ents. Comparison with the NK cell signature from 
IL-2 expanded NK cells vs. freshly isolated human NK cells from metastaƟ c paƟ ents (Park et al. 2010) and 
with data of gene expression of NK cells from myeloma paƟ ents vs. control samples (unpublished 
GSE27838) also idenƟ fi ed genes whose expression was modulated in cancer and aŌ er ionomycin.
Gene expression of ionomycin treated NK cells was also compared with the genes diﬀ erenƟ ally 
expressed in diﬀ erent situaƟ ons associated with hyporesponsivenes of CD4+ and CD8+ T cells (anergy, 
exhausƟ on, tolerance) and again some genes were found with similar or inverse regulaƟ on: studies 
with human non-tumor reacƟ ve CD8+ T cells vs. tumor reacƟ ve CD8+T cells, tolerant murine CD8+ T 
cells (SchieƟ nger et al. 2012), tumour specifi c human CD8+T cells infi ltraƟ ng lymph nodes (TILN) vs. peripheral 
blood tumour infi ltraƟ ng CD8+T cells (Baitsch et al. 2011), mouse HIV exhausted CD8+ T cells (Quigley et al. 2010), 
mouse chronically infected with LCMVclone13 exhausted CD8+ T cells vs. eﬀ ector CD8+T cells (Wherry et al. 
2007). Surprisingly no genes modulated by ionomycin in NK cells were found in common with the genes 
upregulated in ionomycin treated CD4+ T cells described by Macian et al. (Macian et al. 2002).
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Although obviously speculaƟ ve, overall these analyses suggest that ionomcyin treated NK cells have 
reduced expression of genes whose expression is associated with NK cell acƟ vaƟ on and diﬀ erenƟ aƟ on 
for eﬀ ector funcƟ on which could underly their reduced ability to respond to target cells. InteresƟ ngly 
ionomycin treated NK cells also upregulate some of the genes which are upregulated in decidual NK 
cells, which are poorly cytotoxic, and instead exert regulatory funcƟ ons (Kopcow et al. 2005; Hanna et al. 2006). 
InteresƟ ngly, the gene signature of ionomycin treated NK cells didn’t correspond strongly with the 
signature from other hyporesponsive cells under diﬀ erent circumstances, thus although some genes 
were regulated in common no potenƟ al candidate was idenƟ fi ed as a common gene which could 
regulate the responsiveness of both NK and T cells. The only upregulated gene which appeared in 
common between hyporesponsive T cells and ionomycin treated NK cells was tnfrsf9 whose protein 
product is 4-1BB (CD137), a member of the tumor necrosis factor. 4-1BB is expressed on the surface 
of human NK cells aŌ er acƟ vaƟ on, where its interacƟ on with its ligand impairs cytotoxicity and IFN-γ 
producƟ on by human, but not murine, NK cells (Baessler et al. 2009; Buechele et al. 2012). Although ligaƟ on of 
4-1BB does not aﬀ ect the eﬀ ector funcƟ ons of murine NK ells it has been described to inhibit the 
development of these cells in mice (Choi et al. 2010). InhibiƟ on by 4-1BB has been proposed to be mediated 
through TRAF3 and TRAF2 blockade of NF-κB acƟ vaƟ on (Barao 2012), but this has not been studied in 
detail.
Discussion
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The role of the immune system in cancer; tumor-promoƟ ng or tumor-antagonizing is sƟ ll a topic 
of acƟ ve debate. Although the benefi cial role of immunity in the defense from pathogens or tumor 
transformaƟ on is clearly demonstrated in immunocompromised individuals or in diﬀ erent models of 
carcinogen-induced tumors; the immune system response can also have a, paradoxical, tumor pro-
moƟ ng eﬀ ect by secreƟ ng growth factors, matrix modifying enzymes or reacƟ ve oxygen species; or by 
selecƟ ng anƟ gen-escape variants and contribuƟ ng to the immunoediƟ ng of tumor variants. Immune-
surveillance and immune-ediƟ ng are proposed to take place in three steps: eliminaƟ on, equilibrium 
and escape that comprise a mechanism by which tumors and pathogens avoid, resist or suppress im-
mune vigilance and eventually escape from immune control (Dunn et al. 2002). This evasion of the immune 
system has been proposed as an emerging hallmark of cancer (Hanahan and Weinberg 2011). Unresponsive NK 
cells have been characterized in paƟ ents suﬀ ering diﬀ erent types of tumor or diﬀ erent infecƟ ons, how-
ever, as summarized in the introducƟ on many diﬀ erent contradictory phenotypes have been described 
for these cells, due probably to the heterogeneity of diseases and models used; and liƩ le is known 
about the biochemical changes undergone by an NK cell that becomes unresponsive. 
In this work we studied the use of ionomycin as a method to induce NK cell hyporesponsiveness, 
mimicking chronic NK cell sƟ mulaƟ on or unbalanced sƟ mulaƟ on due to an acƟ vaƟ ng signal in the ab-
sence of inhibitory signalling. This model has the advantage of simplicity, reproducibility and as it is a 
non-specifi c sƟ mulaƟ on, it reduces the likelihood of idenƟ fying eﬀ ects associated with specifi c recep-
tors and highlights common processes. Moreover since ionomycin treatment has been used previously 
to study anergy in CD4+ T cells (Macian et al. 2002), we could use this informaƟ on as guidelines to study how 
hyporesponsiveness was produced in NK cells. Release of calcium from intracellular stores and infl ux of 
extracellular calcium, is one of the fi rst steps aŌ er target cell recogniƟ on, and correlates with exocyto-
sis of the lyƟ c granules and IFN-γ producƟ on (Bryceson et al. 2006), so the iniƟ al hypothesis was that mimick-
ing this fi rst infl ux would simulate chronic sƟ mulaƟ on. 
Ionomycin treatment resulted, in a dose and Ɵ me dependent manner, in a reduced ability of IL-2 
cultured NK cells to degranulate in response to K562 target cell sƟ mulaƟ on (Fig. 1). OpƟ mum inhibi-
Ɵ on was obtained using 1μM ionomycin in an overnight treatment. This protocol is almost idenƟ cal to 
that used previously to induce anergy in CD4+ T cells. We decided to include, aŌ er washing and seeding 
in fresh media ionomycin treated cells, a 24 hour resƟ ng Ɵ me with the idea that this would allow the 
ionomycin treated cells to reestablish their cell homeostasis. Carrying out the experiments in this way 
also ensured that the hyporesponsive state was stable for at least 24hours. Culture of the ionomycin 
treated cells for longer Ɵ mes was not carried out because of worries about the reduced viability of 
control and ionomycin treated cells cultured in the absence of IL-2. InteresƟ ngly, a constant level be-
tween donors of about 50%, of the ionomycin treated NK cell populaƟ on was observed to sƟ ll be able 
to degranulate in response to target cells. Moreover, ionomycin treatment produced elevated levels of 
cell death for NK cell lines from some donors, while NK cells from other donors, were relaƟ vely unaf-
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fected and indeed needed a higher dose of ionomycin to induce unresponsiveness. These results sug-
gested the hypothesis that ionomycin could be tuning NK cells responsiveness, and the eﬃ  cacy of this 
treatment would vary depending on the donor. Moreover, if each NK cell clone diﬀ ers in suscepƟ bility 
to ionomycin and in response to sƟ mulaƟ on, there would exist in the NK cell populaƟ on of any given 
individual NK cell clones more sensiƟ ve, and more resistant, to the ionomycin-mediated readjustment.
The ability of ionomycin treated NK cells to kill target cells other than K562 was also studied, and 
although the levels of reducƟ on in response varied, ionomycin treatment consistently led to decreased 
NK cell degranulaƟ on against the panel of targets tested (Fig. 3). This defect in target cell recogniƟ on 
was further evaluated by assay of target cell lysis and ionomycin treated NK cells displayed a marked 
inability to kill K562 and Jurkat target cells (Fig. 4).
No diﬀ erences in the expression of acƟ vaƟ ng or inhibitory NK receptors were found when control 
and ionomycin treated NK cells were compared by fl ow cytometry, indicaƟ ng that ionomycin induced 
loss of NK cell funcƟ on was not due to defects in the NK cell receptor balance, however lower levels 
of integrins (mainly αL, αM and ß2 chain) were expressed by the ionomycin treated cells (Fig. 13 & 
Fig. 14). InteresƟ ngly, treatment with IL-2, that restored NK cell degranulaƟ on led to the recovery of 
expression of various integrin except for the β2 chain (Fig. 14-C). The distribuƟ on of a range of diﬀ er-
ent receptors among the NK cell populaƟ ons that do, or do not, degranulate aŌ er exposed to K562 was 
also analyzed, and again no diﬀ erences were found between them (Fig. 18), thus, it could be discarded 
that in ionomycin treated cells the NK cell repertoire was shaped toward the selecƟ on of NK cells with 
impaired cytolyƟ c acƟ vity. These data also argue against the idea that the populaƟ on of cells inacƟ -
vated by ionomycin treatment represents a parƟ cular subset of NK cells. ModulaƟ on of expression of 
diﬀ erent adaptor molecules has also been described in NK cells aŌ er chronic sƟ mulaƟ on with target 
cells (Coudert et al. 2005), and in NK cells isolated from tumor paƟ ents (Lai et al. 1996) and a decrease in CD3-ζ 
chain expression was noted in the ionomycin treated NK cells. Given that many acƟ vaƟ ng NK recep-
tors can associate with either CD3- or the FcR chain (Vivier et al. 2004), this downmodulaƟ on of adaptor 
molecules together with the maintenance of receptor expression may imply changes in the usage of 
adaptor molecules. DegradaƟ on of adaptor molecules has been described previously in T and B lym-
phocytes aŌ er TCR or BCR sƟ mulaƟ on (Kishimoto et al. 1995; Vilen et al. 1999; Vilen et al. 2002; La Gruta et al. 2004) or aŌ er 
NKG2D chronic sƟ mulaƟ on in T cells (Hanaoka et al. 2010). Moreover, the recruitment of FcεRγI to 
the TCR complex, instead of CD3-ζ has been described in T cells from paƟ ents suﬀ ering Systemic lupus 
erythematosus (Enyedy et al. 2001) and in T cells from tumour bearing mice (Mizoguchi et al. 1992). Although, 
the signifi cance of this FcεRγI-CD3ζ exchange of the TCR is not clear (Frey and Monu 2008), the use of diﬀ er-
ent adaptor molecules implies important changes in cell signaling, as FcεRγI has a higher aﬃ  nity for 
Syk than for ZAP-70 leading to diﬀ erent kineƟ cs in signal transmission (Paolini et al. 1995), moreover CD3-ζ 
expresses three ITAMs whereas FcεRγI has only one. The consequences of specifi c CD3-ζ degradaƟ on 
for NK cell funcƟ on are unknown, but a populaƟ on of NK cells defi cient for FcεRγI in normal individu-
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als has been described. These -defi cient NK cells expressed lower levels of NCRs and were poorly re-
sponsive to tumour target cells, but were highly eﬀ ecƟ ve in mediaƟ ng ADCC (Hwang et al. 2012). These cells 
have also been reported to express a diﬀ erent repertoire of KIR receptors, and the authors proposed 
that they could represent uneducated or unlicensed NK cells that although able to mediate ADCC, are 
unable to respond to other sƟ muli. By analogy, CD3-ζ degradaƟ on could imply lower responsiveness 
either generally, or via specifi c receptors, but no consistent diﬀ erences in acƟ vaƟ ng NK receptor ex-
pression were noted in the inomycin treated NK cell populaƟ on.
The lower level of expression of integrin molecules might possibly be related to the observaƟ on 
of a lower eﬃ  ciency in the formaƟ on of conjugates between NK cells and K562 target cells (Fig. 10). 
Defects in conjugate formaƟ on have been described in NK cells from cancer paƟ ents (Peracoli et al. 1999; 
Montelli et al. 2001). Similarly, cord blood NK cells that also show impaired cytolyƟ c ability, are unable to 
form stable conjugates and express normal levels of various receptor, except for LFA-1 and CD2. IL-2 
sƟ mulaƟ on restored these defects, moreover it was demonstrated that blocking of LFA-1 and/or CD2 
resulted in profound inhibiƟ on of F-acƟ n polarizaƟ on and cytotoxicity, highlighƟ ng the importance of 
these molecules for NK cell cytotoxicity (Xing et al. 2010). β2 integrin-defi cient murine NK cells display a hy-
poresponsive phenotype in vitro, perhaps related to alteraƟ ons in their development and diﬀ erenƟ a-
Ɵ on so that β2 integrins are required for opƟ mal NK-cell maturaƟ on, but this defi ciency is parƟ al and 
can be bypassed during MCMV infecƟ on (Crozat et al. 2011). These data are consistent with the hypothesis 
that the reduced expression of adhesion molecules could play some role in NK hyporesponsiveness. 
However other data argue against this idea. In our hands, LFA-1 blocking of control cells, did not impair 
NK cell cytotoxicity (data not shown), perhaps because in these experiments long term IL-2 cultured 
NK cells were used as eﬀ ectors. The ability of ionomycin treated cells to degranulate when sƟ mulated 
through the CD16 receptor, is also consistent with the idea that the defect in integrin expression of the 
ionomycin treated NK cells, was not suﬃ  cient to explain defecƟ ve conjugate formaƟ on by these cells. 
Finally, integrins have been shown to have an important role in polarizaƟ on of the cytotoxic granules of 
NK cells (Bryceson et al. 2010), and although many ionomycin treated NK cells did not adhere stably to target 
cells, those cells that did form conjugates were able to polarize lyƟ c granules and LFA-1 (Fig. 11 & Fig. 
12). Perhaps, because although lower, integrin levels conƟ nued quite high (Fig. 10) so amelioraƟ ng any 
possible eﬀ ects associated with the integrin downmodulaƟ on in ionomycin treated cells. InteresƟ ngly, 
a reduced ability to form conjugates with target cells has been described in unlicensed human unli-
censed NK cells (Thomas et al. 2013), and this defect has been aƩ ributed to a defect in inside-out acƟ vaƟ on 
of LFA-1. Moreover, lyƟ c granule polarizaƟ on also occurred normally on these cells. Thus, ionomycin 
treatment could be targeƟ ng inside-out acƟ vaƟ on, as we observed a decreased level of staining using 
the NKL-L16 anƟ body (Fig. 14-B), but it could also be aﬀ ecƟ ng a step involved in the release of lyƟ c 
granules following their polarizaƟ on. 
The knowledge that ionomycin treated NK cells expressed the same levels of acƟ vaƟ ng receptors 
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as control cells, allowed evaluaƟ on of the ability of NK cells to respond through diﬀ erent acƟ vaƟ ng 
receptors by using redirected anƟ body mediated cytotoxicity assays. This approach allowed measure-
ment of NK cell responses to specifi c sƟ mulaƟ on of single receptors, and also to test whether combina-
Ɵ ons of receptor sƟ mulaƟ ons produced synergisƟ c signals that might overcome ionomycin restricƟ on. 
Ionomycin treated NK cells were able to degranulate as eﬃ  ciently as control cells when sƟ mulated 
through the CD16 FcgRIII-receptor, which is also the receptor that induces the most potent Ca2+ infl ux. 
Surprisingly, when the NK cells were triggered using pairs of anƟ bodies specifi c for receptors known 
to synergize, although both control and ionomycin treated cells showed higher degranulaƟ on, these 
synergisƟ c sƟ mulaƟ ons weren’t able to overcome the eﬀ ect of the ionomycin treatment (Fig. 19). 
InteresƟ ngly, the ability to respond through Fc-receptors, but not NCRs, has been described as main-
tained in NK cells from HIV infected individuals (Mavilio et al. 2003). 
Normal degranulaƟ on and IFN-γ secreƟ on was re-established following a 24 hour IL-2 treatment, 
implying that the defect was reversible (Fig.5 & 7). This IL-2 driven recovery of funcƟ on is also a feature 
of other models of induced NK cell unresponsiveness (Abrams and Brahmi 1986; Tripathy et al. 2008) and has been 
observed with NK cells recovered from cancer paƟ ents (LeFever and Funahashi 1991; Konjevic et al. 2007; Reiners et al. 2013). 
These observaƟ ons suggested that ionomycin induced hyporesponsive NK cells might sƟ ll respond to 
infl ammatory sƟ muli. However, IFN-α or IL-12 plus IL-18 sƟ mulaƟ on did not lead to the recovery of 
the degranulaƟ on (Fig. 6). When they were sƟ mulated with IL-12 and IL-18, hyporesponsive NK cells 
produced much less IFN-g than untreated NK cells and while the producƟ on of IFN-g by the control 
NK cells was further increased on exposure to target cells, ionomycin treated NK cells did not produce 
more IFN-g aŌ er sƟ mulaƟ on with target cells. (Fig. 7). Analyses for possible defects in IL-12 and IL-18 
receptor expression did not idenƟ fy any diﬀ erences between control and ionomycin treated cells (Fig. 
16).
Experiments done with freshly isolated NK cells, showed that ionomycin is able to induce a hypo-
responsive state in these cells similar to that observed for ionomycin treated acƟ vated NK cells, how-
ever, some diﬀ erences were observed. InteresƟ ngly, IL-2 treatment was only parƟ ally able to restore 
the funcƟ onality of hyporesponsive fNK cells (Fig. 24). One possible explanaƟ on for this discrepancy 
is that IL-2 restored funcƟ onality is due to the acƟ vaƟ on of parallel acƟ vaƟ on pathways that act to 
compensate, but not restore, the ionomycin induced specifi c defect, and that this compensaƟ on can 
recover the funcƟ on of acƟ vated NK cells. but not for fNK cells. Further experiments will be necessary 
to disƟ nguish between these possibiliƟ es, but these diﬀ erences between acƟ vated and freshly isolated 
NK cells, can help to understand the controversy found in the literature related to IL-2 driven recovery 
of hyporesponsive NK cells.
As discussed in the introducƟ on, a threshold for NK cell responsiveness is established during their 
licensing or educaƟ on. This setpoint is not fi xed, but rather is a plasƟ c process since mature NK cells 
are able to be re-educated during their enƟ re lifeƟ me. These previous data and the results from iono-
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mycin treated NK cells suggest that acƟ vaƟ ng signals and ionomycin could be shiŌ ing the NK cell ac-
Ɵ vaƟ on threshold, so that while some cells maintain the ability to respond to target cell sƟ mulaƟ on, 
form stable conjugates and polarize molecules to the immune synapse, aŌ er ionomycin treatment; an-
other part of the populaƟ on is rendered unresponsive, but able to respond when enough sƟ mulaƟ on 
is received, as with CD16 sƟ mulaƟ on. This hypothesis of variaƟ on in thresholds of responsiveness for 
acƟ vaƟ on would also explain why NK cells from some donors were insensible to 1μM ionomycin treat-
ment, whereas others died due to the sƟ mulaƟ on. As NK cell licensing is a fl exible process, ionomycin 
could be reseƫ  ng the responsiveness of each NK cell, re-tuning them and increasing the intensity of 
the signals necessary to mount and eﬀ ecƟ ve response. 
This model is a logical extension of the disarming and rheostat models proposed for NK cell licens-
ing. NK cell educaƟ on is thought to occur in the bone marrow by interacƟ ons between precursor NK 
cells and stromal cells. The disarming model proposes that NK cells are generated as highly cytotoxic 
cells that need to be rescued from oversƟ mulaƟ on induced unresponsiveness in a process of educa-
Ɵ on, or licensing, that depends on the signal delivered by inhibitory receptors counterbalancing the 
acƟ vaƟ ng signal (in the context of NK cell educaƟ on this posiƟ ve signal is likely to come from, as yet un-
idenƟ fi ed, endogenous acƟ vaƟ ng ligands expressed in the bone marrow),  (Fig. 27-A) (Wu and Raulet 1997). It 
is probable that this requirement for responsiveness to an inhibitory signal results in the generaƟ on of 
a more eﬃ  cient acƟ vaƟ ng circuit (Anfossi et al. 2006). The rheostat theory suggests that what guides NK cell 
educaƟ on is the net balance of signals between acƟ vaƟ ng and inhibitory inputs. This “balanced tuning 
input”, defi nes for each NK cell a threshold for response, that will be related to the diﬀ erent intensi-
Ɵ es of responses made by diﬀ erent NK cells and infl uenced by the receptors expressed. This balance 
could be conƟ nuously re-evaluated throughout the NK cell’s life. This way, the NK cell responsiveness 
will be like a rheostat, tuned depending on the balance between acƟ vaƟ ng and inhibitory signals (Fig. 
27-B)  (Joncker et al. 2009). The disarming model can be extended to understand changes in responsiveness 
of a populaƟ on of mature NK cells. When the balance between acƟ vaƟ ng and inhibitory signals is 
below the threshold for response set for each NK cell, the cell would not respond. If the threshold is 
exceeded, the NK cell becomes acƟ vated. However, if the net balance is much higher, as could be hap-
pening in the contest of chronic acƟ vaƟ ng receptor sƟ mulaƟ on, a loss of responsiveness is induced in 
mature NK cells (Raulet and Vance 2006). NK cells would have then two thresholds, one for response, and one 
for inacƟ vaƟ on due to oversƟ mulaƟ on (Fig. 27-C). The repertoire of acƟ vaƟ ng and inhibitory recep-
tors is determined stochasƟ cally for each NK cell clone so these checkpoints are likely to be specifi c 
for each clone and can also vary eg. aŌ er exposure to cytokines. Thus in a populaƟ on of NK cells, cells 
would be present with a spectrum of diﬀ erent sensibiliƟ es to iniƟ ate a response. If the signal received 
exceeded the second threshold, NK cell clones would begin to become inacƟ vated (disarming model), 
or the responsiveness could be readjusted downward unƟ l it is counterbalanced again, seƫ  ng a higher 
threshold for response (rheostat model). 
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Fig. 27. (A) The disarming model proposes that the educaƟ on of each individual NK cell depends on 
the balance of signals received from inhibitory receptors and acƟ vaƟ ng receptors. (B) The rheostat 
model suggests that the threshold for response and the intensity of the response of each individual 
NK cell is fi xed by the inhibitory signal received during educaƟ on. (C) The disarming model also im-
plies that during educaƟ on there exists one threshold for inacƟ vaƟ on, which if exceeded triggers NK 
cell hyporesponsiveness. When licensed, NK cells will have two thresholds: one for acƟ vaƟ on and 
another for inacƟ vaƟ on aŌ er oversƟ mulaƟ on. (D) Ionomycin treatment could cause a recalibraƟ on of 
at least the NK cell threshold for response, increasing the amount of acƟ vaƟ ng signal required for an 
NK cell response.
In
hi
bi
to
ry
si
gn
al
du
rin
g
ed
uc
at
io
n
Threshold for response
Intensity of response
A B
Inhibitory / Activating
balance during education
R
es
po
ns
e
Overstimulation
C
S
in
gl
e 
ce
ll
re
sp
on
se
Activating / Inhibitory balance
Activation
Threshold for response
Inhibition
D
P
er
ce
nt
ag
e
of
 c
el
ls
re
sp
on
di
ng
Activating / Inhibitory balance
Threshold for response 
control cells
Threshold for response 
ionomycin treated cells
Licensing
Threshold for inactivation
121
Discussion
Ionomycin treatment of NK cells, represents an oversƟ mulaƟ on signal, which instead of causing 
higher responses of an NK cell populaƟ on, recalibrates each NK cell rheostat establishing a higher 
threshold on them, so that the NK cell populaƟ on becomes hyporesponsive or tolerant for sƟ muli 
which are able to acƟ vate control cells. Whether the upper threshold is also retuned is unknown (Fig. 
27-D). As the NK cell populaƟ on consists of cells expressing various combinaƟ ons of inhibitory recep-
tors with diﬀ erent tuned thresholds, the ionomycin treatment would aﬀ ect them diﬀ erenƟ ally, so that 
while cells would be rendered hyporesponsive, others would sƟ ll be able to degranulate despite the 
threshold recalibraƟ on
This process might be working when NK cells sense that they are being oversƟ mulated, allowing 
the readaptaƟ on their sensiƟ veness and stopping target cell killing which could cause severe damages 
for the organism, but conserving at the same Ɵ me their killing potenƟ al. This way when later they 
were exposed to more potent sƟ muli, they would sƟ ll be able to respond eﬃ  ciently. The “downside” 
of this mechanism may occur in the case of infecƟ on or tumour transformaƟ on, where infected or 
transformed cells could be exploiƟ ng this “fail-safe” mechanism against exacerbated responses from 
NK cells to escape from immune surveillance.
There are many quesƟ ons sƟ ll unanswered in this model: Does the chronic sƟ mulaƟ on need to be 
potent to cause unresponsiveness? Or would a low intensity, but chronic, sƟ mulaƟ on also be suﬃ  cient 
for inacƟ vaƟ on if maintained enough Ɵ me? Are chronic acƟ vaƟ on signals modifying how inhibitory 
signals are sensed, shaping the balance to a higher threshold?
NK cell threshold is established in a narrow range, and very small changes in MHC class I expres-
sion provoke sharp transiƟ ons of a cell from resistant to suscepƟ ble to NK cell lysis (Almeida and Davis 2006; 
Holmes et al. 2010). In this way, small changes in the levels of expression of acƟ vaƟ ng or inhibitory ligands, 
would profoundly aﬀ ect target cell suscepƟ bility to NK cell aƩ ack. This Ɵ ght control of NK cell reacƟ vity 
acts to increase the sensiƟ vity of the system and to prevent autoimmunity. Indeed it is very interest-
ing that NK cells from disƟ nct organs including the dermis, the gut, the lungs or the liver, which are 
constantly exposed to bacteria or toxins, show reduced cytotoxicity when compared to peripheral NK 
cells and NK cells isolated from pancreas, joints or brain. Similarly, decidual NK cells that are in con-
tact with fetal cells also show reduced cytotoxicity (Shi et al. 2011). The maintenance of immunotolerance 
of organ infi ltraƟ ng immune cells to this constant contact with signals that don’t represent danger, 
while at the same Ɵ me conserving the ability of these leukocytes to be ready to exert a fast response 
when necessary must require very eﬃ  cient regulatory mechanisms (Sun et al. 2013). Constant expression 
in these Ɵ ssues of NK cell ligands, could set the sensiƟ vity of resident/infi ltraƟ ng NK cells to respond 
while prevenƟ ng nonspecifi c acƟ vaƟ on. One possible explanaƟ on for these organ-specifi c diﬀ erences 
could be that the liver, gut or lungs are seeded with NK progenitor cells that generate mature NK cells 
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with characterisƟ cs diﬀ erent from peripheral blood NK cells (Chinen et al. 2007; Wu et al. 2012), for example the 
NK-22 cells that are found enriched in mucosal Ɵ ssues including dermis, Peyer’s patches or tonsils, 
whose generaƟ on is dependent on the microfl ora. NK-22 cells lack cytotoxic proteins and IFN-γ, but 
express RORγt and secrete other cytokines such as IL-22, and funcƟ on to help to constrain infl amma-
Ɵ on (Satoh-Takayama et al. 2008; Cella et al. 2009). Another possibility for the diversity of organ-resident NK cells and 
their basal hyporesponsiveness, is that the microenvironment and the characterisƟ cs of these Ɵ ssues 
are able to shape and modulate the populaƟ on of mature NK cells that arrive to them. For example, 
liver NK cells are poorly cytolyƟ c and although they express normal levels of receptors and cytotoxic 
proteins, they display decreased levels of inhibitory receptors for self-MHC class I. The liver is an organ 
conƟ nuously exposed to toxins, and it could be that the lower levels of MHC class I on hepatocytes and 
the conƟ nuous sƟ mulaƟ on of NK cells, together with the liver microenvironment, change the NK cell 
threshold prevenƟ ng autoimmunity (Burt et al. 2009). In contrast, lung derived NK cells express higher levels 
of inhibitory receptors and lower levels of acƟ vaƟ ng receptors and adhesion molecules compared to 
peripheral NK cells, creaƟ ng an altered threshold for response (Wang et al. 2012). 
Fig. 28. Schema comparing organ infi ltraƟ ng NK cells and hyporesponsive NK cells threshold. 
NK cells infi ltraƟ ng diﬀ erent organs are described to be hyporesponsive. Whether they represent 
NK cells from diﬀ erent origins or peripheral NK cells adapted to their environment is sƟ ll being dis-
cussed. Peripheral NK cells could also be adapted to their milieu during chronic acƟ vaƟ on, exisƟ ng a 
parallelism between organ infi ltraƟ ng and chronically acƟ vated NK cells. 
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A tunable signaling threshold allows a beƩ er interpretaƟ on of the context of ligand presentaƟ on 
and therefore allows the generaƟ on of an immune response or the acƟ vaƟ on of tolerogenic programs 
depending on the circumstances. This equilibrium could be altered by the infl ammatory sƟ mulaƟ on, 
and the secreƟ on of diﬀ erent cytokines, chemokines or anƟ bodies, or the interacƟ on with other cells, 
could lower the NK cell threshold for response, favouring NK cell acƟ vaƟ on. For example, in the pres-
ence of IL-2 (Burt et al. 2009), or in contact with Kupﬀ er cells (Tu et al. 2008) liver NK cells are able to degranu-
late as eﬃ  ciently as peripheral NK cells; and even the NK-22 populaƟ on changes its IL-22 producƟ on 
towards IFN-γ producƟ on when sƟ mulated with IL-2 (Cella et al. 2010). However, if this response becomes 
uncontrolled, it could give rise to immunopathologies (Li et al. 2012) (Fig. 28).
LiƩ le is known about how the threshold for NK responsiveness is maintained and at the same Ɵ me 
can be re-evaluated and varied. Microarray data with NK cells from diﬀ erent mice defi cient in MHC 
class I, and thus with NK cells unlicensed or tolerant, didn’t idenƟ fy any change in gene expression that 
correlated with acƟ vaƟ on state, being the gene of Ly49F the only one commonly overexpressed. How-
ever, this study demonstrated that NK cell acƟ vaƟ ng receptors in unlicensed NK were confi ned togeth-
er with inhibitory receptors in acƟ n meshwork structures, in contrast to the nanodomain structures 
where they localize in educated NK cells and move more freely (Guia et al. 2011), suggesƟ ng that the lack 
of signaling coming from KIR receptors could be suﬃ  cient to alter the spaƟ al localizaƟ on of acƟ vaƟ ng 
receptors in the membrane, without further need for diﬀ erenƟ al gene expression. Recently it has also 
been shown that an acƟ vaƟ ng signal modifi es clustering of inhibitory receptors (Pageon et al. 2013), estab-
lishing that inhibitory and acƟ vaƟ ng signals can aﬀ ect how NK cells are going to respond to posterior 
signals via alteraƟ on of receptor movement in the membrane. AŌ er these two studies, the quesƟ on 
that remains sƟ ll unanswered is, could chronic acƟ vaƟ ng signal diﬀ erenƟ ally aﬀ ect the localizaƟ on of 
inhibitory and/or acƟ vaƟ ng receptors? CompartmentalizaƟ on of membrane receptors and signaling 
molecules in regions of the cell membrane is very important for the iniƟ aƟ on of cell acƟ vaƟ on and 
the regulaƟ on of signaling. DisorganizaƟ on of immune receptor localizaƟ on would aﬀ ect not only the 
recruitment of molecules to the immune synapse, but could also aﬀ ect the potency of the signal gen-
erated, make more diﬃ  cult the establishment of synergies between diﬀ erent acƟ vaƟ ng receptors and 
might also increase the ability of the inhibitory signal to block the acƟ on of acƟ vaƟ ng receptors. The 
balance of acƟ vaƟ ng vs. inhibitory signaling is established not only by a one to one interacƟ on, but 
also, by how these molecules are clustered and organized, as clustering will facilitate downstream sig-
naling by the proximity of signaling molecules; so small changes in the spaƟ al organizaƟ on of receptors 
and signaling molecules could profoundly aﬀ ect cell acƟ vaƟ on.
A number of possible factors could infl uence protein organizaƟ on in the cell membrane, including 
lipid or sugar post-translaƟ onal modifi caƟ ons, anchoring or tethering of proteins to acƟ n fi laments to 
create plaƞ orms that are transported together by acƟ n polymerizaƟ on changes. AlteraƟ ons in these 
protein modifi caƟ ons or in the aƩ achment of proteins to acƟ n, caould aﬀ ect NK cell funcƟ on. 
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AcylaƟ on of proteins, by prenylaƟ on, palmitoylaƟ on, myristoylaƟ on or GPI modifi caƟ on, can me-
diate receptor inclusion in lipid raŌ s and so change their behaviour in the plasma membrane. A small 
number of proteins, such as signaling proteins like LAT or Src family kinases as well as GPI linked CD16, 
are found consƟ tuƟ vely in lipid raŌ s, but others, including “MulƟ chain immune recogniƟ on receptors” 
such as TCR, BCR or NCRs, become raŌ  associated when they undergo transient lipid modifi caƟ ons. 
These receptors have been proposed to exist in an equilibrium; associaƟ ng transiently with raŌ s in 
resƟ ng cells signaling for tonic signals, but when these receptors become acƟ vated, they oligomerize, 
move massively into raŌ s and start the transmission of signals by raŌ  associated signaling proteins. 
Other proteins will then be recruited into raŌ s, the raŌ  plaƞ orms will become larger by clustering and 
aƩ ach to the acƟ n cytoskeleton stabilizing the plaƞ orm and allowing the formaƟ on of an immune 
synapse. This segregaƟ on between raŌ  and non-raŌ  proteins allows the iniƟ aƟ on, maintenance and 
prolongaƟ on of signaling. Diﬀ erent paƩ erns of raŌ  compartmentalizaƟ on have been described in pre-T 
cells, in Th1 vs. Th2 subsets and in naïve vs. eﬀ ector T cells highlighƟ ng the importance of raŌ  organiza-
Ɵ on for the outcome of the response (Dykstra et al. 2003). ZAP-70 has been shown to be excluded from raŌ s, 
by hyperacƟ vaƟ on of Fyn, in anergic CD4+ T cells (Lee et al. 2012) further suggesƟ ng a role for membrane 
segregaƟ on in anergy. In this context it is interesƟ ng to note that diﬀ erent types of lipid raŌ s, with 
diﬀ erent protein composiƟ on, have been described to allow spaƟ al segregaƟ on of diﬀ erent signaling 
proteins, which came close only when the cell become acƟ vated (Filipp et al. 2012). Analysis of the protein 
composiƟ on of lipid raŌ s and their localizaƟ on aŌ er acƟ vaƟ on on control cells compared to ionomycin 
treated NK cells could help to beƩ er understand NK cell hyporesponsiveness. 
Glycoproteins have also been proposed to exert important roles in tuning immune signal thresh-
olds by, for example, favouring the associaƟ on of receptors with other glycoproteins, limiƟ ng receptor 
clustering or prevenƟ ng receptor endocytosis (Rabinovich and Croci 2012). In the case of the TCR it has been 
proposed that its glycosylaƟ on restricts lateral movement of the receptor, increasing the T cell thresh-
old for response, whereas defects in the GnT5 glucosyltransferase lower the threshold, and can predis-
pose to autoimmunity. GalecƟ n-3 has also shown to be able to trap the TCR aŌ er chronic sƟ mulaƟ on 
of CD8+T cells, distancing the TCR from the CD8 cosƟ mulatory molecule and creaƟ ng an anergic state 
(DemoƩ e et al. 2008).
Many transmembrane and cytosolic proteins can interact either directly or through adaptor mole-
cules with ezrin/radixin/moexin (ERM) proteins, anchoring them to the acƟ n cytoskeleton and coordi-
naƟ ng their movements. DephosphorylaƟ on of ERM proteins is thought to be essenƟ al to increase cell 
deformability allowing cell-cell contacts and facilitaƟ ng immune synapse generaƟ on. Dephosphoryla-
Ɵ on also allows the detachment of receptors from ERM proteins enabling their relocaƟ on to diﬀ erent 
zones of the immune synapse (IveƟ c and Ridley 2004). Changes in proteins involved in acƟ n-anchoring have 
already been related to changes in NK cell responsiveness, for example Kindlin-3 whose defi ciency in 
LAD-3 paƟ ents caused a large decrease in the response to single receptor sƟ mulaƟ on, but high levels 
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of ligands or target cell mediated mulƟ ple receptor sƟ mulaƟ on can cause acƟ vaƟ on similar to control 
cells, suggesƟ ng changes in the NK cell threshold (Gruda et al. 2012).
Further analysis of the importance of these modifi caƟ ons, and the localizaƟ on or receptors in spe-
cifi c regions of the NK cell membrane, could provide clues that lead to a beƩ er understanding of NK 
cell acƟ vaƟ on and responsiveness. As it has been described previously the sequestering of inhibitory 
receptors in acƟ n meshworks in uneducated NK cells (Guia et al. 2011), we analyzed the eﬀ ect of the inhibi-
Ɵ on of acƟ n polymerizaƟ on on ionomycin treated NK cells by studying the Ca2+ fl ux triggered by anƟ -
body sƟ mulaƟ on of a synergic combinaƟ on of receptors. Surprisingly, acƟ n polymerizaƟ on seems to 
constrain NK cell responsiveness in both, control and inomycin treated cells (Fig. 21-C), and although 
latrunculin treated hyporesponsive cells achieve to generate similar responses to DMSO control cells 
without disrupƟ on of their microfi lament organizaƟ on,  latrunculin treatment of them increases also 
in our hands the responsiveness of control responsive cells.
With the aim of idenƟ fying factors important for hyporesponsiveness seƫ  ng and maintenance 
the transcriptomes of control and ionomycin-treated NK cells were compared using cDNA microarrays, 
obtaining a signature comprising 75 upregulated and 72 downregulated genes. Comparison of these 
genes with transcripƟ on profi les associated with diﬀ erent NK cell states and hyporesponsive lympho-
cytes of other lineages highlighted few genes in common (Annex 1). However, it was surprising to fi nd 
that many of the genes specifi cally upregulated on the NK cell linage, appeared as downmodulated in 
hyporesponsive cells perhaps indicaƟ ng a loss of the “natural killerness” of the ionomycin-treated NK 
cells. As described in the introducƟ on, lower expression of genes important for NK cell eﬀ ector func-
Ɵ on, including granzyme A and B (Al Omar et al. 2011) or perforin (Bajpai et al. 1991), has been described in NK cells 
from paƟ ents suﬀ ering diﬀ erent types of cancer.
Further, some of the genes upregulated aŌ er exposure to ionomycin appeared in common with 
decidual NK cells (dNK) and NK-22 cells. Human dNK cells express normal levels of lyƟ c granules and 
acƟ vaƟ ng receptors, and are able to polarize LFA-1 and F-acƟ n to the immune synapse, but not their 
cytotoxic granules, thus they are poorly cytotoxic and instead act as immunoregulatory and angiogenic 
cells (Kopcow et al. 2005). However, these cells are able to exert eﬀ ector funcƟ ons in the case of viral infec-
Ɵ ons during pregnancy (Siewiera et al. 2013). It seems reasonable that a more detailed analysis of the genes 
expressed in common between ionomycin treated cells and dNK could give some clues about NK cell 
hyporesponsiveness. IncubaƟ on of peripheral NK cells with TGF-ß, an inhibitory cytokine produced by 
many tumours, has been shown to induce a state similar to dNKs (Keskin et al. 2007). This may indicate that 
chronic sƟ mulaƟ on, as may happen in tumors, can lead to changes in NK cells similar to that suﬀ ered 
by dNKs to avoid maternal immune rejecƟ on during pregnancy. In fact, a process of “decidualizaƟ on” 
has already been proposed to have occurred in NK cells purifi ed from cancer paƟ ents (Belisle et al. 2007; 
Holtan et al. 2011). Another possibility is that the chronic sƟ mulaƟ on together with the tumor microenviron-
ment may be inducing a dediferenƟ aƟ on process in NK cells. It has been proposed that tumors were 
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colonized by NK cells in an early developmental stage, as judged by their phenotype, which were then 
rendered tolerant to the tumor (Carrega et al. 2008; Jin et al. 2013). However another way of interpreƟ ng these 
data could be that the tumor may be promoƟ ng a loss of maturaƟ on of mature NK cells together with 
their conversion into a regulatory phenotype. 
It would be interesƟ ng to idenƟ fy genes whose expression could explain the diﬀ erenƟ al spaƟ al 
localizaƟ on of receptors in ionomycin treated NK cells. In the cDNA microarray studies of the eﬀ ect of 
ionomycin, a number of genes related with post-translaƟ onal modifi caƟ ons of proteins in the mem-
brane were found, such as CTHRC1 (which is involved with N-glycosylaƟ on), heparanase (degrades 
polymeric heparan sulfate molecules) or urokinase (acƟ vates extracellular matrix degradaƟ on). Genes 
related to acƟ n polymerizaƟ on, incuding pls3 which codifi es for PlasƟ n-3 or Fimbrin (which crosslinks 
acƟ n fi laments and also stabilizes acƟ n dynamics without the needing of crosslinking, and has roles in 
integrin signaling were also idenƟ fi ed. InteresƟ ngly, pls3 is a protein whose expression and acƟ vity is 
dependent on Ca2+ (Samstag et al. 2003; Begue et al. 2012)). Future analysis of the role of these proteins in NK cells, 
and the consequences of their inhibiƟ on or overexpression may help to understand how hyporespon-
siveness is established on NK cells. 
InteresƟ ngly the largest group of genes downmodulated by exposure to ionomycin were chemo-
kine receptors and ligands. This deregulaƟ on together with the lower expression of integrin molecules 
could cause defects in NK migraƟ on and Ɵ ssue infi ltraƟ on. Moreover, loss of the ability to detect che-
mokines will aﬀ ect integrin acƟ vaƟ on, and as signaling through chemokines and cytokines are very 
important for NK cell priming, could also aﬀ ect NK cell acƟ vaƟ on. ConsideraƟ ons such as these might 
help to explain the poor NK cell infi ltraƟ on in malignant lung tumours, in contrast to non-malignant 
tumours (Esendagli et al. 2008). Surprisingly, the expression of genes coding for proteins such as E3-ubiquiƟ n 
ligases (Mueller 2004) or caspase-3 (Heissmeyer et al. 2004)  which are known to be upregulated in anergic T cells 
or aŌ er chronic sƟ mulaƟ on through NKG2D in T cells (Hanaoka et al. 2010), and could potenƟ ally modulate 
the NK responsiveness by degrading signaling components was not found to be altered in ionomycin 
treated NK cells.
This review of data in the literature, together with the idea that the threshold for response of NK 
cells coming from diﬀ erent organs could be modifi ed by constant exposure to acƟ vaƟ ng signals or the 
microenvironment, are consistent with the idea that tumors or pathogens might take advantage of the 
Ɵ ght control mechanisms that regulate NK cells, to prevent autoimmunity, and render them tumor-
tolerant/infecƟ on-tolerant NK cells. 
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Ionomycin treatment has shown to be a useful tool to understand NK cell unresponsiveness and 
this thesis reports a detailed characterizaƟ on of the phenotype and funcƟ on of these ionomycin-in-
duced hyporesponsive NK cells. However while mulƟ ple mechanisms that could possibly underly the 
hyporesponsive state have been tested, to date the molecular basis of the lack of response remains 
unclear. However the integraƟ on of the data described in this thesis to derive a plausible model for NK 
hyporesponsiveness should aid further understanding of this phenomenon by providing a conceptual 
framework that will be useful to generate hypotheses to guide future analyses of the properƟ es of 
hyporesponsive NK and invesƟ gaƟ ons into the bases of NK cell unresponsiveness.
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1. The treatment of acƟ vated NK cells with ionomcyin induces a loss of funcƟ on in a Ɵ me and 
dose dependant manner, being the opƟ mal treatment being a 1μM dose of ionomycin for 16 hours 
in the absence of IL-2.
2. AcƟ vated NK cells treated with ionomycin are less able to form conjugates with target cells and 
to degranulate. They are also unable to secrete IFN-γ eﬃ  ciently in response to target cells, even 
aŌ er sƟ mulaƟ on with IL-12 and IL18. However, those ionomycin treated cells that were able to 
create conjugates with target cells, were fully able to polarize their cytotoxic granules, LFA-1 and 
F-acƟ n. SƟ mulaƟ on of acƟ vated NK cells treated with ionomycin with IL-2 restores their funcƟ on-
ality.
3. The expression of the αL, αM and β2 integrins is reduced in acƟ vated NK cells treated with 
ionomycin, although the expression of acƟ vaƟ ng and inhibitory receptors is normal. The responses 
of acƟ vated NK cells treated with ionomycin were dimished aŌ er mAb mediated sƟ mulaƟ on of 
specifi c receptors, with the excepƟ on of CD16 sƟ mulaƟ on which triggered responses comparable 
to those observed in control NK cells.
4. The transcriptomic analysis of acƟ vated NK cells treated with ionomycin revealed the diﬀ er-
enƟ al expression of 75 downregulated and 72 upregulated genes. Comparison of these altered 
paƩ erns of transcripƟ on with transcripƟ onal signatures of other classes of hyporesponsive cells 
showed that the hyporesponsive status induced with ionomycin on acƟ vated NK cells represents a 
state diﬀ erent to those previously defi ned in other hyporesponsive lymphocytes. 
5. Treatment of freshly isolated NK cells from healthy donors with ionomycin induces a hypore-
sponsive state similar to that observed aŌ er the treatment of acƟ vated NK cells. However, fNK cells 
did not recover their ability to degranulate and produce IFN-γ enƟ rely in the presence of IL-2, and 
are unable to exert degranulaƟ on as eﬃ  ciently as control cells when sƟ mulated through CD16.
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1. El tratamiento de las células NK acƟ vadas con ionomicina induce una pérdida de función de 
manera dependiente de la dosis y el Ɵ empo de tratamiento, siendo el tratamiento ópƟ mo para 
inducir un estado de menor respuesta el generado con una dosis 1μM de ionomicina durante 16 
horas en ausencia de IL-2.
2. Las células NK acƟ vadas tratadas con ionomicina muestran menor capacidad de conjugar con 
células dianas y de degranular,  así como de secretar IFN-γ en respuesta a células diana incluso tras 
haber sido esƟ muladas con IL-12 y IL18.  Sin embargo, aquellas células tratadas con ionomicina 
capaces de formar conjugados, son capaces de polarizar sus gránulos citotóxicos, LFA-1 y F-acƟ na 
de manera efecƟ va. La esƟ mulación con IL-2  es capaz de recuperar la función de las células NK 
acƟ vadas tratadas con ionomicina.
3. La expresión de las integrinas αL, αM y β2 se encuentra reducida en las células NK acƟ vadas 
tratadas con ionomicina, manteniéndose normal la expresión de los receptores acƟ vadores e in-
hibidores. La esƟ mulación específi ca a través de los receptores acƟ vadores genera respuestas 
menores en las células NK acƟ vadas tratadas con ionomicina, excepto en el caso de la esƟ mulación 
a través de CD16, que da lugar al mismo nivel de respuesta que en las células control. 
4. Análisis del transcriptoma de las células NK acƟ vadas con ionomicina muestra que estas células 
expresan niveles reducidos de 75 genes y aumentados de 72 genes. La comparación de estos cam-
bios en expresión génica con fi rmas transcripcionales de otros modelos de células que han perdido 
la función efectora, recalcó que el tratamiento con ionomicina de las células NK acƟ vadas genera 
un estado diferente al encontrado en otras células linfoides. 
5. El tratamiento de células NK recién aisladas de donantes sanos con ionomicina induce una 
pérdida de respuesta comparable al observado con el tratamiento de las células NK acƟ vadas. Sin 
embargo, estas células no recuperan totalmente su capacidad de degranular y de secretar IFN-γ en 
presencia de IL-2; ni son capaces de responder a la esƟ mulación a través de CD16 de manera tan 
efi ciente como las células recién aisladas control.
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